The endogenous opioid system in alcoholism: Translational studies in humans and rodents by Hirth, Natalie
  
 
Dissertation 
submitted to the 
Combined Faculties for the Natural Sciences and for Mathematics 
of the Ruperto-Carola University of Heidelberg, Germany 
for the degree of 
Doctor of Natural Sciences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presented by 
Natalie Hirth, Master of Science 
born in: Baden-Baden 
Oral-examination:  30.09.2015 
  
  
  
 
 
 
 
 
 
 
 
 
The endogenous opioid system in alcoholism: 
Translational studies in humans and rodents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referees: Prof. Dr. Rainer Spanagel 
    Prof. Dr. Stephan Frings 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Für meine Familie 
 
  
  
  
ABSTRACT 
In most parts of the world, alcohol is consumed for social and recreational reasons. However, 
the initially controllable use can become compulsive and alcohol dependence develops. Late 
dependence is characterized by persistent neuroadaptations in various brain neurotransmitter 
systems, including the endogenous opioid and dopamine system, which are thought to 
underlie relapse. Many hypotheses on the state of brain neurotransmitter systems are based on 
positron emission tomography (PET) studies. However, the interpretation of those data is 
challenging as PET signals are sensitive not only to receptor but also ligand levels. For 
instance, increased µ-opioid receptor (MOR) PET binding potentials are interpreted as 
elevated receptor levels. Those are thought to be the target of the anti-relapse medication 
naltrexone, an opioid antagonist. However, naltrexone’s effect size is relatively small and 
only a subset of alcohol-dependent patients appears to benefit. Furthermore, only few studies 
on the opioid and dopamine system during protracted abstinence are available. This is 
surprising as this phase is characterized by high relapse propensity and, thus, is clinically 
highly relevant.  
Therefore, this thesis aims to demonstrate the state of the opioid and dopamine system during 
alcohol abstinence. A translational approach was applied by analyzing these systems in four 
separate studies (Study I-IV) in post-mortem brain tissue of human alcoholics and an animal 
model of alcohol dependence. 
 
In Study I, transcriptional and protein levels (receptor binding sites) of the MOR are found to 
be strongly reduced in the striatum of alcoholics. Additionally, a PET study associates 
decreased striatal MOR binding potential with higher relapse risk. Decreased MOR 
expression is mirrored by data from alcohol-dependent rats in Study II. Furthermore, the 
precursor of the MOR-ligand β-endorphin Pomc is significantly reduced. Signaling at the δ-
opioid receptor (DOR) appears to be decreased in alcohol dependence while the κ-opioid 
receptor (KOR) system is upregulated. In Study III, chronic naltrexone treatment counteracts 
the changes in MOR/Pomc levels by significantly increasing expression and further enhanced 
KOR density. The DOR, in contrast, seems not to be a target of naltrexone under the applied 
experimental conditions. Because the endogenous opioid system is known to modulate 
dopamine release, the dopamine system was investigated in Study IV. Here, human post-
mortem tissue reveals strongly decreased dopamine transporter and D1 receptor levels in 
alcoholics while D2 is unchanged. These findings are further supported by the alcohol-
dependent animals where an oscillatory-like regulation of the dopamine system is observed 
during acute withdrawal and protracted abstinence. While previous studies report on a 
hypodopaminergic state during acute withdrawal, here, a hyperdopaminergic state is 
demonstrated during protracted abstinence by measurements of striatal dopamine release and 
a meta-analysis followed by functional validations. Based on these data, both hypo- and 
hyperdopaminergic states are suggested as phases with increased vulnerability for alcohol 
relapse. 
 
In summary, the results presented in this thesis provide consistent evidence for a severe 
dysregulation of the endogenous opioid and dopamine system during alcohol abstinence that 
demands reinterpretation of existing PET data. It is proposed for future studies to combine the 
analysis of human post-mortem tissue and established animal models with PET studies to 
achieve a more precise picture of the state of brain neurotransmitter systems in alcoholic 
patients. Moreover, decreased MOR and dopamine receptor/transporter levels may represent 
molecular markers of the disease course that can be used to develop personalized treatment 
approaches. 
ZUSAMMENFASSUNG 
In den meisten Teilen der Welt wird Alkohol zu gesellschaftlichen Anlässen konsumiert. 
Allerdings kann sich das anfänglich kontrollierbare Alkoholtrinken zum Zwang und zur 
Alkoholabhängigkeit entwickeln. Diese ist durch lang anhaltende Neuroadaptionen in 
verschiedenen Neurotransmittersystemen, einschließlich des endogenen Opiat- und 
Dopaminsystems, im Gehirn geprägt. Zahlreiche Hypothesen zum Status dieser 
Neurotransmittersysteme basieren auf Positronen-Emissions-Tomographie (PET) Studien. 
Allerdings ist die Interpretation dieser Daten schwierig, da PET Signale sowohl von Rezeptor- 
als auch Ligandenkonzentrationen abhängen. Beispielsweise wurden erhöhte µ-Opiatrezeptor 
(MOR) Bindungspotential in PET Studien als erhöhte Rezeptorendichte interpretiert. Es wird 
angenommen, dass dies der Angriffspunkt von Naltrexon ist, einem Opiat-Antagonisten zur 
Rückfallprävention.  Die Effektstärke von Naltrexon ist jedoch relativ gering und nur eine 
Untergruppe von Patienten profitiert von der Behandlung. Außerdem gibt es nur relativ 
wenige Studien, die sich mit dem Opiat- und Dopaminsystem in der Langzeitabstinenz 
beschäftigen. Dies ist überraschend, da diese Phase durch eine hohe Rückfallrate 
gekennzeichnet und dadurch klinisch hoch relevant ist. 
Aus diesen Gründen setzt sich diese Dissertation das Ziel, den Status des Opiat- und 
Dopaminsystems in der Alkoholabhängigkeit zu charakterisieren. In einem translationalen 
Ansatz werden in vier Studien (Studien I-IV) post-mortem Gehirngewebe von Alkoholikern 
sowie ein Tiermodell für Alkoholabhängigkeit untersucht. 
 
In Studie I wird eine starke Verminderung von MOR Transkripten und Proteinen im Striatum 
von Alkoholikern berichtet. Eine PET-Studie assoziiert die reduzierten striatalen MORs mit 
einem erhöhten Rückfallrisiko. In Studie II spiegeln sich diese Effekte in alkoholabhängigen 
Ratten wider. Zudem ist hier der Vorläufer des MOR-Liganden β-endorphin Pomc stark 
reduziert. Die Signalweiterleitung am δ-Opiatrezeptor (DOR) ist vermindert während das κ-
Opiatrezeptor (KOR) System hochreguliert ist. Chronische Behandlung mit Naltrexon steuert 
den Veränderungen in der MOR/Pomc Expression in Studie III entgegen indem es sowohl 
MOR als auch Pomc signifikant erhöht. Die Dichte von KOR wird ebenfalls verstärkt. Unter 
den verwendeten experimentellen Bedingungen scheint DOR jedoch kein Angriffspunkt von 
Naltrexon zu sein. Da bekannt ist, dass das Opiatsystem das Dopaminsystem moduliert, 
wurde letzteres in Studie IV untersucht. Die Analyse der humanen Gehirnproben zeigt stark 
verminderte Dopaminrezeptor D1 und –transporter Level in Alkoholikern, während der D2 
Rezeptor unverändert ist. Diese Beobachtung wird zudem von Ergebnissen in den 
alkoholabhängigen Ratten unterstützt, die eine dynamische Regulation des Dopaminsystems 
im akuten Alkoholentzug und in der fortgeschrittenen Abstinenz aufweisen. Während 
bisherige Studien von einer hypodopaminergen Phase im akuten Entzug berichten, wird hier 
eine hyperdopaminerge Phase in der Langzeitabstinenz gezeigt. Beides, also sowohl die hypo- 
als auch die hyperdopaminerge Phase, werden als Zustände mit erhöhtem Rückfallrisiko 
interpretiert.  
 
Zusammenfassend liefern die Ergebnisse dieser Dissertation Beweise für die Dysregulation 
des endogenen Opiat- sowie des Dopaminsystems in der Alkoholabhängigkeit und Abstinenz, 
die eine Neuinterpretation der vorliegenden PET-Daten fordern. Zukünftige PET-Studien 
sollten mit der Analyse von humanem post-mortem Material und etablierten Tiermodellen 
kombiniert werden, um ein präziseres Bild der Neurotransmittersysteme in Alkoholikern zu 
erlangen. Zudem wird vermutet, dass verminderte MORs und Dopaminrezeptoren/-transporter 
als molekulare Marker für die Krankheit gesehen und zur Entwicklung personalisierter 
Behandlungsmöglichkeiten genutzt werden können. 
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ABBREVIATIONS 
AcbC   nucleus accumbens core region 
AcbS   nucleus accumbens shell region 
BLA   basolateral nucleus of the amygdala 
BPND   binding potential 
CeA   central nucleus of the amygdala 
CIE   chronic intermittent exposure to alcohol vapor 
CPM   counts per minute 
CPu   caudate putamen 
DA   dopamine 
DALYs  disability adjusted life years 
DAT   dopamine transporter 
DOR   δ-opioid receptor 
DSM-IV/DSM-5 Diagnostic and Statistical Manual for Mental Disorders, 4th/5th edition 
D1   dopamine receptor D1 
D2   dopamine receptor D2  
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GPCR   G-protein coupled receptor 
HPLC   high pressure liquid chromatography 
ICD-10  International Classification of Disease, 10th edition 
KOR   κ-opioid receptor 
MOR   µ-opioid receptor 
MSN   medium spiny neuron 
NC   nucleus caudatus 
NTX   naltrexone 
Pdyn   preprodynorphin 
Penk   preproenkephalin 
Pomc   proopiomelanotropin 
qRT-PCR  quantitative real-time polymerase chain reaction 
RIN    RNA integrity number 
ROI   region of interest  
SNP   single nucleotide polymorphism 
VS   ventral striatum (including nucleus accumbens) 
VTA   ventral tegmental area 
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1 INTRODUCTION 
1.1 ALCOHOL DEPENDENCE 
As a psychoactive substance, alcohol has addiction- and dependence-inducing properties and 
its harmful use is a major risk factor for death, disease and disability. Worldwide, it accounts 
for 5.9 % of all deaths and 5.1 % of disability-adjusted life years (DALYs, years of life lost 
due to premature mortality or lost due to time lived in less than full health) (1). It not only 
affects the consumer but has serious impact on society and economy, and on every person 
connected to the consumer. The European Union (EU) is one of the heaviest drinking regions 
in the world, with alcohol consumption almost double of the global average. In 2010, every 
person older than 15 years consumed an average of 10.2 liters of pure alcohol. As a result, 
alcohol is a major factor for premature deaths in the EU that can be attributed to cancers, liver 
cirrhosis and injuries caused by alcohol (2).    
In the EU, 7.5% of the population older than 15 years is thought to suffer from alcohol use 
disorders (AUD) with 4 % actually being alcohol dependent (1). The term “dependence” 
refers to physical adaptations that result in withdrawal symptoms whereas “addiction” 
describes behavioral changes that cause the loss of control over drug consumption despite its 
consequences. It is a major challenge to understand why some individuals become alcohol 
dependent whereas others do not. Genetic (3, 4), developmental, as well as environmental 
factors (5) have an impact on the risk to develop dependence. Alcohol dependence has been 
described as chronically relapsing disorder. Initially controllable drug consumption relies on 
the subjective drug-induced effects, i.e. the increase of positive subjective feelings or relieve 
of negative states (Figure 1A). In some individuals, this limited drug consumption shifts to 
compulsive drug seeking and taking which no longer can be controlled or limited. Withdrawal 
symptoms and negative emotional states emerge when alcohol use is discontinued. This stage 
is characterized by craving for positive and negative reinforcing effects of alcohol that were 
previously experienced. Craving can be induced by drug-associated (conditioned) cues (6), 
drug priming, or stress, and is contributing to relapse (7, 8). Living through this cycle of 
intoxication, withdrawal, craving, and relapse repeatedly results in neuroadaptive changes in 
various brain neurotransmitter systems, including the dopamine (DA) and endogenous opioid 
system (9)(Figure 1A).  
Various brain regions are involved in mediating the rewarding effects of alcohol (Figure 1B). 
As early as 1954, Olds and Milner (10) started to identify those regions by implanting 
16 
 
electrodes into the brain of rats. By pressing a lever the animals could voluntarily self-
stimulate themselves by directly activating brain reward pathways while bypassing normal 
physiological inputs. The medial forebrain bundle, a complex axon bundle including 
serotonergic and noradrenergic projections as well as dopaminergic projections from the 
ventral tegmental area, was identified as critical for self-stimulation (11). Alcohol dependence 
and withdrawal induce severe dysregulations in this brain reward system (Figure 1B). 
Simultaneously, stress and anti-reward systems are increasingly activated (12-15). 
 
 
Figure 1: Development of alcohol dependence over time. (A) Initial alcohol use that is linked to positive 
reinforcing and pleasurable effects of alcohol is followed by the loss of control and compulsive alcohol intake. 
This progression is accompanied by the shift of positive to negative reinforcement where alcohol is consumed to 
achieve relief from negative emotional states. The state of late dependence is characterized by long-lasting 
neuroadaptations that also persist into protracted abstinence. (B) In a non-dependent individual alcohol is 
consumed for its positive reinforcing and rewarding effects. These are mediated by neurocircuitries involving the 
nucleus accumbens (Acb), ventral tegmental area (VTA) and prefrontal cortex (PFC). During alcohol 
dependence, the reward processes within these systems are dysregulated and the amygdala (Amy) is increasingly 
active. Thereby, negative emotional states are emerging and alcohol is consumed for its relieving effects 
(negative reinforcement). Adapted from (12, 14).  
 
In summary, alcohol dependence is a chronically relapsing disorder that is characterized by 
reduced reward functions and increased dysphoric states. A clear diagnosis of the disease is 
needed to successfully help patients to remain abstinent. 
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1.1.1 DIAGNOSIS OF ALCOHOL DEPENDENCE 
Diagnosis of alcohol use disorders and dependence often is challenging and physicians use 
psychiatric manuals as a guideline. In 2013, the 5th edition of the Diagnostic and Statistical 
Manual of Mental Disorders was published (DSM-5, (16)). It differs from the previous edition 
DSM-IV which distinguished between alcohol abuse and dependence, now integrating these 
two disorders into a single one (alcohol use disorder, AUD). It is defined by the occurrence of 
at least two specified symptoms (see below) and its severity is indicated by the number of 
symptoms present (mild 2-3, moderate 4-5, severe 6 or more symptoms) as shown in Table 1. 
Another widely used diagnostic manual is the “International Statistical Classification of 
Disease and Related Health Problems” (ICD-10) which was introduced by the World Health 
Organization. Diagnostic criteria of ICD-10 and DSM coincide. 
 
Table 1: Diagnostic criteria for alcohol use disorder according to DSM-5 (from (16)) 
1) “Alcohol is often taken in larger amounts or over a longer period than was intended.” 
2) “Persistent desire or unsuccessful efforts to cut down or control alcohol use.” 
3) “A great deal of time is spent in activities necessary to obtain alcohol, use alcohol, or recover from its 
effects.” 
4) “Craving, or a strong desire or urge to use alcohol.“ 
5) “Recurrent alcohol use resulting in a failure to fulfill major role obligations at work, school, or home.”  
6) “Continued alcohol use despite having persistent or recurrent social or interpersonal problems caused or 
exacerbated by the effects of alcohol.”  
7) “Important social, occupational, or recreational activities are given up/reduced because of alcohol use.“ 
8) “Recurrent alcohol use in situations in which it is physically hazardous.”  
9) “Alcohol use is continued despite knowledge of having a persistent or recurrent physical or 
psychological problem that is likely to have been caused or exacerbated by alcohol.” 
10) “Tolerance, as defined by either of the following:  
a. A need for markedly increased amounts of alcohol to achieve intoxication or 
desired effect  
b. A markedly diminished effect with continued use of the same amount of alcohol“ 
11) “Withdrawal, as manifested by either of the following:  
a. The characteristic withdrawal syndrome for alcohol (refer to criteria A and B of 
the criteria set for alcohol withdrawal)  
b. Alcohol (or a closely related substance, such as a benzodiazepine) is taken to 
relieve or avoid withdrawal symptoms“ 
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1.1.2 PHARMACOLOGICAL INTERVENTIONS FOR RELAPSE PREVENTIONS 
A major challenge in the treatment of alcohol dependence is the reduction of relapse to 
drinking behavior. The risk for relapse can be reduced by psychological interventions such as 
cognitive-behavioral therapies or motivational enhancement interviewing but also 
pharmacotherapy or the combination of both. To date, only few pharmacological anti-relapse 
medications are approved. 
 
Disulfiram (Antabus®) 
Disulfiram has been used to treat alcohol dependence since the 1940’s and interacts with the 
alcohol metabolism by inhibition of the enzyme acetaldehyde dehydrogenase. Thereby it 
leads to elevated acetaldehyde levels causing hangover-like symptoms such as sweating, 
headache, nausea, and vomiting. Patients associate these aversive states with drinking and can 
be discouraged to further ingest alcohol. However, the efficacy is weak with showing low 
effects on alcohol craving and those patients that want to drink can easily stop taking 
disulfiram. Thus, it should be taken by patients that are motivated to stop drinking or receive 
their medication under supervision (17, 18).  
 
Acamprosate (Campral®) 
Acamprosate (calcium-bis(N-acetylhomotaurinate)) is a well-tolerated and safe 
pharmacological treatment and it has been shown to reduce the risk for relapse (19). However, 
it does not affect craving (20). Acamprosate is thought to modulate glutamatergic systems by 
interacting with N-methyl-D-aspartate (NMDA) and metabotropic-5 glutamate (mGlur5) 
receptors (21-23). A common theory in the alcohol research field is that chronic alcohol leads 
to a hyperglutamatergic state in alcohol withdrawal which may drive relapse (24, 25). 
Acamprosate therapy has been shown to reduce glutamate concentrations in alcohol-
dependent patients (26) and to reduce consumption in alcohol drinking mice by dampening 
this hyperglutamatergic state (27, 28). However, the exact molecular mode of action of 
acamprosate is not clear and it has been suggested that acamprosate’s effects are caused by 
calcium as the active moiety of the drug (29).  
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Naltrexone (ReVia®, Vivitrol®) 
The unselective opioid receptor antagonist naltrexone (NTX) displays the highest affinity for 
the MOR followed by KOR and DOR was approved in the US by the Food and Drug 
Administration (FDA) in 1994 after two studies reported reduced drinking in dependent 
subjects after NTX therapy (30, 31). In Germany, NTX is available since 2010. As MOR 
antagonist, NTX is thought to block the rewarding effects of alcohol by reducing MOR-
mediated dopamine release in the striatum. The recommended dose of 50 mg of NTX has 
been shown to almost completely block the MOR (95 %) and to a lower percentage (21%) the 
DOR in human subjects (32). A dose of 150mg was sufficient to block about 90% of the KOR 
(33). 
The efficacy of NTX has been shown by a meta-analysis (34). However, its effect size is 
relatively small and only a subset of patients appears to benefit from NTX therapy. Thus, 
many scientists and physicians demand for personalized treatment approaches (35).  
 
Nalmefene (Selincro®) 
Nalmefene received authorization for the European Union in 2013 and is the first 
pharmacotherapy approved for reduction of alcohol consumption and for “as-needed” use. 
Patients are asked to take their medications if they feel at risk to return to heavy drinking (36). 
The efficacy of nalmefene treatment to reduce alcohol consumption in dependent patients was 
demonstrated in “as-needed” clinical trials (37, 38). 
In contrast to NTX which is an opioid receptor antagonist, nalmefene shows antagonistic 
activity at the MOR and DOR but also partial agonistic activity at the KOR (39). Its affinity 
for KOR and DOR is higher than that of NTX. It is assumed that nalmefene could be more 
helpful than NTX by acting at the KOR and thereby antagonizing the rewarding and 
reinforcing effects of alcohol. Administration of nalmefene into the nucleus accumbens (Acb) 
of alcohol-dependent rats reduced self-administration to a higher degree than in non-
dependent rats and this effect was attributed to KOR mediated mechanisms (40, 41). 
However, the superiority of nalmefene over NTX in humans remains to be under debate and 
additional studies are warranted (42). 
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Off-label use  
In addition to the medications specifically approved for the reduction of alcohol intake, 
different pharmaceutics approved for other indications are studied and used for the therapy of 
alcohol dependence. A brief overview is given in Table 2.  
 
Table 2: Approved (light grey) and off-label (white) pharmacotherapies for the treatment of 
alcohol dependence. References show reviews on the use of the medication in alcohol 
dependence. 
Compound Mode of action Approved 
in US 
Approved 
in EU 
Reviewed 
in/ 
Reference 
Naltrexone Opioid receptor 
antagonist 
1994 2010 (34) 
Nalmefene Opioid receptor 
antagonist 
1995 2013 (43, 44) 
Disulfiram Acetaldehyde 
dehydrogenase inhibitor 
1948 1950’s (17, 18) 
Acamprosate Modulator of glutamate 
system 
2004 1989 (19, 45) 
Gabapentin Enhancement of GABA 
activity 
1993 
(adjuvant) 
1995 (antiepileptic, to 
treat neuropathic pain) 
(46) 
Baclofen GABAB receptor agonist 1988 (to treat multiple 
sclerosis, spinal cord injury) 
1970 
(myotonolyticum) 
(47) 
Ondansetron Serotonin receptor 
antagonist 
2006 (to treat chemotherapy 
and postsurgical nausea)  
1990 (to nausea and 
vomiting) 
(48) 
Topiramate Glutamate receptor 
antagonist, facilitates 
GABA currents 
1996 (anticonvulsant/ 
antiepileptic) 
1998 (antiepileptic) (48, 49) 
 
Gabapentin is an approved medication for the treatment of epilepsy and neuropathic pain but 
has also been successfully used for the therapy of mild withdrawal and alcohol dependence. It 
appears to increase the time to first heavy drinking, reduces the number of heavy drinking 
days, and has positive effects on mood and sleep (46).  
Baclofen’s effects have been studied preclinically where it reduced alcohol self-
administration. Although some clinical trials report promising results (50-52) the overall 
picture is inconsistent and more clinical trials are required (47).  
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Ondansetrone which is approved for chemotherapy and the reduction of postsurgical nausea 
has positive effects on abstinence days and drinking intensity (48, 53, 54). However, more 
studies are needed to establish its beneficial effects in the treatment of alcohol dependence.  
Topiramate has been shown to reduce heavy drinking but side effects are strong and reduce 
clinical utility (48).  
 
As only few approved pharmacotherapies are available for alcohol relapse prevention, further 
studies on potential treatment targets are warranted.  
 
1.2 THE ENDOGENOUS OPIOID SYSTEM 
Opium has been used for recreational and medical reasons for thousands of years as it induces 
euphoria, analgesia, and sleep. However, the most prevalent and active alkaloid in opium, 
morphine, has only been isolated at the beginning of the 19th century by the German 
pharmacist Sertüner (Figure 2) (55). While the term “opiates” summarizes natural alkaloids 
like morphine contained in opium, “opioids” refers to all substances inducing morphine-like 
effects which can be blocked by opioid receptor antagonists such as NTX. This includes 
opiates, synthetic substances, and endogenous opioid peptides. 
 
 
Figure 2: Timeline of the discovery of the endogenous opioid system. Even though morphine, a natural 
alkaloid of opium, was known since the early 19th century, it took until the 1970’s to identify the opioid receptors 
and their endogenous ligands (56-60). 
 
Although it was believed that opioid-like compounds have endogenous binding sites in the 
nervous tissue, it took several years to identify and classify the opioid receptors (56-60). 
Eventually, three different receptors were characterized: µ- (MOR), δ- (DOR), and κ- (KOR) 
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opioid receptors. Also in the 1970’s, the endogenous opioid peptides, Leu-enkephalin and 
Met-enkephalin (61), β-endorphin (62), and dynorphins were discovered (63).  
 
1.2.1 THE ENDOGENOUS OPIOID LIGANDS 
All endogenous opioid peptides are produced by proteolytic cleavage of the three precursor 
proteins proopiomelanocortin (Pomc), preproenkephalin (Penk), and preprodynorphin 
(PDYN) (64-67). In the mammalian brain, Penk and Pdyn mRNA expression is widely 
distributed while Pomc expressing cell bodies are restricted to only few regions: the median 
eminence/arcuate nucleus of the hypothalamus, the pituitary, and nucleus tractus solitarius 
(68, 69)(Figure 3). However, Leriche et al. (70) detected Pomc mRNA also in the prefrontal 
cortex, the Acb and ventral tegmental area (VTA). Pomc is the precursor of several 
biologically active neuropeptides, such as β-endorphin, β-lipotropin, adrenocorticotropic 
hormone (ACTH) and α-melanocyte-stimulating hormone (68, 71). Penk gives rise to Leu-
enkephalin, Met-enkephalin, Met-enkephalin-Arg6-Phe7, and Met-enkephalin-Arg6-Gly7-
Leu8 (72). Dynorphin A and B as well as neoendorphin and leu-enkephalin are derived from 
Pdyn (65, 73).  
All endogenous opioids possess a common NH-terminal Tyr-Gly-Gly-Phe-[Met/Leu] 
sequence which is referred to as the opioid motif. This sequence is responsible for the 
interaction with the opioid receptors. However, the opioid peptides show varying affinities for 
the different receptors. While endorphins bind equally strong to the MOR and DOR (74, 75), 
enkephalins show higher affinity for DOR than MOR and almost negligible affinity for KOR 
(60). Dynorphins exert their effects primarily through KOR (76).   
 
Table 3: Endogenous opioid peptides and their receptors (for references see text and (77)) 
Precursor Endogenous peptide Affinity for opioid receptors 
Preproenkephalin  Met-enkephalin 
Leu-enkephalin 
DOR, MOR 
(DOR >> MOR) 
Proopiomelanocortin  β-endorphin MOR, DOR 
(MOR = DOR) 
Prodynorphin  Dynorphin A and B 
Leu-enkephalin 
α- and β-neoendorphin 
KOR, MOR, DOR 
(KOR >> MOR and DOR) 
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1.2.2 THE OPIOID RECEPTORS 
Cloning of the MOR, DOR, and KOR revealed the characteristic topology of G-protein 
coupled seven-transmembrane receptors (GPCRs) and a high sequence homology among the 
receptors. Intracellularly, they interact with Gi/Go proteins. Upon activation of the receptor by 
endogenous or exogenous ligands the membrane potential, neuronal excitability and 
neurotransmitter release decreases by opening of G-protein gated inwardly rectifying 
potassium ion channels (GIRK), inhibiting voltage gated calcium ion channels and decreasing 
intracellular adenylyl-cyclase-mediated cAMP production. Moreover, second-messenger 
systems and gene expression are affected. 
 
1.2.2.1 THE NEUROANATOMICAL DISTRIBUTION OF OPIOID RECEPTORS 
The opioid receptors and endogenous opioids are broadly distributed throughout the 
peripheral and central nervous system. Their distribution and expression level can be analyzed 
by receptor autoradiography and in situ hybridization and is well studied in the rodent brain. 
Each opioid receptor has a defined expression pattern in the rodent brain, with MOR being the 
most represented opioid receptor in many subregions of the amygdala, thalamus, 
mesencephalon, and in the striatum. KOR is most expressed in brain structures such as the 
striatum, basal anterior forebrain, hypothalamus, and pituitary. DOR distribution is more 
restricted with expression in the striatum, olfactory tract, cortices and some subregions of the 
amygdala. In few brain structures, there is only one opioid receptor present, e.g. the MOR in 
specific thalamic nuclei while in many other regions the MOR and KOR are co-distributed 
(for review see (69)).  
 
The pattern of the distribution of opioid receptors and their ligands in the rodent brain is 
shown in Figure 3. 
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Figure 3: Anatomical distribution of opioid receptors and their endogenous ligands. (A) Receptor protein 
distribution in the rodent brain (red – MOR, yellow – DOR, green – KOR). The size of the icon representing the 
specific receptor indicated the amount of expression in the shown brain area. (B) Distribution of opioid receptor 
mRNA expressing cell bodies. (C, D) Expression of proopiomelanocortin (POMC – purple), preproenkephalin 
(PENK – orange), and dynorphin (DYN – blue) peptides (C) and mRNA (D). Adapted from (69).  
 
 
In the human brain, expression of opioid receptors has been studied since the early 1980s and 
the expression pattern of MOR (78-93), DOR (79, 82, 84, 86, 89, 90, 93, 94), and KOR (79, 
86, 89, 90, 92, 93, 95) are well known. Overall, the distribution is similar to the rodent brain. 
However, human brain structures do not always match the rodent brain, e.g. the caudate 
putamen (one combined structure) in the rodent brain corresponds to two regions in the 
human brain (nucleus caudatus and putamen). Thus, the expression pattern of receptors can be 
different. For instance, Voorn et al. (78) demonstrated MOR expression in a dorso-ventral 
gradient with higher expression in the ventral part of the nucleus caudatus in human post-
mortem brain slices. In the rodent brain, however, the MOR is enriched in striatal patches 
(striosomes). 
 
1.2.2.2 REGULATION OF OPIOID RECEPTORS 
Opioid receptors can be regulated at different levels, including transcription and translation, 
de-/resensitization and internalization processes, or receptor affinity (Figure 4). Additionally, 
intracellular signaling can be affected by disturbances in signaling cascades or altered 
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coupling of the receptor to G-proteins. The adapter protein β-arrestin (βArr) is an important 
modulator of opioid receptor signaling. After ligand-induced activation, G-protein receptor 
kinases (GRK, mainly GIRK2 and GRK3) phosphorylate the receptor which increases the 
affinity for β-arrestin2 binding and, thus, triggers endocytosis. The receptor can afterwards be 
degraded or recycled back to the cell surface membrane (96). In various animal models, a role 
of β-arrestin2 in alcohol reward processes has been proven. For instance, alcohol-preferring 
AA rats show elevated levels of β-arrestin2 expression (97). Furthermore, knockout mice 
lacking β-arrestin2 show maximum alcohol-induced DA release at lower doses as compared 
to wildtype mice and display increased conditioned place preference indicating an important 
role of β-arrestin2 in alcohol reward.  
Interestingly, the β-arrestin2 protein has been shown to be associated with MOR availability 
and function (98-102). For instance, enhanced MOR G-protein coupling was observed in the 
β-arrestin2 knockout mice after a low dose of alcohol (98). However, the β-arrestin2-
dependent receptor regulation is not specific for opioid receptors but occurs in various GPCRs 
including DA receptors (103). Additionally, arrestins can mediate G-protein-independent 
signaling processes.  
In the presented thesis, various levels of opioid receptor regulation, i.e. transcription, cell 
surface density, G-protein coupling and β-arrestin2 expression in association with MOR, are 
analyzed.   
 
Figure 4: Possible levels of regulation of opioid receptors. Expression of receptors can be affected by changes 
on the transcriptional or translational level, thereby affecting cell surface densities. Post-translational or 
conformational changes may have an impact on receptor-ligand affinity. Intracellularly, the opioid receptors are 
coupled to G-proteins. A decrease in coupling can influence receptor signaling. Upon ligand binding, G-protein 
subunits (α and βγ) are activated and signaling cascades are initiated. The receptor is phosphorylated and β-
arrestin binding induces receptor internalization.   
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1.2.3 THE ENDOGENOUS OPIOID SYSTEM IN ALCOHOL DEPENDENCE 
The endogenous opioid system is – together with other neurotransmitter systems, mainly the 
dopamine system – involved in modulating reward and is critical in addictive behaviors and 
has been the subject of numerous preclinical and clinical studies.  
 
1.2.3.1 THE µ-OPIOID RECEPTOR (MOR) 
Human studies 
In human subjects, positron emission tomography (PET) brain scans are the method of choice 
to investigate alterations of neurotransmitters or receptors. Mitchell et al. (104) measured the 
displacement of the radiolabelled MOR agonist [11C]-carfentanil to study alcohol-induced 
changes in the level of endogenous opioids before and immediately after alcohol consumption 
in heavily drinking and control subjects. In both groups, carfentanil binding was significantly 
reduced in the Acb following alcohol consumption indicating alcohol-induced accumbal β-
endorphin release (104). Furthermore, it is proposed that this activation of the endogenous 
opioid system also leads to increased dopamine release. Indeed, remifentanil activation of 
MOR causes dopamine release as measured by displacement of the radiotracer [18F]-fallypride 
(105). 
Various studies investigated the opioid receptor status in human alcoholics using [11C]-
carfentanil or [11C]-diprenorphin PET studies reporting increased or unchanged MOR 
availability (106-108). Furthermore, Heinz et al. correlated the increased MOR availability 
with craving (107). This and the ability of opioid antagonists to block [11C]-carfentanil 
binding in abstinent alcoholics (32) gives the rational to treat alcohol dependence with opioid 
antagonists such as naltrexone and nalmefene.  
The interpretation of PET studies, however, is challenging. When using receptor agonists such 
as [11C]-carfentanil as tracers, the measured binding potential BPND cannot directly be 
translated into the amount of surface receptors because endogenous opioids compete with the 
tracer for receptor binding sites (Figure 5). Hence, increased MOR availability as measured in 
the studies mentioned above could represent a decrease in endogenous ligands leaving more 
receptors available for the PET tracer. It is therefore highly important to determine the actual 
state of the opioid receptors in alcohol dependence and abstinence as they are the target of the 
anti-relapse pharmacotherapies naltrexone and nalmefene. One method to achieve this, is the 
autoradiographic analysis of human post-mortem brain tissue.  
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Figure 5: An increase in PET signal can be caused by altered receptor density or peptide levels or both. 
PET signals measured in healthy controls and diseased individuals are indicated by solid and dashed arrows, 
respectively. (A) Elevated receptor densities with stable ligand levels result in an increase in PET signal. (B) 
Similar results can be observed when receptor levels stay constant but ligand levels are decreased since the 
radiotracer does not have to compete with the endogenous ligand. (C) When receptors and ligands both are 
decreased to a similar extent, no alterations in PET signal intensity can be found. (D) With a stronger decrease in 
peptide levels, however, an increased in PET signal is seen. RC/RD – receptor density in controls/diseased 
individuals, PC/PD – peptide levels in controls/diseased individuals, SC/SD – signal intensity measured by PET in 
controls/diseased individuals. 
  
 
Animal studies 
The MOR is the most studied opioid receptor in the context of alcohol addiction. Mice 
deficient of the MOR gene have been generated in various labs. Those animals do not self-
administer alcohol and show reduced anxiolytic effects of low doses of alcohol (109). This 
indicates an important role of the MOR in alcohol dependence. However, the state of the 
MOR after chronic alcohol administration is unclear as results on MOR expression appear to 
be inconsistent (Table 4). This is most likely caused by the differences in study designs as 
various animal strains, alcohol administration paradigms, and methods for MOR detection 
were used. Furthermore, animals used in these studies are most likely not severely alcohol 
dependent. The focus of most studies was to analyze the expression of MOR immediately 
after chronic alcohol administration or during acute withdrawal. 
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Table 4: Overview of studies investigating the state of MOR after chronic alcohol. 
Results are inconsistent. ↑  increase,  ↓  decrease, ↔  unchanged MOR expression or G-
protein coupling, 2BFC – voluntary alcohol consumption in a two bottle free choice 
paradigm. 
Animals Alcohol 
paradigm 
MOR detection Finding (Striatum) Reference 
C57BL6 and 
DBA/2 mice 
2BFC (10% 
ethanol) 
PCR ↔ 
also during acute 
withdrawal 
(110) 
Fawn-Hooded 
rats 
2BFC (5% 
ethanol) 
[125I]FK-3382 binding ↑ (111) 
Wistar rats Ethanol as only 
liquid source 
[3H]-Damgo binding ↓ 
Also during acute 
withdrawal 
(112) 
Fawn-Hooded 
rats 
2BFC (5% 
ethanol) 
Damgo stimulated 
[35S]-GTPγS binding 
↓ 
slight recovery after 
48h withdrawal 
(113) 
Fawn-Hooded 
rats 
2BFC (5% 
ethanol) 
[125I]FK-3382 binding ↑ 
at different time points 
during withdrawal 
(114) 
Long Evans rats Ethanol self-
administration 
Damgo stimulated 
[35S]-GTPγS binding 
↔ 
 
(115) 
Sprague-
Dawley rats 
Liquid diet (6.7% 
ethanol) 
Damgo stimulated 
[35S]-GTPγS binding 
↔ 
 
(116) 
Sprague-
Dawley rats 
Liquid diet (6.7% 
ethanol) 
Immunohistochemistry ↓ (117) 
Wistar rats 2BFC (10% 
ethanol) 
Damgo stimulated 
[35S]-GTPγS binding 
↓ (118) 
Wistar rats Ethanol as only 
liquid source 
Membrane binding 
[3H]-Damgo 
↔ 
 
(119) 
Wistar rats 2BFC (6% 
ethanol) 
PCR ↑ 
after 2 and 4 months of 
2BFC, but not after    
10 months 
(120) 
 
 
The influence of the MOR single nucleotide polymorphism A118G 
Many polymorphisms have been found in the opioid receptor genes. For the OPRM1 gene 
encoding the MOR, the single nucleotide polymorphism (SNP) A118G (rs1799971) is the 
most studied in the context of drug dependence (121). It was first described in 1998 (122) as 
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an exchange of adenine by guanine at nucleotide 118 (A118G) resulting in an amino acid 
exchange in the amino-terminal extracellular domain of the MOR, i.e. asparagine (N) is 
replaced by aspartate (D) (N40D). It affects MOR glycosylation, stability (123) and has been 
proposed to increase the receptors affinity for the endogenous ligand β-endorphin (122). 
However, several studies failed to replicate the latter (124-127). The frequency of the less 
common (minor) G-allele varies among populations with about 40-50% in Asians but only 
15-30% in Europeans and is very rare (1-3%) in individuals of African or Hispanic ancestry 
(128-130). It might cause decreased OPRM1 expression in G-allele carriers (125, 131, 132). 
However, these studies did not include striatal brain tissue but rather analysed the global brain 
than specific areas, post-mortem pons tissue or cell cultures.  
Various studies indicate a role of this genetic variant in alcohol dependence. Results on the 
association between the SNP and the risk for alcohol dependence vary (133-137) but a meta-
analysis shows no increased risk for substance dependence (138). A number of studies 
indicate a role of this genetic variant on the reinforcing and rewarding effects of alcohol (139-
142). 
To extend the knowledge on the impact of the OPRM1 SNP A118G (rs1799971) different 
transgenic animal models were generated, including rhesus macaques with a functionally 
equivalent SNP (C77G resulting in P26R)(143), a mouse model carrying the equivalent 
substitution in the mouse Oprm1 gene (A112G) (144), and two mouse lines possessing the 
human MOR sequence carrying either the A- or G-allele (127). Studies in these animals 
support the assumption of a role of this SNP in alcohol-related behavior and suggest better 
treatment outcome of G-allele carriers after NTX therapy (145). 
 
1.2.3.2 THE δ-OPIOID RECEPTOR (DOR) 
Human studies 
The DOR is far less well studied than MOR. Human PET imaging studies in alcoholic 
subjects are very limited and revealed unchanged DOR availability measured with the 
radiotracer [11C]-methyl-naltrindole (106, 146). Plasma levels of the DOR ligand enkephalin 
appears to be unchanged during alcohol withdrawal and abstinence (147). This is in contrast 
to the decline in plasma β-endorphin levels that have been observed during withdrawal (147). 
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Animal studies 
Mice deficient of DOR consume more alcohol as compared to wildtype mice indicating a role 
of DOR in alcohol intake behavior. This may be linked to increased anxiety in these animals 
and, thus, represent a self-medication approach to reduce anxiety levels (148, 149). After 
chronic alcohol intake, however, DORs are increased or unchanged (110, 112, 117).  
Application of DOR antagonists in the VTA induce alcohol consumption while activation of 
the DOR by the specific agonist DPDPE ([D-Pen2,5]Enkephalin, [D-Pen2,D-Pen5]enkephalin) 
decreases alcohol intake (150). This most likely is mediated by inhibiting GABAergic 
terminals by DOR agonists in alcohol consuming rats and this is linked to anxiety (150, 151).  
However, the state of DOR in alcohol-dependent animals during protracted abstinence was, so 
far, not subject to investigations and remains unclear. 
 
1.2.3.3 THE Κ-OPIOID RECEPTOR (KOR) 
The development and evaluation of KOR-selective ligands suitable for PET studies is in 
progress (33, 152) but no data of KOR availability in alcoholic subjects are available. 
Therefore, studies of the state of the KOR/dynorphin system are restricted to post-mortem 
tissue analysis of control and alcoholic subjects. Previous post-mortem studies found 
increased dynorphin A and B in prefrontal brain regions and the hippocampus (153, 154) 
while dynorphin A was decreased in the putamen (155). In the nucleus caudatus, dynorphin A 
and B were unchanged (155). Unfortunately, neither OPRK1 mRNA nor KOR surface density 
were analyzed in the same sample set of human post-mortem tissue and, thereby, no complete 
overview can be given on the state of KOR/dynorphin system in the striatum of those 
alcoholics.  
 
Animal studies 
Kissler et al. found increased G-protein coupling and dynorphin immunoreactivity in alcohol-
dependent rats during withdrawal and these increases in KOR activity have been linked to 
aversion as measured by augmented 22 kHz ultrasonic vocalizations (156). Interestingly, 
blockade of KOR by intra-amygdala infusions of nor-BNI resulted in decreased alcohol self-
administration in dependent but not non-dependent rats in the same study (156). Also intra-
accumbal and intra-cerebroventricular infusion of nor-BNI attenuated operant responding for 
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alcohol selectively in dependent animals while not affecting non-dependent self-
administration (40, 41). Moreover, primates voluntarily consuming alcohol display 
supersensitivity of the KOR/dynorphin system in the ventral and dorsal striatum that 
correlates with drinking behavior (157).  
These observations indicate an upregulation of the KOR/dynorphin system in alcohol 
dependence which increases the anhedonic effects associated with alcohol consumption and 
withdrawal. Indeed, increased dynorphin and KOR mRNA expression in the Acb has been 
reported (158-160). 
 
1.2.3.4 COMBINED ACTION OF OPIOID RECEPTORS AND THEIR LIGANDS 
Acute alcohol administration releases β-endorphin, enkephalin, and dynorphin in a time 
specific profile: β-endorphin increases within 30 min after acute alcohol administration which 
is followed by an increase in dynorphin 1.5 to 2 hours later (161, 162). While β-endorphin 
and enkephalin are known to mediate the positive reinforcing effects by activating MOR and 
DOR, dynorphins are implicated in mediating the aversive effects of alcohol by stimulating 
KOR. It has been proposed that after chronic alcohol consumption positive effects are 
attenuated and negative effects are increased (163, 164)(Figure 1).  
 
1.2.3.5 THE OPIOID SYSTEM AS TARGET FOR PHARMACOLOGICAL RELAPSE PREVENTION 
As briefly mentioned above, the pharmacotherapies naltrexone (NTX) and nalmefene are 
targeting the endogenous opioid system to reduce alcohol relapse in dependent individuals.  
In human alcoholics, the efficacy of NTX has been supported by meta-analysis (34). 
However, its effect size is small (165). This might reflect heterogeneity among patients as 
some individuals seem to improve dramatically while others show no response to NTX 
pharmacotherapy demanding for personalized treatment approaches (165). Indeed, it has been 
reported that a family history of alcoholism, which can reflect both environmental and/or 
genetic factors, positively influences therapeutic effects (166-168), while NTX can even 
increase alcohol drinking in individuals without a family history of alcohol dependence (167).  
In animals with high alcohol consumption NTX has been proven to reduce alcohol intake  
(169) as well as preference (170) and to block alcohol-seeking in rats (171-173). On the 
cellular level, NTX reduces dopamine release in the striatum of rats (174, 175). This is 
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somehow surprising considering the PET studies stating a hypodopaminergic state during 
abstinence.  
NTX has a relatively low plasma half-life of about four hours in humans and is metabolized to 
β6-naltrexol by the enzyme dihydrodiol dehydrogenase. This active metabolite has a half-life 
of about eleven hours but its role in NTX therapy is, so far, unresolved (176). In Wistar rats, 
NTX’s half-life is only about one hour after intravenous bolus injection but β6-naltrexol is 
below the detection limit indicating that it is not a major metabolite in rats (177).  
 
The majority of studies, however, focus on the influence of the SNP A118G of the OPRM1 
gene as a determinant of treatment outcome. The first meta-analysis reviewing publications on 
the association between the SNP A118G and response to NTX treatment in alcohol dependent 
patients found that G-allele carriers had lower relapse rates than AA-allele carriers (178). 
However, some studies do not support the hypothesis that the G-allele moderates the response 
to NTX (179-181) and a more recent meta-analysis states that more studies are needed to 
prove the impact of this genetic variant on NTX treatment outcome (182). On the molecular 
level, a PET study demonstrated slightly higher NTX occupancy in G-allele carriers as 
compared to controls although the results did not reach significance (132).  
Animal models for the A118G SNP in mice and monkeys support the assumption of a better 
treatment outcome in G-allele carriers. NTX attenuated alcohol preference (143) and intake in 
monkeys carrying the minor allele that were trained to self-administer alcohol (183). In a 
mouse model carrying the A118G SNP, naltrexone moderated alcohol reward processes and 
reduced alcohol consumption in 118GG but not 118AA mice (145).  
Another factor influencing NTX efficacy might be the severity of alcohol dependence. 
Various authors suggest that more severely diseased patients benefit less from NTX 
pharmacotherapy (37, 184).  
Furthermore, several studies report that NTX modulates cortisol release by affecting the 
hypothalamic-pituitary-adrenal (HPA) axis (Figure 6), a major stress response pathway, 
which is dysregulated in alcohol-dependent patients (185, 186). Alcohol-dependent patients 
display a dysregulated HPA axis response, i.e. blunted cortisol response. By antagonizing 
MOR function, NTX has been shown to enhance cortisol levels in healthy controls and 
alcohol-dependent subjects.  
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Figure 6: Stress and alcohol induce the production of corticotropin-releasing hormone (CRH) in the 
hypothalamus. The release of CRH is regulated by opioids, GABA, norepinephrine (NE), and serotonin (5-
HAT). CRH causes β-endorphin release in the same brain region. Additionally, CRH is transported to the 
pituitary gland where it stimulates the production of Pomc. Pomc is then transformed to ACTH, β-endorphin 
(bEND) and others. ACTH induces cortisol synthesis and release from the adrenal gland. When cortisol reaches 
a certain level, CRH and ACTH production are reduced via feedback mechanisms. Adapted from (185). 
 
Taken together, previous research on the endogenous opioid system proves its importance in 
the development and maintenance of alcohol dependence. However, the state of the opioid 
system in alcohol abstinence as target of the anti-relapse therapies naltrexone and nalmefene 
remains unclear as human PET studies are ambiguous to interpret.  
 
1.3 THE DOPAMINE SYSTEM  
The description of dopamine (DA) as an independent neurotransmitter of the central nervous 
system (187, 188) was followed by the identification and classification of the dopamine 
receptors (189, 190) which are now divided into two classes: D1-like (including D1 and D5 
receptors) and D2-like (including D2, D3, and D4 receptors) dopamine receptors. All 
dopamine receptors are members of the GPCR family but differ in their affinity for dopamine, 
pharmacological profiles, mechanisms of action, and have distinct expression patterns 
throughout the nervous system (191). D1 receptors are highly expressed in nigrostriatal, 
mesolimbic, and mesocortical areas, including the dorsal (caudate-putamen) and ventral (Acb) 
striatum, amygdala and frontal cortex. D2 receptors are also enriched in the striatum but 
additionally expressed in other regions such as the substantia nigra and VTA. D3, D4, and D5 
receptors appear to have lower and/or more restricted patterns of distribution in the brain 
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(191). The postsynaptically expressed D1-like receptors enhance the formation of cyclic 
adenosine monophosphate (cAMP) and protein kinase A activity (192). D2-like receptors, 
which are pre- and postsynaptically located (193), inhibit cAMP synthesis. Presynaptically 
expressed receptors act as autoreceptors that are usually activated at lower dopamine 
concentrations and provide an important negative feedback mechanism by regulating neuronal 
firing rate and dopamine synthesis and release (194-197). 
Dopamine itself is synthesized in neurons and stored in vesicles until the dopaminergic 
neurons are activated. The dopamine containing vesicles fuse with the cell membrane by 
calcium-dependent mechanisms and dopamine is released into the synaptic cleft. The 
dopamine transporter (DAT) on presynaptic cells clears the dopamine from the synaptic cleft 
into the cytosol from which it is transported back into vesicles. Dopaminergic neurons are 
tonically active, meaning low amounts of neurotransmitter in the nanomolar scale are 
continuously released by single spike action potentials and achieve a stable extracellular 
dopamine level. In response to behaviorally relevant stimuli the neurons respond with phasic 
burst firing releasing dopamine in micro- to millimolar concentrations (198).  
 
 
Figure 7: Dopaminergic pathways in the human brain. Dopaminergic cell bodies within the substantia nigra 
(SN) project via the nigrostriatal pathway to the dorsal striatum (DS). Dopaminergic neurons within the ventral 
tegmental area (VTA) innervate the ventral striatum (VS) and the prefrontal cortex (PFC) via the mesolimbic 
and mesocortical pathway, respectively.  
 
 
Dopaminergic neurons in the brain are relatively few in number and their somata are 
restricted to defined areas. Fuxe and Dahlström (199) were the first to map these cell groups 
in 1964 which are organized in several pathways that originate in the midbrain. In the rodent 
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nigrostriatal pathway (Figure 7, blue), neurons with their cell bodies located in the substantia 
nigra project mainly to the dorsal striatum, i.e. the caudate (200) and are particularly 
important for locomotor regulation. Limbic and cortical areas are innervated by dopaminergic 
neurons from the VTA (201). Based on the projection fields the mesocortical and mesolimbic 
dopamine pathways are distinguished (Figure 7, red). The mesocortical projections innervate 
prefrontal cortical areas and are implicated in higher motor execution of behavior, motivation 
and cognition. The dopaminergic neurons of the mesolimbic pathway project to the ventral 
striatum, including the Acb, olfactory tubercle, septal area, amygdala, and the bed nucleus of 
the stria terminalis (202) which is crucial for the mediation of emotion and reward.  
 
 
1.3.1 THE DOPAMINE SYSTEM IN ALCOHOL DEPENDENCE 
Human studies 
The method of choice to investigate the brain dopamine system in humans is brain imaging by 
positron emission tomography (PET). While there are no PET data available on the state of 
the dopamine D1 receptor in human alcoholics, studies focusing on D2-like receptors mostly 
used the radiotracer [11C]-raclopride. Displacement of this PET tracer has been used as 
indirect measure of alcohol-induced dopamine release in healthy social drinkers (127, 203). In 
alcohol dependent patients, a blunted dopamine response to drug administration and reduced 
availability of D2-like receptors has been reported (204-210). This decrease in [11C]-
raclopride binding has collectively been interpreted as a decrease in D2-like receptors and low 
mesolimbic extracellular dopamine levels. However, the interpretation of in vivo PET data is 
ambiguous as decreases in PET signal can either be caused be decreased receptor availability 
or increased endogenous ligands (Figure 5). Endogenous ligands compete with the radiotracer 
for binding the receptor and, thus, can change the signal intensity. However, some studies 
report unchanged or even increased D2 receptor densities (211, 212). Interestingly, naltrexone 
reduces alcohol-induced striatal dopamine release (174, 175) which seems to be at odds with 
the importance of a hypodopaminergic state for relapse propensity.  
 
Animal studies 
Various studies established that alcohol consumption results in dopamine release in animals 
and human subjects that is associated with reward (13), while acute withdrawal from chronic 
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alcohol decreases dopamine neurotransmission (213-215). This is accompanied by reduced 
levels of tyrosine hydroxylase, the enzyme catalyzing the rate limiting step in the production 
of dopamine (213), an increase in reuptake of dopamine by the DAT and D2 autoreceptor 
supersensitivity (215).  
Decreased activity of dopaminergic neurons originating within the VTA and the reduced 
accumbal dopamine release during withdrawal have led to the assumption that alcohol 
dependence is a reward deficit disorder (216-218). These findings are supported by human 
positron emission tomography studies (see above “Human studies”). 
 
In summary, the state of the dopamine system during acute withdrawal is well established 
showing decreased dopamine release. Although human PET studies also investigated changes 
in this system during abstinence, the interpretation of the available data is challenging. 
Additionally, the state of the dopamine system during (protracted) alcohol abstinence remains 
unclear.  
 
1.4 THE DOPAMINE AND OPIOID SYSTEM INTERACT TO MEDIATE REWARD 
The mesolimbic dopamine and endogenous opioid system interact to mediate rewarding 
effects. Alcohol enhances dopamine release in the Acb via a GABAergic feedback 
mechanism to the VTA. Alcohol increases the firing rates of accumbal GABAergic neurons 
innervating the VTA by activating MORs. This results in inhibition of tonically activated 
GABAergic neurons within the VTA which normally hold dopaminergic neurons of the 
mesolimbic pathway under inhibitory control. Dopaminergic neurons projecting to the Acb 
are thereby disinhibited resulting in increased dopamine release in the Acb after alcohol 
administration (219, 220). Additionally, DORs in the Acb and VTA increase striatal 
dopamine release and KORs located in the Acb inhibit dopamine release (220-222). This 
feedback mechanism is described in Figure 8. 
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Figure 8: Feedback loop between the nucleus accumbens (Acb) and ventral tegmental area (VTA). In an 
alcohol-free state, small GABAergic interneurons (red) keep the dopaminergic neurons (yellow) of the 
mesolimbic pathway under inhibitory control. With alcohol present, the firing rate of accumbal GABAergic 
neurons projecting innervating the VTA is increased, thereby inhibiting the small interneurons within the VTA. 
Additionally, endogenous opioids, i.e. β-endorphin, are released which are further decreasing neuronal 
excitability of the small GABAergic neurons by activating the MOR. This causes disinhibition of dopaminergic 
projection neurons and increased accumbal dopamine release. Adapted from (223).  
 
In the late 1970’s and early 1980’s, also endorphins and enkephalins have been proposed to 
possess intrinsic rewarding properties (224-226) as endogenous opioids as well as other MOR 
and DOR agonists such as Damgo and DPDPE are self-administered into the Acb and VTA 
by laboratory animals (227, 228). KOR agonists, however, produce aversive effects (229). 
The endogenous opioid system is thought to exert its rewarding effects, at least in part, by 
modulating the mesolimbic dopamine system (220, 222, 230). However, only in 2001 Olive et 
al. (231) finally demonstrated that drugs of abuse, including alcohol, trigger rewarding effects 
by releasing endogenous opioids.  
 
Additionally, several studies suggest the existence of a reverse regulation of the endogenous 
opioid system by dopamine. Stimulation of dopamine D1 receptors appears to activate the 
dynorphin system whereas D2 receptors hold the enkephalin system under inhibitory control 
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(232). Furthermore, dopamine-induced release of β-endorphin has been observed in the Acb 
by in vivo microdialysis experiments and was blocked by dopamine antagonist pre-treatment 
(233). 
 
Even though many studies investigated alcohol dependence-induced alterations in the brain, 
the focus was set on time points during acute or chronic alcohol administration or alcohol 
withdrawal. Studies on neuroadaptive changes during protracted alcohol abstinence are less 
frequent. One aim of this thesis is to fill these gaps.  
   
1.5 THE POST-DEPENDENT ANIMAL MODEL 
Animal models of psychiatric disorders, including alcohol dependence, are usually evaluated 
by their face, predictive and construct validity (234).  Face validity describes the similarity of 
the model to the actual disease symptoms in humans. Predictive validity, refers to the model’s 
ability to accurately respond to (pharmacological) treatments, meaning a treatment that has 
been found to be useful in human alcoholics has a comparable effect in the animal model. 
Construct validity can be described as the similarity between mechanisms underlying the 
behavior of the model and the actual disease.  
To date, various animal models for alcohol dependence have been established which can be 
divided into two main classes. The first category depends on alcohol-induced 
neuroadaptations after chronic drug exposure while the second class is based on genetically 
encoded alcohol preference. In this thesis a model of the first category, the post-dependent 
animals, has been used to study long-lasting neuroadaptations in protracted abstinence. 
Alcohol dependence develops through the repeated exposure to and withdrawal from the drug 
resulting in increased withdrawal severity. To mimic these processes, the chronic intermittent 
exposure to alcohol vapor (CIE) is a well-established tool (Figure 9). It is a reliable and easily 
controllable method to increase brain alcohol to relevant levels. Alcohol vapor is inhaled by 
the animals for 14 to 16 hours/day over several weeks or months. Consequently, animals 
show excessive voluntary alcohol intake, compulsive behavior with loss of control, increased 
tolerance to the drug, and hypersensitivity to stress (235). This phenotype, comprising long-
lasting neuroadaptations that remain even during long periods of abstinence, was named the 
“post-dependent state” (14).  
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Figure 9: The post-dependent animal model. (A) Rats are housed in their home-cages in the exposure 
chambers and are exposed to chronic intermittent cycles of alcohol vapor (CIE) or air (controls) for 7 weeks. (B) 
Ideally, blood alcohol concentrations (BAC) rise daily to levels of 150-250 mg/dl. The inlet shows the time 
course of blood alcohol levels over one day of alcohol exposure. During the 16 hours of alcohol vapor exposure 
levels increase continuously. The remaining hours, animals are exposed to air and blood alcohol concentrations 
decrease rapidly. This procedure results in the post-dependent phenotype. (C) Following three weeks of 
abstinence, the post-dependent rats consume high amounts of alcohol in a two-bottle fee choice paradigm. 
Adapted from (235). 
 
The construct validity of the alcohol-vapor induced post-dependent state has been shown for 
different brain neurotransmitter systems and regions. For example, similar dynamic changes 
in brain glutamate levels during withdrawal and abstinence have been observed in humans 
and post-dependent rats (236). Additionally, increased activity of the amygdala in response to 
stress has been shown in post-dependent animals (237, 238) as well as human alcoholics 
(239). Concerning the face validity of this animal model, there has been some criticism as the 
alcohol administration is forced onto the animals and the mode of intake differs from human 
alcoholics. However, the consequences of dependence are the major subject of studies and are 
more important than how dependence develops. The disease symptoms in post-dependent 
animals correspond well to the human situation and fulfill several criteria of the DSM-IV/-5, 
such as withdrawal signs, tolerance, loss of control and an increase in voluntary alcohol 
consumption. Most importantly, the post-dependent animal model shows high predictive 
validity and allows for studies aiming at the development of new medications. For example, 
the administration of the opioid receptor antagonists naltrexone and nalmefene, both of which 
are clinically approved anti-relapse medications, produces a decrease in alcohol consumption 
in post-dependent animals. In addition, acamprosate has been shown to reduce alcohol intake 
in post-dependent rats but did not affect non-dependent drinking (240). Established 
medication effects in post-dependent animals were recently reviewed in (235).  
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In this thesis, the term “post-dependent” will be used to describe animals where alcohol 
dependence was induced by seven weeks of CIE. 
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2 AIMS 
Lack of knowledge: 
 Theories on the state of the endogenous opioid and dopamine system during alcohol 
abstinence are based on human PET studies, e.g. using [11C]-carfentanil, investigating 
patients in long-term abstinence. However, the interpretation of PET data is very 
challenging as results are not only influenced by the density of the receptor itself but 
also by the availability of the endogenous ligand. Additionally, the impact of the 
OPRM1 SNP A118G on MOR density levels has not conclusively been established.  
 
 Many studies focused on alcohol-induced neuroadaptations in MOR system that is 
thought to be the target of the anti-relapse medications naltrexone and nalmefene. 
However, the nature of these neuroadaptations during alcohol abstinence and their 
underlying mechanisms remain unclear as the focus of preclinical alcohol research 
was set on the acute effects of the drug and withdrawal after induction of alcohol 
dependence.  
 
 The state of the endogenous opioid system, i.e. the DOR/enkephalin system, in 
protracted abstinence is so far not clear, even though it may also be a target of NTX 
and nalmefene treatment.  
 
 The regulation of the dopamine system and its state during protracted abstinence is not 
completely resolved, although a hypodopaminergic state has been observed during 
acute withdrawal. However, this appears to contradict the observation that NTX 
reduces alcohol-induced dopamine release in dependence.  
 
The knowledge on the state of the endogenous opioid and dopamine system during protracted 
abstinence is crucial for the development of new and the improvement of existing 
pharmacotherapies for relapse prevention. Furthermore, it may help to establish personalized 
treatments as many researchers and physicians are demanding for (184, 241). 
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The following aims were defined for this thesis:  
 
Aim 1:  
To demonstrate the state of the endogenous opioid system in alcohol 
dependence 
 
Aim 2:  
To study the effects of chronic naltrexone on the endogenous opioid system in 
protracted alcohol abstinence 
 
Aim 3:  
To demonstrate neuroadaptations in the dopamine system during acute alcohol 
withdrawal and protracted abstinence  
  
 43 
 
List of studies: 
 
Study I:  
Low µ-opioid receptor status in alcohol dependence assessed by combined PET and 
post-mortem brain analysis (Aim 1) 
 
Study II:  
Neuroadaptations in the endogenous opioid system in protracted abstinence (Aim 1) 
 
Study III:  
Impact of chronic naltrexone on the endogenous opioid system in alcohol dependence 
(Aim 2) 
 
Study IV:  
Convergent evidence from alcohol dependent humans and rats for a hyperdopaminergic 
state during abstinence (Aim 3) 
 
44 
 
  
 45 
 
3 MATERIALS AND METHODS 
3.1 HUMAN STUDIES 
3.1.1 HUMAN POST-MORTEM TISSUE 
Microdissected frozen brain tissue samples of alcoholic and healthy control subjects were 
obtained from the New South Wales Tissue Resource Centre (NSW TRC) at the University of 
Sydney, Australia (http://www.neura.edu.au/sydneybrainbank). Brain regions included in the 
experiments were the nucleus caudatus (NC) and the ventral striatum including the Acb (VS). 
Control subjects (n=43) consumed less than 20 g of alcohol per day while alcoholics (n=43) 
were mostly drinking more than 80 g of alcohol. Subjects assigned to the “alcohol 
abuse/dependence” group were diagnosed using the Diagnostic Instrument for Brain Studies – 
Revised (DIBS-R) which is consistent with the criteria of the Diagnostic and Statistical 
Manual for Mental Disorders, 4th edition (DSM-IV). Out of 43 alcoholic subjects, 16 
displayed blood alcohol levels of 0.195 ± 0.132 g / 100 ml (“intoxicated”) while the 
remaining 27 subjects were “not intoxicated”. Smokers and ex-smokers were combined in one 
group while non-smokers and “unknown” were also pooled, as to include only the two 
variables “smoker” or “non-smoker” in the statistical analysis. Detailed information on 
subjects such as age, toxicology, tissue pH, post-mortem interval, is shown in Suppl. Table 1.  
Additionally, a smaller and more homogenous sample set (here referred to as “core sample 
set”) was selected consisting of age-matched alcoholic and control subjects. All subjects have 
a post-mortem interval <40 hours, brain tissue pH~6, no positive blood alcohol levels and no 
significant amounts of substances known to affect the expression of neurotransmitter systems 
(e.g. opioids, benzodiazepines, concentrations <0.1 mg/L).  
 
3.1.2 POSITRON EMISSION TOMOGRAPHY (PET) STUDY IN ALCOHOL-DEPENDENT 
PATIENTS 
The PET study to assess MOR availability ([11C]-carfentanil binding potential BPND) in 
alcohol-dependent patients was conducted by Derik Hermann (Department of Addictive 
Behavior and Addiction Medicine, Central Institute of Mental Health Mannheim, Medical 
Faculty Mannheim, Heidelberg University, Germany), Matthias Reimold (Department of 
Nuclear Medicine, University of Tübingen, Germany) and colleagues and data are kindly 
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provided for this thesis. Because these data are part of a combined manuscript and helpful for 
interpretation, they are included in this thesis.   
 
Participants 
Forty alcohol-dependent patients from the Central Institute of Mental Health Mannheim, 
Germany, and the University of Tübingen, Germany, were included in this study. All patients 
were treated according to a protocol similar to the PREDICT study protocol (37) and the time 
until first heavy relapse (defined as 5 or more drinks per day for men or 4 or more drinks per 
day for women) was set as primary outcome. Inclusion criteria for the PET study were age 
(18-65 years), current DSM-IV⁄ICD 10 diagnosis of alcohol dependence, minimum of 14 
drinks (females) or 21 drinks (males) per week over a consecutive 30-day period prior to 
detoxification, at least 2 weeks of inpatient detoxification, and an alcohol abstinence of 3-28 
days. Exclusion criteria were other psychiatric diagnoses, psychotropic medication, positive 
drug urine screen test within the last 30 days, severe medical illness, pregnancy or lactating, 
and 5-fold elevated liver enzymes. Two patients did not meet criteria and were excluded from 
the statistical analysis due to considerably decreased striatal perfusion or lack of genetic 
information. Of the remaining 38 patients, 31 were carriers of the OPRM1 genotype 118AA 
and seven 118AG. Clinical characteristics of participants are shown in Table 5. 
Inpatients were treated for 2-3 weeks for withdrawal symptoms (if necessary) and with a 
psychosocial program to enhance motivation and abstinence. At the end of the inpatient 
treatment, the PET scan was performed in medication-free patients. One day afterwards, 
double-blind randomized naltrexone (50 mg, N=20) or placebo (N=18) treatment started for 
three months. This was accompanied by a simultaneous outpatient follow-up with biweekly 
medical management sessions for six months and a final visit after one year.  
All participants signed an informed consent statement that had been approved by the Ethics 
Committee of the Mannheim Medical Faculty of the University of Heidelberg. 
 
PET scan and image reconstruction 
The patient’s head was placed on an elastic mould and fixed with adhesive tape inside the 
PET scanner (GE Advance PET scanner, GE-Medical Systems, Milwaukee, USA). Three 
fiducial markers were attached to the scull to allow for support correction of head movements. 
 47 
 
After intravenous bolus injection of a maximum of 19 mCi (700MBq) [11C]-carfentanil, the 
cerebral distribution of radioactivity was measured over 72 minutes (2-dimension acquisition 
mode). A transmission scan with 500 000 kilo counts was used for attenuation correction and 
filtered back-projection (128 x 128 pixels = 30 cm) with a Hanning filter (cutoff, 4.6 mm) was 
employed to reconstruct attenuation corrected images.  
  
Characteristic  Alcohol-dependent patients 
(N = 38) 
Sex (female/male) 11 / 27 
Age (years) 46 ± 7 
OPRM1 genotype A118G 31 AA / 7 AG 
Married 37 % 
OCDS  15 ± 6 
OCDS thoughts 5 ± 3 
OCDS behavior 10 ± 4 
Alcohol dependence scale (ADS) 16 ± 6 
AUDIT 26 ± 7 
Age of onset alcohol dependence (years) 32 ± 10 
Genotype A118G 31 AA / 7 AG 
Drinking days in the last 90 days (N)  73 ± 23 
Drinks (12g) per drinking day (N) 17 ± 10 
Gamma-glutamyl transferase (U/l) 128 ± 160 
Alanine transaminase (U/l) 44 ± 27 
Volume of erythrocytes (MCV in fL) 95 ± 5 
Depressiveness (BDI) 8 ± 5 
Anxiety (STAI State) 44 ± 8 
Current smokers/ex-smoker/never 30 / 2 / 6 
ICD-10 criteria alc.-dep. (N; max 6) 5.1 ± 1.1 
DSM-IV criteria alc.-dep. (N; max 7) 5.9 ± 1.2 
Table 5: Clinical characteristics of alcohol-dependent participants of the PET study. OCDS: Obsessive 
Compulsive Drinking Scale, ADS: Alcohol dependence scale AUDIT: Alcohol Use Disorders Identification 
Test, BDI: Beck Depression Inventory, STAI: State trait anxiety inventory 
 
Image Analysis 
The availability of the MOR, as defined as [11C]-carfentanil binding potential BPND, was 
assessed from time activity curves from three striatal regions of interest (ROI). These three-
dimensional ROIs, predefined in MNI space, were placed on PET images after correction for 
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head movement, stereotactic normalization with SPM5 and spatial smoothing (8 mm full 
width at half maximum). ROI positions were adjusted with the aid of ROI outlines being 
projected on early (0-5 min after injection) and late (30-72 min after injection) summation 
images without changing their size and shape in order to adjust for anatomic variations.   
For pharmacokinetic analysis, the multi-linear reference tissue method (242) was used that is 
algebraically identical to the widely used Logan method (243) but exhibiting a lower noise 
dependent bias (242). The occipital cortex was chosen as reference tissue as MOR density is 
negligible in this region. Reference tissue washout of 0.1 min-1 and a pre-equilibrium interval 
of t*=18 min was used as parameters. The resulting BPND usually is interpreted in terms of 
BPND = fND x Bmax/KD, with fND being the free fraction of tracer in the first tissue 
compartment; Bmax, the concentration of available binding sites (MOR); and KD, the 
equilibrium dissociation constant (244). 
 
3.1.3 GENOTYPING FOR OPRM1  A118G (RS1799971) 
Post-mortem samples 
Genomic DNA was isolated from tissue samples using the QIAam DNA micro kit (Qiagen, 
USA) and the OPRM1 A118G single nucleotide polymorphism was detected by TaqMan® 
SNP Genotyping Assay (C_8950074_1; Applied Biosystems, Carlsbad, USA) on an ABI 
7900 HT RT-PCR system with SDS 2.2.2 software (10 µl reaction volume containing 10 ng 
genomic DNA, 40 cycles of 95 °C for 15 sec and 60 °C for 1 min). 
 
PET study participants 
Genomic DNA from whole blood was isolated. Genotyping was performed by primer 
extension reaction, using matrix-assisted, laser-desorption/-ionization, time-of-flight mass-
spectrometry (iPLEX Assay, Sequenom, San Diego, USA) and with a 7900HT Fast Real-
Time PCR System (C_8950074_1; Applied Biosystems, Carlsbad, USA). 
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3.2 ANIMALS 
3.2.1 CHRONIC INTERMITTENT ALCOHOL VAPOR EXPOSURE (CIE) - POST-DEPENDENT 
ANIMAL MODEL 
Male Wistar rats obtained from Charles River were group-housed (four animals per cage) 
under a 12 hours light/dark cycle with ad libitum access to water and food. Animals were 
exposed to alcohol vapor for 16 hours per day followed by normal air for 5 days a week to 
achieve blood alcohol levels of 150-250 mg/dl. This CIE lasted seven weeks and has been 
shown to induce alcohol dependence including increased voluntary alcohol consumption, 
long-lasting neuronal and behavioral adaptations (173, 235, 240).  Animals of the control 
group were kept under similar conditions breathing air. Except for the time course 
experiment, animals were sacrificed three weeks after the last alcohol exposure. All animals 
for the opioid system studies were sacrificed during their active cycle (3–5 hours after light 
off, Study II and III) but during their inactive phase for the time course experiment (2–3 
hours after light on, Study IV, see 3.2.2). After decapitation, brains were snap frozen in          
-40 °C isopentane and stored at -80 °C until further processing. 
 
3.2.2 ANALYSIS OF DIFFERENT TIME POINTS DURING ABSTINENCE IN POST-DEPENDENT 
RATS 
For the time course analysis (Study IV), animals were subjected to CIE for seven weeks as 
described above and either sacrificed immediately after the last exposure (day 0), one day 
(day 1), three (day 3) or seven days (day 7) or three weeks later (day 21).  On day 0, the 
animals still displayed positive blood alcohol values of 273 ± 52 mg/dl. Animals were kept 
under a 12 hours light /dark cycle and were killed at the same Zeitgeber time (2–3 hours after 
light on).  
 
3.2.3 NALTREXONE EFFECTS IN POST-DEPENDENT RATS 
To investigate the effects of chronic alcohol treatment on receptor and ligand expression, rats 
were exposed to CIE (“exposed”) or air (“not exposed”) for seven weeks as described above 
and kept abstinent for three weeks. Afterwards, the alcohol exposed as well as control animals 
received one daily naltrexone (2.5 mg/kg) or saline injections (i.p., 1.5 hours after light off) 
for 14 days. Three to four hours after the last injection, animals were sacrificed. The 
experimental design is visualized in Figure 20.  
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3.3 TISSUE PREPARATION (CRYOSECTIONS) OF HUMAN AND RAT TISSUE 
Transcript levels, receptor/transporter densities, and G-protein coupling of specific receptors 
were analyzed by in situ hybridization, receptor autoradiography, and [35S]-GTPγS assay 
techniques, respectively, on cryosections of human as well as rat brain tissue. For this, 
cryosections were prepared using a cryostat (Leica CM1950) and mounted onto glass slides. 
For receptor autoradiographies and [35S]-GTPγS assays, glass slides were coated with gelatin 
beforehand. 
Cryosections of human microdissected tissue samples of the caudate nucleus (NC) and the 
ventral striatum including the Acb (VS) were cut at a thickness of 10µm. For quality control 
each section was stained with a Nissl staining (Cresyl Violet) for morphological analysis after 
performing the quantitative measurements by receptor autoradiography as described below.  
For the Nissl staining, the sections were incubated in 4% paraformaldehyde for 15 min, 
washed in PBS and water for 2 min, followed by incubation in 0.1 % Cresyl Violet for 20 
min. Sections were briefly washed in water and dehydrated in increasing ethanol 
concentrations (70%, 80%, 99% EtOH) and xylene, coverslipped and analyzed under light 
microscope. Overall, the morphology was intact in most cases, with some minor extent of 
artifacts. Based on this and reports on remarkable stability of proteins in post-mortem brain 
tissue (245), no samples were excluded for quantitative analyses. 
Coronal cryosections of rat brains (12µm) were collected at Bregma levels (i) 1.2 to 0.7mm 
(striatum) and (ii) -5.2 to -5.6mm (midbrain) according to the brain atlas “The Rat Brain in 
Stereotaxic Coordinates” (246).  
 
3.4 EXPRESSION ANALYSES –  MRNA QUANTIFICATION IN HUMAN AND RAT TISSUE 
3.4.1 QUANTITATIVE REAL-TIME PCR FOR RNA FROM HUMAN POST-MORTEM TISSUE 
Quantitative real-time PCR (qRT-PCR) was used to analyze mRNA expression in human 
post-mortem brain tissue samples. After isolation (RNeasy Micro Kit), 100 ng total RNA 
were reverse transcribed using the High Capacity RNA-to-cDNA Master Mix. Quantitative 
RT-PCR was perform on triplicates of each sample using the Power SYBR®Green PCR 
Master Mix (reaction volume 20 µl, 40 cycles of 95 °C for 15 sec, 60 °C for 1 min). Melting 
profiles of each sample were recorded to check for aberrant fragment amplifications. Primer 
details are listed in Table 6. 
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Gene RefSeq Forward Reverse 
OPRM1 NM_000914.4 5‘-AGAGACCACCCCTCCACGGC-3‘ 5‘-ACCCTGTTAGGGCAACGGAGCA-3‘ 
DRD1 NM_000794.3 5‘-ACGACCCCAAGGCAAGGCGT-3‘ 5‘-TCGGGGCTGTTGCTTTTCTGGT-3‘ 
DRD2 NM_016574.3 5‘-CAGACGCCGCAAGCGAGTCA-3‘ 5‘-TCCTCTCGGGTGGGCTGGTG-3‘ 
AluSx --- 5‘-TGGTGAAACCCCGTCTCTACTAA-3‘ 5‘-CCTCAGCCTCCCGAGTAGCT-3‘ 
GAPDH NM_002046.4 5‘-CATGAGAAGTATGACAACAGCCT-3‘ 5‘-AGTCCTTCCACGATACCAAAGT-3‘ 
Table 6: List of primers used for qRT-PCR in human post-mortem tissue.  
 
SDS 2.2.2 software (ABI) was employed to analyze SYBR®Green fluorescence intensity and 
calculation of the theoretical cycle number when a defined threshold was reached (Ct-value). 
Relative quantification was done by the ΔΔCT-method with glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as internal normalizer. AluSx (173) was tested as internal 
normalizer in a smaller sample set (n = 10/group) but was not used for subsequent 
experiments as results were similar to GAPDH.    
To ensure good RNA quality, RNA integrity number (RIN) values were recorded and samples 
with RIN values <7 and tissue pH<6 were excluded from qRT-PCR experiments in the 
analysis of the complete sample set (N=43/group). 
 
3.4.2 IN SITU HYBRIDIZATION ON RAT BRAIN SECTIONS 
Fixation 
For fixation, sections were warmed to room temperature and incubated in 4 % PFA in PBS for 
15 min, washed for 10 min in PBS, and twice in sterile water for 5 min.  After treatment with 
0.1 M HCl for 10 min and two times 5 min with PBS, brain sections were incubated in 0.1 M 
triethanolamine (pH 8) and 0.25 % acetic anhydride for 20 min in order to acetylate proteins. 
Subsequently, sections were washed twice in PBS for 5min, once in sterile water for 1 min 
and dehydrated in a graded series of ethanol (70 %, 80 %, 99 %; 2 min each). After air drying, 
sections were stored at -80 °C in sealed boxes with silica gel to avoid moisture. 
 
Probe generation 
Gene-specific riboprobes are described in Table 7 and were generated by PCR. Product size 
was checked by 1.5 % agarose gel electrophoresis. Radioactively-labelled riboprobes were 
generated by in vitro transcription. For this, 200 ng unlabeled riboprobe was incubated with 
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1x transcription buffer, 12.5 nmol ATP, CTP, GTP, 50 pmol UTP, and 125 pmol Uridine 5-
(α-thio)triphosphate-[35S] (Perkin Elmer, Massachusetts, USA), 1 U RNase inhibitor and 1 U 
polymerase for 90 to 120 min at 37 °C. Afterwards, the DNA template was digested by 
DNAseI (20 min, 37 °C) and riboprobes were purified using IllustraTM MicrospinTM S-200 
HR Columns.  
 
Gene RefSeq Position (bp) from - to Reference 
Oprm1 NM_013071 1226 1479 (247) 
Oprd1 NM_012617 148 569 (247) 
Oprk1 NM_017167 1298 1555 (247) 
Pomc NM_139326 11 344 - 
Penk NM_017139 1086 779 (247) 
Pdyn NM_019374 586 991 (247) 
Arbb2 NM_012911.1 1238 1679 (97) 
Th NM_012740 1594 1843 (248) 
Table 7: Gene-specific RNA riboprobes used for in situ hybridizations on rat brain sections. 
 
Probe hybridization and washing 
Fixed tissue sections were incubated in prehybridization buffer (100 mM Tris-HCl, pH 7.6, 5 
mM EDTA, 5x Denhardt’s solution, 1.25mg/ml yeast tRNA, 40 mM NaCl) diluted 1:1 with 
deionized formamide for 2 to 4 hours at 37 °C followed by incubation with hybridization mix 
containing 10 000 CPM / µl at 55 °C over night. The hybridization mix consisted of 50 % 
deionized formamide, 150 mM DTT, 330 mM NaCl, and 10 % dextran sulfate, 1x basic mix 
(10x basic mix: 200 mM Tris-HCl, pH 7.6, 10 mM EDTA, 10 x Denhardt’s solution, 5 mg/ml 
yeast tRNA, 1 mg/ml polyadenylic acid). Sections were washed once for 40 min followed by 
two washing steps for 30 min in 1x SSC at 42 °C. If necessary, sections were incubated in 
formamide (1:1 diluted with 1x SSC) for 1 hour followed by two times 1x SSC. RNase 
treatment (2mg / 100 ml RNase buffer) was carried out at 37 °C for 1 hour. Enzyme reaction 
was stopped by washing the sections in 1x SSC at 55 °C twice for 30 min. Sections were 
dipped in water for 2 min and dehydrated in a graded series of ethanol (70 %, 80 %, 99 %;     
2 min each). Fujifilm BAS imaging plates were exposed to the sections for 1 week.   
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3.5 EXPRESSION ANALYSES - PROTEIN QUANTIFICATION IN HUMAN AND RAT TISSUE 
3.5.1 RECEPTOR AUTORADIOGRAPHIES ON HUMAN AND RAT BRAIN TISSUE SECTIONS 
All receptor/transporter autoradiographies were performed under saturated conditions. Kd-
values, the dissociation equilibrium constant describing the affinity for a specific receptor, as 
well as Bmax-values, describing the maximum density of the receptor, are listed in Table 8.  
 
 Rat brain Human brain 
Kd [nM] Bmax [fmol/mg] Kd [nM] Bmax [fmol/mg] 
[3H]-Damgo 0.7 ± 0.1 (249) 10.3 ± 1.8 (249) 1.6 ± 0.3 (250) 37 ± 5 (250) 
[3H]-DPDPE 1.8 ± 0.6 (251) 2.2 ± 0.2 (251) 2.72 ± 0.21 (251) 20.78 ± 3.13 (251) 
[3H]-U-69,593 3.8 ± 0.2 (252) 12.6 ± 0.8 (252) 3.94 (253) 1.5 (253) 
[3H]-raclopride 2.08 (254) 20.0 (254) 1.25 (255) ~9.5 (255) 
[3H]-SCH23390 0.7 (256) 347 (256) 1.37 (255) ~13 (255) 
[3H]-mazindol 18.2 (257) 0.0073 (257) 18.5 (258) 1.6 (258) 
Table 8:  Kd and Bmax values of radioligands used for saturated receptor autoradiographies on human and rat 
brain tissue sections.  
 
MOR autoradiography 
Sections were preincubated in 50 mM Tris, pH 7.4, 5 mM MgCl2, and 1 mM EDTA twice for 
15 min. Afterwards, incubation buffer containing 1 nM or 8 nM [3H]-Damgo (Damgo, 
[Tyrosyl-3,5-3H(N)]-, spec. activity 50-51 Ci/mmol, Perkin Elmer, Massachusetts, USA) for 
rat and human tissue, respectively, was applied onto sections and incubated for 2 hours at     
30 °C. Incubation buffer consisted of 50 mM Tris, pH 7.4, 5 mM MgCl2, 1 mM EDTA,       
0.1 mM Bacitracin, and 0.1 % bovine serum albumin. For measuring non-specific binding on 
adjacent sections, 1µM CTOP (Tocris, Bristol, UK) was added. Sections were washed three 
times for 2 min at 4 °C in 50mM Tris-HCl, pH 7.4, dipped in ice-cold water and dried in a 
cold air stream.  
 
DOR autoradiography 
Sections were washed in 50 mM Tris-HCl, pH 7.4, for 30 min followed by incubation in 8 nM 
of [3H]-DPDPE (Enkephalin, [Tyrosyl-2,6-3H(N)]- (2-D-Penicillamine,5-D-Penicillamine, 
Perkin Elmer, Massachusetts), spec. activity 51.3 Ci/mmol) for 1 hour at 4 °C. Non-specific 
binding was determined in presence of 1µM naltrindole (Sigma-Aldrich, Missouri, USA). 
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Sections were then twice washed in washing buffer for 30 sec at 4 °C, dipped in ice cold 
water and air dried.  
 
KOR autoradiography 
For KOR, the same buffers as for MOR receptor autoradiography were used. Sections were 
preincubated twice for 20 min, followed by incubation in 10 nM [3H]-U69,593 (spec. activity 
44.6 Ci/mmol, Perkin Elmer, Massachusetts) for 1 hour at room temperature. Non-specific 
binding was determined in presence of 1 µM nor-BNI (Tocris, Bristol, UK). Washing was 
done as for MOR receptor autoradiography. 
 
D1 and D2/D3 receptor autoradiography 
Sections were pretreated in 50 mM Tris, pH 7.4, 5 mM MgCl2, and 1 mM EDTA two times 
for 15 min, followed by incubation with the radioligand in incubation buffer (50 mM Tris-
HCl, pH 7.4, 5 mM MgCl2, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1% bovine serum 
albumin). Total binding of the D1 receptor was determined using 3 nM [3H]-SCH23390 
(SCH23390, [N-Methyl-3H]-, spec. activity 81.9 Ci/mmol, Perkin Elmer, Massachusetts) and 
10 µM Mianserin (Tocris, Bristol, UK) in human tissue. Non-specific binding was achieved 
by adding 10 µM flupenthixol (Tocris, Bristol, UK). For rat tissue, 1nM [3H]-SCH23390 with 
(non-specific) or without (total) 10 µM SKF were used. To determine the density of D2/D3 
binding sites, 5 nM [3H]-raclopride (total binding, spec. acitivity 74.4 Ci/mmol, Perkin Elmer, 
Massachusetts) and 30 µM sulpiride (non-specific, Tocris, Bristol, UK) were used. After 2 h 
incubation at 30 °C, the sections were twice washed in 50 mM Tris-HCl, pH 7.4, dip in cold 
water and dried in a cold air stream.  
 
DAT autoradiography 
Sections were preincubated in 50 mM Tris-HCl, pH 7.9, 300 mM NaCl, and 5 mM KCl for    
5 min at 4 °C. Total binding was determined by adding 2 nM or 4 nM [3H]-mazindol (spec. 
activity 20.7 Ci/mmol, Perkin Elmer, Massachusetts) and 0.3 µM desipramine (Tocris, 
Bristol, UK) for human and rat tissue, respectively. For non-specific binding, 100 µM 
nomifensine (Tocris, Bristol, UK) were added. Incubation took place at 4 °C for 40 min, 
followed by two times 1 min in ice-cold buffer and dipping in ice-cold water.  
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3.5.2 G-PROTEIN COUPLING OF OPIOID RECEPTORS ASSESSED BY [35S]-GTPΓS ASSAYS  
MOR [35S]-GTPγS assay 
Sections were washed in 20 mM Tris-HCl, pH 7.4, 5 mM MgCl2 and 1 mM EDTA twice for 
15 min and then pretreated in incubation buffer containing 1 mM GDP. Incubation buffer 
contained 20 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 1 mM EDTA, 100 mM NaCl, 1 mM DTT 
and 0.1 % bovine serum albumin. G-protein coupling of MOR was determined by adding     
10 mM GDP, 80 pM [35S]-GTPγS (Perkin Elmer, Massachusetts) and the MOR specific 
agonist Damgo (1µM, Tocris, Bristol, UK). Basal G-protein coupling was measured in 
absence of Damgo but presence of the vehicle (acetonitrile). Incubation took place at 30 °C 
for 1 hour. Sections were then washed in 20 mM Tris-HCl and 100 mM NaCl two times for 2 
min, rinsed in ice-cold water and air dried.  
 
DOR and KOR [35S]-GTPγS assay  
Sections were rinsed in preparation buffer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl2, 0.2 mM 
EGTA, 100 mM NaCl) for 10 min followed by incubation in preparation buffer containing     
1 mM GDP for 20 min. The sections were then incubated for 2 hours at room temperature in 
preparation buffer with 1 mM GDP, 40 pM [35S]-GTPγS and either DOR (10 µM DPDPE, 
Sigma-Aldrich, Missouri, USA) or KOR (10 µM U50,488H, Tocris, Bristol, UK) specific 
agonist or vehicle (acetonitrile or water). Afterwards, sections were washed twice in 50 mM 
Tris-HCl, pH 7.4, at 4 °C, dipped in ice cold water and air dried. 
 
3.5.3 AUTORADIOGRAPHIC IMAGE ANALYSIS 
After performing in situ hybridizations, receptor bindings or [35S]-GTPγS autoradiograhpies 
on tissue sections, Fujifilm BAS imaging plates (Fujifilm, Tokyo, Japan) were exposed to the 
sections. The plates were then scanned with a phosphoimager (Typhoon FLA 700, GE 
Healthcare, Germany). Mean grey values were measured using the MCID software (MCID 
Image Analysis Software Solutions for Life Sciences). For in situ hybridization experiments, 
a sense probe was generated to measure unspecific binding that was subtracted from antisense 
signals. In [35S]-GTPγS assay studies, basal and stimulated (in presence of a specific agonist) 
was measured on adjacent sections and the percentage of stimulated after agonist application 
was calculated for every sample. Total and non-specific binding (in presence of a specific 
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blocker) were determined for receptor binding assays on adjacent sections and the non-
specific signal was subtracted from the total signal. Based on the known radioactivity in 14C 
standards, image values of in situ hybridization and [35S]-GTPγS assay measurements were 
converted to nanocurie per mg (nCi/mg). Values of measurements of the autoradiographies 
were converted to femtomol per mg (fmol/mg) based on 3H standard values and the specific 
activity of the tritiated ligand. These values were used for statistical analysis. 
 
3.6 NEUROTRANSMITTER MEASUREMENTS 
3.6.1 DOPAMINE IN VIVO  MICRODIALYSIS 
This experiment was performed by Dr. Marcus Meinhardt and Dr. Stéphanie Perreau-Lenz 
(Institute of Psychopharmacology, Central Institute of Mental Health Mannheim, Medical 
Faculty Mannheim, Heidelberg University, Germany) and results are part of a combined 
manuscript. The results are presented here to support the interpretation of my data.  
 
Surgery 
Post-dependent and control rats (450-550g) were group housed before surgery and single 
housed afterwards. Animals were anesthetized with 1.5 – 2 % isofluran and placed in a 
stereotaxic frame (Kopf Instruments, California, USA). Guide cannulas (CMA11, 20 gauge, 
14mm, CMA Microdialysis, Kista, Sweden) were implanted 2.0 mm above the Acb shell 
region unilaterally at the coordinates anterior/posterior + 1.6 mm, medial/lateral ± 0.8 mm, 
and dorsal/ventral 5.6 mm based on Bregma, midline, and dura (246). The implant was 
anchored using stainless steel screws and dental acrylic. After surgery, animals were allowed 
to recover for one week.  
 
In vivo microdialysis procedure 
The microdialysis experiment was conducted in freely moving rats on day 21 after the last 
alcohol-exposure. The dialysis probes (CMA11 11/2, 2 mm active membrane) were inserted 
into the implanted guide cannula 12 hours before starting the experiment to minimize 
damage-induced release of neurotransmitters and metabolites. Samples were then collected 
every 15 min at a flow rate of 1.5 µl/min. In order to measure baseline dopamine levels in 
 57 
 
control and post-dependent animals, six baseline samples were collected. Afterwards, the 
animals were injected with saline (i.p.) as a control. This was followed by consecutive 
injections of ethanol (15 % v/v in water): 1 g/kg ethanol 30 min after the saline injection and 
2 g/kg ethanol 60 min after the first ethanol injection. Sampling continued for the whole 
experiment. Placement of the dialysis probes was verified after the experiment and the 
location of at least 80 % of the active membrane within the AcbS was the inclusion criterion 
for this study. 
 
High pressure liquid chromatography (HPLC) analysis 
HPLC was used to determine the dopamine content in the microdialysis samples. An ALEXIS 
100 cooled-micro LC-EC system (Antec Leyden, Zoeterwoude, Netherlands) with a 
microbore VT-03 flow cell was employed for electrochemical detection. The working 
potential of the cell was set at 400 mV and the oven temperature of the DECADE II at 35°C. 
The mobile phase (pH 6, containing 50 mM phosphoric acid, 400 mg/l OSA, 0.1 mM EDTA, 
8 mM KCl, 15% methanol) and was perfused with a flow rate of 200 µl/min. Duplicates of 
each sample (4 µl aliquots) were injected onto a reversed phase column (C18, ALF-205 
column, 50x2, 1 mm ID, 3 µm; Axel Semrau GmbH & Co. KG, Sprockhövel, Germany). 
Using the area under the peak and an external standard curve, the dopamine content was 
determined. Detection limits for dopamine was 200 pM with a signal-to-noise ratio of 2. 
 
3.6.2 RADIOMMUNIASSAY 
Brains of post-dependent and control rats were microdissected and micropunches of the Acb, 
CPu, and VTA were prepared. These tissue samples were sent to Uppsala, Sweden, where 
they were further processed in the laboratory of Prof. Dr. Georgy Bakalkin (Department of 
Pharmaceutical Biosciences, Uppsala Universitet, Sweden).  
Frozen tissue of microdissected brain regions (Acb, CPu, VTA) was finely powdered and 1M 
hot acetic acid was added. The samples were boiled for 5 min, ultrasonicated, and centrifuged. 
The tissue extracts were run through a SP-Sephadex ion exchange C-25 column and peptides 
were eluted and analyzed by RIA. The samples were then incubated with 125I-labeled peptide 
and the primary antiserum over night at 4 °C. This was followed by 10 min centrifugation at 
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12 000 g. The pellet was then used for counting on a gamma counter. The method is described 
in detail elsewhere (153, 155, 259). 
 
3.7 LOCOMOTOR ACTIVITY  
Locomotor activity of control and post-dependent animals was measured in their homecage 
and in an OpenField experiment. These data were kindly provided by Dr. Marcus Meinhardt.  
 
Homecage locomotion 
For homecage locomotion, rats were single house 24 h prior to the experiment and an infrared 
sensor (Infra E-Motion GmbH, Henstadt-Ulzburg, Germany) was placed on top of the 
homecage. Body movements of every animal were monitored for 72 h starting on day 17 after 
the last alcohol exposure.  
 
OpenField 
OpenField locomotion was analyzed on day 25 after the last alcohol-exposure in an arena 
made of dark PVC (51 cm x 51 cm x 50 cm) at a light intensity of 50 lx. Over a period of 60 
min, the distance traveled (cm) was recorded and the locomotor activity was analyzed with 
the observation program Viewer2 (Bioserve GmbH, Bonn, Germany). 
 
3.8 ELECTROPHYSIOLOGY 
Electrophysiological data were provided by the research group of Dr. Georg Köhr (Institute of 
Psychopharmacology, Central Institute of Mental Health Mannheim, Medical Faculty 
Mannheim, Heidelberg University, Germany) to give further insight into the functional 
consequences of the post-dependent state on the synaptic level. The results are part of a 
combined manuscript and support the interpretation of the data.  
 
Patch-clamp whole-cell recordings 
Coronal rat brain slices (300 µm) containing the AcbS were prepared using the HM 650 V 
microtome (Microm International, Walldorf, Germany) from four control and three post-
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dependent rats at the age of 15-16 weeks. Rats were anesthetized by inhalation of isofluorane 
and brains were rapidly removed and placed in dissection buffer (220 mM sucrose, 3.5 mM 
KCl, 1.25 mM NaH2PO4, 3 mM MgCl2, 1 mM CaCl2, 25 mM NaHCO3 and 10 mM dextrose) 
at 4 °C. Individual slices were stored in artificial cerebrospinal fluid (ACSF) for at least      
1.5 hours before recording. ACSF was similar to the dissection buffer except that sucrose was 
replaced by 124 mM NaCl, MgCl2 and CaCl2 were changed to 1.5 mM and 2.5 mM, 
respectively. Both dissection buffer and ACSF were saturated with 95 % O2 / 5 % CO2       
(pH 7.4). 
For the recordings, slices were transferred to a submerged recording chamber, perfused with 
ACSF at 2 ml/min and imaged using a Zeiss Axioskop 2 microscope (Carl Zeiss AG, 
Göttingen, Germany). Whole-cell recordings were performed at 30°C from medium spiny 
neurons (MSNs) located in the AcbS with the EPC-9 amplifier interfaced to Patchmaster 
software (HEKA Elektronik, Lambrecht, Germany). Borosilicate recording pipettes (outside-
diameter, 1.5 mm; 2-4 MΩ) were pulled on the Flaming/Brown puller P-97 (Sutter 
Instruments, Novato, CA) and were filled with internal solution containing 130 mM K-
Gluconate, 10 mM KCl, 0.2 mM EGTA, 10 mM HEPES, 4 mM Mg-ATP, 0.5 mM Na-GTP 
and 10 mM Na-Phosphocreatine (pH 7.25, 280–290 mOsm). For electrical stimulation, 
borosilicate glass pipettes filled with ACSF were placed in the AcbS to evoke excitatory 
postsynaptic currents (EPSCs) in MSNs around 200 pA at the holding potential (Vh) of           
-80 mV. GABAergic transmission was antagonized by picrotoxin (1 mM) which was added to 
the internal solution (260). Electrophysiological data were filtered at 2 kHz and digitized at  
10 kHz. Input resistance was monitored via hyperpolarizing pulses (-10 mV, 100 ms). Only 
cells with holding currents ≤100 pA at Vh = -80 mV and series resistance ≤20 MOhm were 
studied. Cells were discarded if any of these parameters changed by ≥20 % during the course 
of the experiment. 
 
3.9 STATISTICS 
Expression data from human post-mortem brain studies (complete sample set) 
To examine differences in qRT-PCR and autoradiography data between the control, non-
intoxicated, and intoxicated alcoholic groups an analysis of covariance was performed. Tissue 
pH-values, post-mortem interval, age, smoker state and RIN values (but only for the analysis 
of qRT-PCR data) were considered as candidate covariates. By a stepwise backward selection 
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procedure non-significant variables were sequentially removed. This was followed by a 
Fisher’s LSD post-hoc test to determine which means differed between groups. In an 
analogous way the interaction effect of alcoholic group and A118G genotype was analyzed by 
stepwise analysis of covariance with factors alcoholic group (control, non-intoxicated, and 
intoxicated alcoholics), A118G genotype (AA and AG) and their interaction.  
Parametric Pearson’s analysis was used to correlate MOR binding sites and OPRM1 mRNA 
to PMI, brain pH and RIN in NC and VS of alcoholics and controls. 
 
Expression data from human post-mortem brain (core sample set) and animal studies 
Expression data from human post-mortem “core samples” as well as post-dependent animals 
were statistically analyzed within a region by one-way ANOVA (treatment effect) followed 
by Fisher’s PLSD post-hoc test.  
For the analysis of NTX effects on expression levels (Study III), data of NTX-treated rats 
were normalized to their respective saline control and compared by group- and region-wise 
one-way ANOVA, i.e. saline treated not exposed animals vs. NTX treated not exposed 
animals and saline treated exposed vs. NTX treated exposed animals. For better visualization, 
exposed and not exposed animal groups are shown in the same graphs. 
 
Clinical and PET data 
Relapse data were analyzed according to an intention-to-treat analysis. A Kaplan Meier 
estimation of naltrexone response was performed comparing survival curves of relapse in 
naltrexone versus placebo groups.  
For the PET scans, [¹¹C]-carfentanil BPND derived from pharmacokinetic analysis of regions 
of interest (ROI; ventral striatum, nucleus caudatus, putamen, and total striatum) were 
statistically analyzed using a Cox regression analysis to analyze the relation between MOR 
BPND and time until first relapse. Data were optionally censored with end of follow-up, for 
each ROI and the analysis was performed with SPSS22 and/or JMP 7 (SAS Institute, Inc). To 
control for the covariates age, sex, medication, tobacco use or OPRM1 genotype additional 
cox analyses were performed.  
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Microdialysis and locomotion data 
Data from the microdialysis experiment were analyzed by two-way ANOVA with repeated 
measures followed by Fisher’s PLSD post hoc test. Data of the locomotion experiments were 
evaluated by two-way ANOVA followed by Fisher’s PLSD post-hoc test. 
 
Electrophysiology – Patch-clam whole-cell recordings 
Statistical analysis during perfusion of drugs was performed for the last 10 min of every 
condition using two-way ANOVA followed by Bonferroni’s post-hoc test and comparisons 
between control and dependent rats were performed using unpaired Student’s t test.  
 
All data are expressed as mean ± SEM. Throughout statistical significance was defined at the 
0.05 level. Statistical analysis was carried out using the Statistica 10 (StatSoft, Tulsa, USA) or 
SPSS22 (IBM, Chicago, USA). For graphical representation of the data the Prism 5 
(GraphPad, San Diego, USA) software was used. 
 
3.10 META-ANALYSES 
All meta-analyses were performed by Dr. Dr. Hamid R. Noori (Institute of 
Psychopharmacology, Central Institute of Mental Health Mannheim, Medical Faculty 
Mannheim, Heidelberg University, Germany) and his group and are part of two combined 
manuscripts. To support the interpretation do the data, they were kindly provided for this 
thesis. 
 
Meta-analysis: Oprm1 mRNA expression and Damgo binding in alcohol-dependent rats 
A systematic selection of original research articles was performed using the online portal of 
the National Library of Medicine http://www.ncbi.nlm.nih.gov/pubmed/. The literature search 
was based on the general keywords: µ opioid receptor, expression, chronic and 
alcohol/ethanol. Based on a simultaneous search of those keywords 28 publications were 
found. Of these 28 articles, 12 using 233 rats provided complete sets of biological (gender, 
age, weight and strain) and procedural (measurement method, number of animals, alcohol 
administration paradigm in terms of dose of alcohol, duration of exposure, and alcohol 
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availability, length of withdrawal period) variables as well as control and ethanol-induced 
expression and binding values. The latter were used to calculate the relative changes in 
Oprm1 expression and/or receptor binding properties following chronic alcohol intake. 
Interestingly, all studies under investigation utilized a two bottle free-choice paradigm to 
induce alcohol dependence in male adult animals, which was defined by physical withdrawal 
symptoms. The duration of alcohol administration varied between 16 days and 10 months. 
Following studies were used for the meta-analysis (110-120, 261). 
For the meta-analysis, a fixed effect model was used (13, 262) with respect to the variables 
“OPRM1 expression” or “Damgo binding” and analysed the time-dependent effects of 
abstinence following chronic alcohol exposure. 
?̅? =  
1
𝑁
 ∑ 𝑛𝑖𝑥𝑖
𝑘
𝑖=1
 
was used as the weighted average effect of chronic alcohol intake or withdrawal as the 
weighted sum of the products of the mean effects  from each experiment i and the number 
of animals used in that particular study.  𝑛𝑖  , whereby  
𝑁 =  ∑ 𝑛𝑖
𝑘
𝑖=1
 
denotes the total number of animals considered in the meta-analysis of the k studies. Data are 
taken from following publications. 
 
Meta-analysis: Dopamine and its metabolites in alcohol-dependent rats 
For the meta-analysis on dynamics of dopamine release during withdrawal and abstinence, the 
literature search was based on the keywords “alcohol/ethanol” AND “withdrawal/abstinence” 
AND “dopamine” AND “accumbens” OR “striatum” OR “Ventral Tegmental Area/VTA”. 
Further selection criteria were (i) chronic administration of only alcohol (no other 
pharmacological interventions) and (ii) the presence of withdrawal symptoms. From 
approximately 225 publications, 29 (including 352 rodents chronically exposed to alcohol and 
96 alcoholic individuals) fulfilled the abovementioned criteria. The subsequent variables (i.-
vii.) were obtained from the publications and used for further analysis:  
xi
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i. Weight, age, gender and consciousness (if anaesthetics applied: agent and dose).  
ii. Exact method of measurement (in vivo microdialysis, patch-clamp recordings, tissue 
HPLC, PET etc.) 
iii. Alcohol administration paradigm (self-administration, free-choice, i.p. injections etc.) and 
daily doses of alcohol in animals; the history of alcohol dependence and average daily alcohol 
consumption in humans 
iv. Number of the alcoholic individuals and ethanol-exposed animals used in each experiment. 
v. Extracellular and in situ dopamine, DOPAC and HVA concentrations, firing frequency and 
burst rates of dopaminergic neurons, availability of D1 and D2 receptors and dopamine 
transporter (DAT). 
vi. Time of measurement after alcohol withdrawal  
vii. Relative change (percentage) of the obtained variable (v) in comparison to the controls. 
Based on the same fixed effect model as for the meta-analysis of MOR expression were 
employed (13, 262) with respect to the extracted variables (v) and analyzed the withdrawal 
interval of [0, 60] days. 
 
?̅? =  
1
𝑁
 ∑ 𝑛𝑖𝑥𝑖
𝑘
𝑖=1
 
represents the weighted average effect of the concentrations of dopamine and its metabolites 
respectively as the weighted sum of the products of the mean effects xi from each experiment i 
and the number of animals used in that particular study ni, whereby 
𝑁 =  ∑ 𝑛𝑖
𝑘
𝑖=1
 
denotes the total number of animals considered in the meta-analysis of the k studies. If the 
amount of extracellular dopamine was not directly specified by the measurement (e.g. tissue 
punches), the ratio of DOPAC to dopamine was calculated as an estimate for active dopamine 
concentrations. 
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4 RESULTS 
4.1 STUDY I: LOW µ-OPIOID RECEPTOR STATUS IN ALCOHOL DEPENDENCE ASSESSED 
BY COMBINED PET AND POST-MORTEM BRAIN ANALYSIS 
A major hypothesis in the addiction research field states increased levels of MOR in the 
striatal brain regions of human alcoholics during abstinence as measured by [11C]-carfentanil 
PET. The elevated MORs are thought to be blocked by the non-selective opioid receptor 
antagonist NTX. However, NTX is only effective in a subpopulation of patients. Moreover, 
the most commonly used radiotracer [11C]-carfentanil is especially sensitive to levels of 
endogenous opioids. 
To give more insight into the state of the MOR system during abstinence, post-mortem tissue 
samples of human alcoholics and control subjects were analyzed. Additionally, a PET study 
was performed in a subgroup of alcoholic patients.   
 
4.1.1 POST-MORTEM STUDY: MOR EXPRESSION IS DECREASED IN STRIATAL BRAIN 
REGIONS OF ALCOHOLICS 
For expression analysis of OPRM1 mRNA and MOR binding sites, striatal brain tissue of 
deceased alcoholic (n=43) and control subjects (n=43) was investigated. Detailed information 
on each subject is shown in Suppl. Table 1. The group of alcoholics was further divided into 
subjects with positive blood alcohol levels at the time of death (“intoxicated”, n=16) and 
subjects without detectable blood alcohol levels (“non-intoxicated”, n=27). 
A significant decrease of MOR binding sites, as assessed by [3H]-Damgo autoradiography, 
was observed in the caudate nucleus (NC) and the ventral striatum (VS) in both the 
intoxicated and non-intoxicated alcoholics when compared to control subjects (NC: 
F[2,77]=13.83; p<0.001; VS: F [2,75]=12.6, p<0.001, Figure 10A, C, D). MOR binding sites 
in the NC were reduced by ~30 % in both alcoholic groups. Notably, there seems to be an up-
regulation of MOR with age in the NC (p<0.001, β = 0.337 ± 0.093). In the VS, however, 
non-intoxicated alcoholics showed a decrease by 23 % while the reduction in binding sites 
was even more pronounced in intoxicated alcoholics (51 %, Figure 10A). There was a 
significant difference in binding sites between non-intoxicated and intoxicated alcoholics in 
the VS.   
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Figure 10: μ-opioid receptor (MOR) binding sites and OPRM1 mRNA expression in the nucleus caudatus 
and ventral striatum of human striatal post-mortem tissue. Controls (white bars) are compared to non-
intoxicated (lined and colored bars) and intoxicated (colored bars) alcoholic subjects. (A-B) Data show protein 
and mRNA expression of MOR on post-mortem brain sections measured by saturated [3H]-Damgo receptor 
autoradiography (A) and qRT-PCR (B). Data are expressed as mean ± SEM (autoradiography n=14-40/group, 
OPRM1 mRNA n=12-35/group). Statistical analysis was performed by analysis of covariance followed by 
Fisher’s LSD post-hoc test, *p<0.05, **p<0.01, ***p<0.001 non-intoxicated/intoxicated alcoholics vs controls, 
#p<0.05 intoxicated alcoholics vs non-intoxicated alcoholics. (C) Schematic overview of the nucleus caudatus 
(NC) and ventral striatum (VS) on a coronal human brain section. (D) Representative [3H]-Damgo receptor 
autoradiography on a frontal lobe section (upper panel) showing a specific pattern of MOR similar to Hiller and 
Fan (80) and Mathieu-Kia et al. (79). Non-specific signal was determined by [3H]-Damgo binding in presence of 
the MOR antagonist CTOP (lower panel). 
 
OPRM1 mRNA measured by qRT-PCR was also significantly reduced in both striatal brain 
regions of alcoholic subjects as compared to controls, mirroring the changes on binding site 
levels (NC: F[2,58]=5.65, p=0.006; VS: F[2,59]=4.76, p=0.012; Figure 10B). The decrease in 
transcripts of the intoxicated alcoholics in the NC did not reach significance but showed a 
trend towards a decrease (p=0.058) when compared to controls. 
MOR expression can be affected by various confounding factors, i.e. nicotine use. For this 
reason, we included “smoking” into our statistical model. However, the statistical stepwise 
backward procedure excluded “smoking” as a non-significant co-variant.  
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Excluding additional confounding factors 
In addition to nicotine use, various confounding factors can influence OPRM1 mRNA and 
MOR binding site expression. For example, the single nucleotide polymorphism (SNP) 
OPRM1-A118G has been proposed to have an impact on receptor expression. Thus, a 
sensitivity analysis investigating a genotype x condition (controls, intoxicated, non-
intoxicated alcoholics) interaction was performed including the A118G genotype but did not 
find a significant effect of the genotype on the expression levels of OPRM1 mRNA or binding 
sites (Suppl. Table 2). However, number of G-allele carriers is low (n=4-13) and results have 
to be interpreted with caution. 
The analyzed sample set of 43 controls and 43 alcoholics (Figure 10) also includes subjects 
which either committed suicide or were positive for substances known to alter MOR binding 
(i.e. benzodiazepines, opioids, cannabis) at the time of death. Therefore, these cases were 
excluded in an additional analysis resulting in group sizes of 30-38 controls and 21-31 
alcoholics, depending on brain region and group. As reported above, lower MOR binding 
sites and transcript levels were detected in alcoholic subjects also in this sample set.  In the 
NC (F[2, 65]=11.892, p=0.00004, controls: 166.08 ± 6.94, non-intoxicated: 119.01 ± 9.85, 
intoxicated: 110.86 ± 12.44), MOR binding sites were decreased in both alcoholic groups 
when compared to controls (p<0.001). In the VS (F[2,64]=7.7430, p=0.001, controls: 119.60 
± 6.40, non-intoxicated: 98.30 ± 9.29, intoxicated: 67.86 ± 11.89), there was only a trend 
towards a decrease in the not-intoxicated alcoholics (p=0.06) but a significant reduction in the 
intoxicated alcoholic subjects (p=0.0002 when compared to controls, p=0.048 when compared 
to non-intoxicated alcoholics). 
Parametric Pearson’s analysis was used to correlate MOR binding sites and OPRM1 mRNA 
expression to PMI, brain pH and RIN values in the NC and VS of alcoholics and controls and 
no significant effects were found. This shows the decent quality of the post-mortem specimen.   
 
Meta-analysis of MOR expression in rats 
A meta-analysis in 233 rats to analyze striatal Oprm1 mRNA and MOR binding sites during 
abstinence found decreased mRNA and receptor expression during the first three days of 
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abstinence (Table 9). This is in line with the human post-mortem data and further supports the 
existence of decreased MOR cell surface expression during alcohol abstinence 
 
DAMGO binding (%) Chronic 
alcohol effect 
Abstinence  
day 1 
Abstinence  
day 2 
Abstinence  
day 3 
Caudate putamen/Striatum 74 ± 4 73 ± 5 88 ± 7 73 ± 7 
Nucleus accumbens core 84 ± 5 71 ± 10 79 ± 7 61 ± 7 
Nucleus accumbens shell 86 ± 9 71 ± 10 61 ± 7 61 ± 7 
 
Oprm1 mRNA (%) Chronic alcohol  
effect 
Abstinence 
day 3 
Abstinence 
day 21 
Caudate putamen/Striatum 80 ± 12 79 ± 10 138 ± 16 
Nucleus accumbens 72 ± 10 - - 
Table 9: A meta-analysis found reduced mRNA levels especially during the first 3 days of alcohol 
withdrawal. A total of 233 rats were included in the meta-analysis. Performed by Dr. Dr. H.R. Noori. 
 
 
4.1.2  [11C]-CARFENATNIL PET STUDY: LOW BINDING POTENTIAL PREDICTS RELAPSE 
The PET study was performed by Dr. Derik Herman (Department of Addictive Behavior and 
Addiction Medicine, Central Institute of Mental Health Mannheim, Medical Faculty 
Mannheim, Heidelberg University, Germany), Matthias Reimold and colleagues. 
 
After three weeks of abstinence, a [11C]-carfentanil PET scan was performed in medication-
free alcohol dependent patients (n=38). One day afterwards, patients were assigned to a 
randomized placebo-controlled NTX treatment (n=20 NTX, n=18 placebo) for 90 days and 
were followed-up for 1 year. There were no significant differences in the abstinence rates 
between both groups neither after 90 days nor after 1 year (90 days: NTX 40 % vs. placebo  
55 %; 1 year: NTX 30 % vs. placebo 17 %; log rank test p=0.8, chi square=0.07, df=1, 
Kaplan-Meier estimates are provided in Figure 11) allowing to further use all n=38 patients 
for the analysis of MOR BPND and time to relapse. 
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Figure 11: PET study – no significant differences in abstinence rates were observed between the NTX 
(blue) and placebo (green) group. Alcohol-dependent patients were treated with NTX (n=20) and placebo 
(n=18) for 90 days and relapse rates monitored over one year. Six of 20 NTX treated and three of 18 placebo 
treated patients remained abstinent over one year. This analysis was performed by Dr. D. Hermann, Dr. M. 
Reimold, and colleagues.  
 
A cox regression analysis revealed an association of low MOR BPND in the putamen and an 
increased relapse risk during the 1 year follow-up (p=0.04, B= -2.05). In the ventral and total 
striatum a trend towards the same association was detected (ventral striatum: p=0.09,           
B= -1.15); total striatum: p=0.058, B= -1.7).  
 
 MOR BPND and relapse risk 
(N=38) 
B                      P 
Nucleus caudatus -1.38 0.107 
Putamen -2.05 0.040 
Ventral striatum -1.15 0.093 
Total striatum -1.70 0.058 
Table 10: PET study – a Cox regression found an association of low MOR BPND and with increased relapse risk 
in the putamen. This analysis was performed by Dr. D. Hermann, Dr. M. Reimold and colleagues. 
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Excluding confounding factors 
Even though NTX treatment was ineffective in reducing relapse rates, medication effects 
cannot completely be excluded due to small sample size. However, an additional cox 
regression analysis of MOR BPND and relapse controlling for NTX/placebo treatment showed 
no influence of the medication (p=0.96) while the association of low MOR BPND in the 
putamen and increased relapse risk was replicated (p=0.04). Additionally, age, sex, tobacco 
use and the A118G genotype can influence MOR (132, 263). Therefore, additional cox 
regression analyses were performed controlling for these variable. They did not have a 
significant effect on BPND and the risk of relapse in all ROIs (Suppl. Table 3). 
 
4.1.3 SUMMARY  
Taken together, Study I shows a strong decreased of MOR binding sites in striatal post-
mortem brain tissue of alcoholic subjects which appears to be independent of the OPRM1 
A118G genotype. Furthermore, the results suggest that patients with low MOR availability 
are more vulnerable to relapse.  
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4.2 STUDY II:  NEUROADAPTATIONS IN THE ENDOGENOUS OPIOID SYSTEM IN 
PROTRACTED ABSTINENCE 
4.2.1 MOR 
Based on the findings in human post-mortem tissue, i.e. the strong down-regulation of MOR 
binding sites in alcoholic subjects, this thesis aimed to investigate the nature of the 
endogenous opioid system’s regulation in alcohol dependence. Thus, the studies were 
extended to the established post-dependent animal model.  
Alcohol dependence was induced in rats by seven weeks of CIE and brains were analyzed 
after three weeks of abstinence. Alcohol dependence-induced alterations of opioid receptor 
expression were studied on transcript, protein as well as functional levels (i.e. G-protein 
coupling) in striatal regions and the VTA. Furthermore, expression levels of the β-endorphin 
precursor Pomc provided evidence for a dysregulation of the endogenous MOR ligand. 
Transcripts of the adaptor protein β-arrestin2 were analyzed to suggest a possible mechanism 
of the regulation of MOR cell surface receptor availability.  
 
In three weeks abstinent post-dependent animals, MOR binding sites as measured by [3H]-
Damgo receptor autoradiography were significantly reduced by about 10 % in both 
subregions of the ventral striatum, the AcbS and AcbC, as compared to controls. In the dorsal 
striatum as well as in the VTA no alterations have been detected (Figure 12A, E and Figure 
13A). Accumulation of [35S]-GTPγS, representing coupling of the receptor to intracellular G-
proteins, was significantly upregulated by 67 % and 248 % in the AcbS and AcbC, 
respectively, while the dorsal striatum was unaffected. In the VTA, G-protein coupling was 
reduced by 13 % (Figure 12B, F). Oprm1 transcript levels as measured by specific riboprobe 
in situ hybridization were not changed (Figure 12C, G). Statistical values are shown in Suppl. 
Table 4, Suppl. Table 5, Suppl. Table 6. 
Transcript levels of the β-endorphin precursor Pomc were analyzed within the median 
eminence (ME, Figure 12D) and Pomc mRNA levels were significantly decreased by 17 % in 
post-dependent animals as compared to controls. F- and p-values are shown in Suppl. Table 7. 
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Figure 12: MOR binding sites are decreased in the ventral striatum but G-protein coupling is increased. 
(A) MOR binding sited were measured by [3H]-Damgo receptor autoradiography in the ventral striatum (AcbS – 
light blue, AcbC – dark blue), dorsal striatum (CPu – green), and ventral tegmental area (VTA – yellow) of post-
dependent animals as compared to controls (white).  G-protein coupling of the MOR (B) and Oprm1 mRNA 
levels (C) were analyzed in the same regions. MOR binding sites as well as G-protein coupling is changed in the 
ventral striatum while the dorsal striatum is unaffected by the induction of alcohol-dependence. (D) Pomc 
mRNA, the precursor of the MOR ligand β-endorphin, was measured by in situ hybridization in the median 
eminence (ME, orange) and its specific expression pattern is displayed. The reduction of Pomc suggests a 
decrease in the endogenous opioid β-endorphin. The specific distribution of MOR binding sites (E), [35S]-GTPγS 
accumulation in presence/absence Damgo stimulation (F), and Oprm1 mRNA (G) in the striatum (left image) 
and midbrain (right image) is shown in representative autoradiograms. (H) Schematic illustration of coronal rat 
brain sections with regions analyzed according to (246).  
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4.2.1.1 ELEVATED Β-ARRESTIN2 LEVELS 
Since the adaptor protein β-arrestin2 is known to influence MOR function and trafficking and 
has been shown to be involved in the rewarding effects of alcohol (98, 101), bArr2 mRNA 
levels were studied by in situ hybridization. Transcripts of bArr2 were specifically in regions 
with decreased MOR binding sites (Figure 13A, B). In the AcbS and AcbC, bArr2 mRNA 
was upregulated by 52 % and 54 %, respectively (Statistics are shown in Suppl. Table 8). 
 
 
Figure 13: bArr2 transcript levels are significantly increased in regions with decreased MOR binding sites. 
(A) MOR bindings sites were measured by [3H]-Damgo receptor autoradiography and are here represented as 
normalized data as compared to air exposed control animals (% control ± SEM).  Data in fmol receptor/mg tissue 
are displayed in Figure 12A. (B) bArr2 mRNA levels were measured by in situ hybridization and are presented 
as % control ± SEM. Levels are strongly increased in the AcbS and AcbC of post-dependent animals. In the 
same region, a significant reduction of MOR was detected indicating a role of β-arrestin2 in MOR regulation. 
(C) Representative autoradiograms of the expression pattern of bArr2 mRNA in striatal and midbrain regions.  
 
 
4.2.1.2 SUMMARY: MOR IN ALCOHOL DEPENDENCE 
In post-dependent animals, MOR binding sites were significantly reduced mirroring the 
situation in human post-mortem tissue. G-protein coupling was increased. The increased 
bArr2 mRNA levels in regions with decreased MOR indicates a role in receptor regulation. 
Pomc transcript levels, the precursor of β-endorphin, were significantly decreased. 
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4.2.2 DOR 
Even though the importance of the DOR for alcohol intake behavior and dependence has been 
established, the state of the DOR during protracted alcohol abstinence is relatively 
understudied. Several preclinical reports proof the ability of DOR antagonists to reduce 
alcohol consumption and increased DOR activity is hypothesized to contribute to alcohol 
dependence. To broaden our knowledge on the role of DOR during alcohol abstinence, this 
study analyzed this receptor in both human post-mortem tissue and post-dependent animals. 
The RIA analysis of endogenous opioids was performed by the lab of Dr. Bakalkin in 
Sweden. 
 
4.2.2.1 DOR HUMAN POST-MORTEM BRAIN TISSUE 
Measurement of DOR binding sites in human striatal post-mortem tissue by [3H]-DPDPE 
receptor autoradiography revealed increased DOR binding sites  by 57 % in the ventral 
striatum (VS) of alcoholic subjects as compared to controls (one-way ANOVA: 
F[1,17]=0.045, p=4.69, Figure 14A, n=9-10/group). In the NC, DOR availability was 
numerically increased. However, this effect did not reach significance (one-way ANOVA: 
F[1,17], p=0.463, Figure 14A, n=9-10/group). 
 
 
 
Figure 14: DOR binding sites are increased in the ventral striatum of human alcoholic subjects. (A) 
Analysis of DOR binding sites by [3H]-DPDPE receptor autoradiography in the ventral striatum (VS, blue) and 
nucleus caudatus (NC, green). (B) Schematic representation of a coronal section of the human brain. The ventral 
striatum (VS, blue) and nucleus caudatus (NC, green) are highlighted. Statistical analysis was performed by one-
way ANOVA and data are shown as mean ± SEM. 
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4.2.2.2 DOR IN POST-DEPENDENT RATS 
In post-dependent rats, DOR binding sites were increased in the striatum as well as in the 
VTA as compared to control animals. In the AcbS, there was a trend towards an increase 
(p=0.06). In the AcbC and CPu, binding sites were significantly upregulated by 36 % and 14 
%, respectively. An increase of 34 % was detected in the VTA of post-dependent rats (Figure 
14A, Suppl. Table 9). Receptor functionality, as analyzed by [35S]-GTPγS accumulation 
representing G-protein coupling of the receptor, was significantly decreased in all striatal 
brain regions by 60 % to 64 % but increased in the VTA by 90 % (Figure 14B, Suppl. Table 
10). Transcript levels of Oprd1 were non-significantly decreased in the ventral striatum 
(AcbS, AcbC). In the dorsal striatum (CPu) and VTA, however, Oprd1 mRNA was 
significantly reduced by 29 % and increased by 26%, respectively (Figure 14C, Suppl. Table 
11). 
Messenger RNA levels of the enkephalin precursor Penk, were increased in the AcbS (by     
26 %) and AcbC (by 24 %). In the CPu, Penk mRNA levels were unaltered and decreased by 
21% within the VTA (Figure 14, Suppl. Table 12). The changes in Penk transcripts, however, 
do not appear to translate into protein since no changes in Met-enkephalin-Arg-Phe (MEAP) 
levels were detected by a radioimmunoassay (Acb: F[1,11]=2.912, p=0.116; CPu: 
F[1,10]=3.680, p=0.084; VTA: F[1,13]=0.104, p=0.752, Figure 16). Peptide levels of Leu-
enkephalin-Arg (Arg6-Leu), which is actually a marker for Pdyn expression and the 
dynorphin system but binds to DOR and MOR (155), was increased in the Acb of post-
dependent rats (F[1,13]=8.072, p=0.014) but not in the CPu or VTA (CPu: F[1,14]=0.421, 
p=0.527; VTA: F[1,14]=0.293, p=0.597).  
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Figure 15: DOR binding sites are increased in the striatum of post-dependent rats but G-protein coupling 
is significantly decreased. Bar graphs show DOR binding sites analyzed by [3H]-DPDPE receptor 
autoradiography (A), DPDPE-stimulated G-protein coupling (B), Oprd1 (C) and Penk (D) mRNA in post-
dependent animals in the AcbS (light blue), AcbC (dark blue), CPu (green) and VTA (yellow) as compared to 
control animals (white). DOR Binding sites are increased in the striatum of post-dependent rats while G-protein 
coupling of the receptor is decreased. Within the VTA binding sites as well as G-protein coupling is increased. 
(E-H) Representative autoradiograms on coronal striatal and midbrain sections.  
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Figure 16: Radioimmunoassay for Met-enkephalin (A, MEAP) and Leu-Enkephalin (B, Arg6-Leu) in controls 
(white) post-dependent rats (colored). The RIA experiment was performed by the group of Dr. G. Bakalkin. 
 
 
4.2.2.3 SUMMARY: DOR IN ALCOHOL DEPENDENCE 
In human alcoholics and post-dependent animals, DOR binding sites were increased. DOR 
function is significantly decreased in the striatum of post-dependent rats. In the VTA, both 
DOR binding sites and G-protein coupling are increased. Peptide levels of the DOR-ligand 
Met-enkephalin were unchanged. Leu-enkephalin was increased only in the Acb. Please note, 
Leu-enkephalin is derived from Pdyn rather than Penk. 
 
 
4.2.3 KOR  
The KOR is known to mediate the negative, anhedonic effects of alcohol consumption. It is 
hypothesized that the KOR/dynorphin system is upregulated during alcohol dependence. So 
far, information on this system during protracted abstinence is missing. 
 
4.2.3.1 KOR IN HUMAN POST-MORTEM TISSUE  
KOR binding sites were analyzed in human striatal post-mortem tissue of alcoholic and 
control subjects by [3H]-U69,593 binding that was specifically blocked in the presence of 
norbinaltorphimine (nor-BNI). In the VS, KOR availability was slightly increased. However, 
this was not significant (one-way ANOVA: F[1,15]=2.1086, p=0.17, n=8-9/group). In the NC, 
no differences have been observed (F[1,13]=0.3573, p=0.56, n=7-8/group) (Figure 17A). 
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Figure 17: KOR binding sites a s measured by [3H]-U69,593 autoradiography were measured on brain 
sections of the ventral striatum (VS) and caudate nucleus (NC) of human control (white bars) and 
alcoholic (colored bars) subjects. (A) KOR binding sites are numerically increased in the ventral striatum of 
human alcoholics; however, this is not significant. In the NC, binding sites are unchanged. Statistical analysis 
was performed by one-way ANOVA and data are shown as mean ± SEM. (B) Representative KOR 
autoradiography on a human frontal lobe brain section. When adding nor-BNI, a selective KOR antagonist, [3H]-
U69,593 binding is blocked proofing the specificity of the experimental approach.  
 
 
4.2.3.2 KOR IN POST-DEPENDENT RATS 
KOR binding sites were assessed in post-dependent and control rats by [3H]-U69,593 receptor 
autoradiography. In the ventral as well as dorsal striatum, KOR availability was increased by 
22 % – 37 % (Figure 18A, Suppl. Table 13). This was accompanied by an increase of [35S]-
GTPγS accumulation by 153 % in the AcbS of alcohol-dependent rats indicating increased 
signaling via the KOR in this region. No significant effects were detected in the other regions 
(Figure 18B, Suppl. Table 14). Oprk1 transcripts were only changed in the CPu and increased 
by 11% (Figure 18C, Suppl. Table 15). 
Transcript levels of the dynorphin A and B precursor Pdyn were unchanged in either region. 
These results were confirmed on the peptide level by a radioimmunoassay showing unaltered 
dynorphin A and dynorphin B levels in post-dependent rats when compared to control animals 
(Dynorphin A: Acb: F[1,12]=0.065, p=0.854; CPu: F[1,14]=0.890, p=0.362; VTA: 
F[1,14]=0.216, p=0.649; Dynorphin B: Acb: F[1,14]=0.029, p=0.868; CPu: F[1,14]=1.175, 
p=0.297; VTA: F[1,14]=0.308, p=0.588, Figure 19). 
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Figure 18: KOR binding sites are increased in the striatum of post-dependent rats and indicate increased 
signaling via this receptor. KOR binding sites measured by [3H]-U60,593 receptor autoradiography (A), KOR 
G-protein coupling (B), Oprk1 (C) and Pdyn (D) mRNA analyzed by in situ hybridization in the AcbS (light 
blue), AcbC (dark blue), CPu (green) and VTA (yellow). Neither KOR binding sites nor KOR G-protein 
coupling nor Oprk1 mRNA were detectable within the VTA (n.d. – not detectable). (E-H) Representative 
autoradiograms of the regions analyzed on coronal rat brain sections of the striatum and midbrain. 
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Figure 19: Radioimmunoassay for Dynorphin A (A) and Dynorphin B (B) in controls (white) post-dependent 
rats (colored). RIA experiment was performed by the group of Dr. G. Bakalkin. 
 
4.2.3.3 SUMMARY: KOR IN ALCOHOL DEPENDENCE 
In human alcoholics, KOR binding sites were non-significantly increased in the VS. In post-
dependent rats, however, KOR expression as well as function was elevated indicating 
augmented activity of this system. Dynorphin A and B peptides, the endogenous ligands of 
the KOR, were unchanged in all regions. 
 
 
4.2.4 OVERALL SUMMARY 
Taken together, the data of Study II show a similar regulation of the MOR, DOR, and KOR 
in human striatal post-mortem tissue and the striatum of post-dependent rats. MOR binding 
sites are significantly decreased while receptor functionality is upregulated. In contrast, DOR 
density is increased but its functionality decreased. The KOR system appears to be 
hyperfunctional in post-dependent rats.  
These results suggest a severe dysregulation of the endogenous opioid system with a decrease 
in MOR/DOR but an increased in KOR signaling. This might cause increased aversive states 
in alcohol withdrawal and abstinence contributing to relapse. 
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4.3 STUDY III: IMPACT OF CHRONIC NALTREXONE ON THE ENDOGENOUS OPIOID 
SYSTEM IN ALCOHOL DEPENDECE 
The opioid receptor antagonist NTX is one of the few approved pharmacotherapies for 
alcohol dependence. As an MOR antagonist it is thought to counteract increased MOR 
receptor densities to reduce alcohol craving and relapse. However, the above results proof 
consistently, in human alcoholic subjects as well as post-dependent rats, that the availability 
of cell surface MORs is strongly reduced in the striatum. Even though opioid antagonists, 
including NTX, have been shown to increase opioid receptor densities, the results of this 
study have news value by reporting on changes induced by chronic NTX treatment (14 days, 
2.5mg/kg, i.p.) in alcohol-dependent abstinent rats, here referred to as “alcohol exposed”. So 
far, the focus has been set on actively drinking rats subjected to (mostly) short-time NTX. The 
applied dose of NTX in the here presented study was comparably high and sufficient to inhibit 
alcohol self-administration in rats. However, it did not block alcohol intake the day after 
cessation of NTX treatment (personal communication with Dr. Wolfgang Sommer). After 
seven weeks of CIE and three weeks of abstinence, animals were daily injected with 2.5 
mg/kg naltrexone (NTX) or saline (i.p.) for 14 days (Figure 20E). Three to four hours after the 
last injection the animals were sacrificed in their active phase and the brains analyzed. Results 
are normalized to the respective saline control and compared by group- and region-wise one-
way ANOVA. For a detailed description of the statistics please see “Materials and Methods 
(3.9)”.  
 
MOR binding sites - Chronic NTX treatment caused a comparable increase of MOR binding 
sites in the AcbS of not alcohol exposed and exposed animals by 16 % and 22 %, 
respectively. In the AcbC, by contrast, only a trend towards an elevation (p=0.06) was 
observed in exposed rats. No effects were observed in the CPu. The strongest effects were 
observed within the VTA. Here, MOR binding sites were increased by 61 % and 120 % in not 
exposed and exposed animals, respectively (Figure 20A). For statistical details see Suppl. 
Table 17. 
Pomc - Transcript levels of Pomc in the median eminence were strongly increased following 
daily NTX injections in both groups of animals with an increase by 45 % in not exposed rats 
and by 13 % alcohol exposed rats (Figure 20 D, Suppl. Table 19).  
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bArr2 - Transcripts were mainly unaffected by chronic NTX-treatment with an increase only 
in the CPu of not exposed rats (for raw data and statistics see Suppl. Table 18). 
 
 
Figure 20: Chronic 
naltrexone (NTX) increases 
MOR and KOR binding 
sites and Pomc expression. 
Alcohol exposed (lined bar 
graphs) and not exposed (not 
lined) animals were treated 
with daily injections of NTX 
(2.5 mg/kg, i.p.) or saline for 
14 days. Expression data of 
NTX-treated animals were 
normalized to their 
respective saline control 
(NTX not exposed to saline 
not exposed; NTX exposed 
to saline exposed). The 
effect of NTX treatment in 
each group (not exposed or 
exposed) was analyzed by 
region-wise one-way 
ANOVA. Effects of chronic 
NTX on MOR (A), DOR 
(B), and KOR (C) binding 
sites as well as Pomc (D) 
mRNA expression are 
shown. Data are expressed 
as mean ± SEM in % of 
respective saline control. (E) 
Timeline of the experiment. 
After chronic intermittent 
alcohol exposure (CIE, 7 
weeks) and abstinence (3 
weeks), rats were subjected 
to daily injections of NTX or 
saline. AcbS – nucleus 
accumbens shell, AcbC – 
Acb core, CPu – caudate 
putamen, VTA – ventral 
tegmental area, ME – 
median eminence 
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DOR binding sites - Chronic treatment with the opioid antagonist NTX did not affect DOR 
binding sites in the ventral striatum. However, DOR availability was significantly increased 
by 15 % in the CPu of not exposed animals after NTX treatment. In alcohol exposed rats, the 
increase only reached trend level (p=0.06).  The strongest upregulation of DOR binding sites 
by 63 % was detected in the VTA of not alcohol exposed rats while no changes were observed 
in alcohol exposed rats (Figure 20B). Moreover, NTX appears to affect DOR binding sites 
exclusively in non-dependent animals. Statistical values are presented in Suppl. Table 20. 
KOR binding sites - KOR binding sites were significantly increased in response to chronic 
NTX treatment in the ventral and dorsal striatum of alcohol exposed and not exposed rats. In 
the AcbS, binding sites increased by 50 % in not exposed animals and by 64 % in alcohol 
exposed animals. An elevation of 22 % and 44 % in the AcbC of not exposed and exposed 
rats, respectively, after NTX treatment has been found. In the CPu of both groups of animals, 
KOR expression was elevated by ~30 %, respectively, when compared to their saline control 
(Figure 20 C, Suppl. Table 21). 
 
4.3.1 SUMMARY 
Study III identified the MOR and KOR system as main targets of NTX treatment in the post-
dependent animals. Significant increases of the densities of both receptors have been 
observed. While the main effects on the MOR were observed within the VTA, KOR binding 
was strongly altered in the striatum. This corresponds well with the knowledge of the role of 
the receptors in the regulation of rewarding striatal dopamine release.  
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4.4 STUDY IV: CONVERGENT EVIDENCE FROM ALCOHOL DEPENDENT HUMANS AND 
RATS FOR A HYPERDOPAMINERGIC STATE DURING ABSTINENCE 
Human brain imaging studies (PET) using the radiotracer [11C]-raclopride, report reduced D2-
like receptor availability in alcoholic subjects. Based on these data, the hypothesis of a 
hypodopaminergic state during abstinence developed and this is seen as a driving force for the 
relapsing course of the disorder. However, the interpretation of PET data is challenging as the 
used radiotracers compete with the endogenous ligand dopamine. Thus, a decrease in PET 
signal can reflect both, reduced receptor density or increased endogenous ligand. 
The following study aimed to clarify the state of the dopamine system during alcohol 
withdrawal and abstinence in human post-mortem tissue of alcoholic and healthy subjects and 
in the post-dependent animals to provide support for the interpretation of PET data and the 
development of therapeutic targets.  
 
This study is the joint work of a group of researchers. Dr. Dr. Hamid R. Noori performed the 
meta-analysis. Dr. Marcus Meinhardt and Dr. Stéphanie Perreau-Lenz provided in vivo 
microdialysis and locomotion data. The group of Dr. Georg Köhr performed the 
electrophysiology experiments. I am very grateful for the possibility to present this work in 
my thesis to support the interpretation of my results. 
 
 
4.4.1 POST-MORTEM BRAIN ANALYSIS SUGGESTS A HYPERDOPAMINERGIC STATE IN 
HUMAN ALCOHOLICS 
Ten alcoholic and ten control subjects (“core samples”) were included in this study and all 
subjects were free of positive blood alcohol levels at the time of death. Sections of the VS and 
NC were analyzed for D1 receptor ([3H]-SCH23390), D2-like receptor ([3H]-raclopride) and 
dopamine transporter (DAT, [3H]-mazindol) expression by autoradiography.  
D1 receptor binding sites were significantly reduced in both striatal brain regions (VS: 59%, 
[F1,15=31.7], p<0.001; NC: 61%, [F1,16=104.2], p<0.001, Figure 21A) as compared to 
controls. In contrast, D2-like receptor density was unchanged (VS: [F1,16=0.005], p>0.5; NC: 
[F1,15=1.3], p>0.5., Figure 21B). For DAT, a similar decrease in transporter density was 
detected (VS: 62%, [F1,14=139.8], p<0.001; NC: 56%, [F1,14=65.4], p<0.001; Figure 21C).  
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Additionally to the analysis of the D1 receptor by [3H]-SCH23390 autoradiography in a small 
samples set of n=10/group (Figure 21), the investigation was extended to a large sample set 
(controls vs. non-intoxicated and intoxicated alcoholics, n=9-26/group). Tissue pH, post-
mortem interval, age and smoker state were considered as candidate covariates but a stepwise 
analysis of covariance did exclude them as non-significant. In both regions analyzed, the NC 
and VS, non-intoxicated as well as intoxicated alcoholics displayed significantly reduced D1 
binding sites (NC: [F2,43=7.62], p=0.001, controls: 34.78 ± 2.54, non-intox: 21.47 ± 4.02, 
intox: 19.05 ± 3.83 fmol/mg ± SEM; VS: [F2,43=10.36], p=0.0002, controls: 37.36 ± 2.39, 
non-intox: 24.38 ± 3.16, intox: 19.93 ± 3.50 fmol/mg ± SEM). No significant differences 
were observed between non-intoxicated and intoxicated alcoholics. In the NC, D1 binding 
sites were decreased by 38% and 45% in non-intoxicated and intoxicated alcoholics, 
respectively. Similar effect sizes (reduction by 35% in non-intoxicated and 47% in intoxicated 
alcoholics) were found in the VS. 
 
 
Figure 21: Autoradiography in human striatal post-mortem tissue suggests a hyperdopaminergic state. 
Bar graphs show expression of D1 (red, A), D2 (blue, B) and DAT (green, C) binding sites in human post-
mortem tissue of alcoholic subjects as compared to controls (white). D1 and DAT are significantly decreased in 
the striatum of human alcoholics. Data were analyzed by one-way ANOVA and are represented as mean ±SEM, 
n=8-9/group. (D) Schematic presentation of a coronal section of a human brain with regions used for analysis 
highlighted (NC – nucleus caudatus, VS – ventral striatum). 
 
Transcript levels as assessed by quantitative real-time PCR did not show any differences 
between groups for DRD1 and DRD2 (Table 6). SLC6A3 mRNA encoding for the DAT was 
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not determined as transcripts are mostly located in cell bodies of nigrostriatal projections and 
VTA neurons but not in the striatum. These data suggest that the changes observed on the 
protein levels are not caused by alterations on the transcriptional level but rather by other 
mechanisms such as receptor internalization or degradation.  
 
Transcript Region Controls 
dCt 
Alcoholics 
dCt 
ddCt F p 
DRD1 VS 4.91 ± 0.17 5.03 ± 0.30 -0.12 [1,18] 0.13 0.73 
  NC 4.37 ± 0.10 4.35 ± 0.11 0.02 [1,18] 0.02 0.89 
 
DRD2 
 
VS 
 
0.60 ± 0.30 
 
0.84 ± 0.31 
 
0.24 
 
[1,18] 0.30 
 
0.60 
  NC 3.99 ± 0.10 4.23 ± 0.22 -0.24 [1,18] 0.93 0.35 
Table 11: No changes of dopamine D1 and D2 receptor mRNA expression in post-mortem striatal tissue of 
heavy alcoholics. QRT-PCR for DRD1 and DRD2 mRNA; data are expressed as mean ± SEM, n = 9-10/group. 
GAPDH Ct values in NC, alcoholics: 22.0 ± 0.3, controls: 21.6 ± 0.1; GAPDH Ct values in VS, alcoholics: 23.6 
± 0.3, controls: 23.2 ± 0.2; NC, nucleus caudatus; VS, ventral striatum.  
 
The data from this post-mortem striatal brain tissue analysis indicate reduced dopamine 
signaling via the D1 receptor accompanied by potentially higher extracellular dopamine levels 
due to decreased DAT and unaltered D2-like receptor levels. 
To provide convergent evidence for these surprising findings, a systematic meta-analysis on 
dopamine concentrations and its metabolites during abstinence was performed. Additionally, 
the dopaminergic system was examined at different time points during alcohol abstinence in 
post-dependent rats.   
 
4.4.2 ALCOHOL-DEPENDENT RATS MIRROR THE HYPERDOPAMINERGIC STATE 
OBSERVED IN HUMAN ALCOHOLICS: META-ANALYSIS ON DOPAMINE RELEASE 
DURING ABSTINENCE 
Neither human imaging (204-207, 210, 264) nor animal studies using electrophysiological 
methods on D1 and D2 receptor or DAT availability (214, 217, 265-269) provide sufficient 
data for a robust meta-analysis of the dynamics of dopaminergic processes. Therefore, the 
analysis was focused on alterations of concentrations of dopamine and its metabolites. The 
presented meta-analysis on dopamine release and its metabolites in the Acb during abstinence 
is based on 16 published studies on rats including a total of 192 animals chronically exposed 
to ethanol (214, 216, 270-283). The time course of dopamine, DOPAC and HVA 
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concentrations in Acb (Figure 22) was obtained by continuous interpolation of the averages of 
experimental values with respect to the time of measurement after alcohol withdrawal. While 
the paradigm to history (pattern) of ethanol intake did not affect the analysis, the withdrawal 
period may be considered as a vanishing swing between two states. 
While the studies showed increased dopamine release on day 0 of abstinence, a decrease 
followed on day 1 to 3. Within the first 6 days of withdrawal, dopamine levels declined about 
30% below baseline reflecting a hypodopaminergic state. However, afterwards levels again 
increased and the system moves to a hyperdopaminergic state reaching its peak during the 
second and third week of abstinence (Figure 22 and Figure 23A). The concentration changes 
of dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid 
(HVA) followed a similar pattern as observed for dopamine. 
The data suggest a hypodopaminergic state during early abstinence which is followed by a 
hyperdopaminergic state during protracted abstinence. 
 
 
Figure 22: Dopamine and its metabolites in the Acb were investigated during alcohol abstinence by a 
meta-analysis (performed by Dr. Dr. H. R. Noori). During the first six days of abstinence, dopamine, HVA 
(homovanillic acid), and DOPAC (3,4-dihydroxyphenylacetic acid) concentrations decline up to 30 % of the 
baseline condition (hypodopaminergic state). Afterwards, concentrations rise above baseline levels 
(hyperdopaminergic state). The inlet shows the dynamic regulation of dopamine and the two metabolites during 
the first 24 hours (h) of abstinence.  
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4.4.3 DYNAMIC REGULATION OF DOPAMINE RECEPTORS AND TRANSPORTER DURING 
ABSTINENCE 
To extent the knowledge on the dopamine system obtained in the human post-mortem tissue, 
a time course experiment to analyze D1, D2 receptors and DAT at different time points during 
abstinence in post-dependent rats was performed. After seven weeks of CIE the animals were 
sacrificed at day 0, 1, 3, 7, and 21 after the last alcohol exposure according to previous studies 
(236, 284). On day 0, the animals were sacrificed immediately after the last alcohol exposure 
still having positive blood alcohol levels of 273 ± 52 mg/dl. Dopamine receptors and 
transporters in the AcbS, AcbC, and CPu were analyzed by quantitative receptor 
autoradiographies and are presented as normalized data to respective control group at every 
time point. Raw data of controls are summarized in Suppl. Table 22. 
 
In the AcbS (Figure 23B), binding sites of D1 and DAT varied as a function of time from 
alcohol exposure (two-way ANOVA treatment x time; D1: [F4,54=4.6], p<0.01; DAT: 
[F4,54=4.8], p<0.01). On day 0, D1 receptors were significantly reduced by 11 % but reached 
controls levels one day later (day 1). After three days of abstinence (day 3), a slight increase 
was observed (10 %, p=0.07) that reached significance on day 7. After three weeks of 
complete abstinence (day 21), dopamine D1 receptors were decreased by 14%. Expression of 
DAT binding sites is regulated differently with a trend towards an increase on day 0 (22 %, 
p=0.07). One day afterwards (day 1), DAT was decreased by 33 % and returned to control 
levels on day 7. On day 21, DAT was again significantly reduced by 35 %.  
In the AcbC (Figure 23C), the regulation of D1 receptor and DAT binding sites followed a 
similar pattern as in the AcbS (two-way ANOVA treatment x time; D1: [F4,58=7.9], p<0.001), 
DAT: (F4,61=6.2], p<0.001). D1 was reduced by 15 % on day 0 but increased on day 7 by     
30 % and reduced again on day 21 by 15 %. DAT binding sites were significantly increased 
by 24 % on day 0 and returned to controls levels on days 1 to 7. On day 21, there was a trend 
towards an increase by 11 % (p=0.05). 
In the CPu, alterations in D1 receptor and DAT binding sites paralleled the regulation in the 
AcbS (two-way ANOVA treatment x time; D1: [F4,58=10.8], p<0.001, DAT: [F4,55=25.2], 
p<0.001, Figure 23D). However, D1 receptors were not reduced on day 21.  On day 0, D1 
receptors were decreased by 14 % but increased on day 3 (by 8 %) and day 7 (11 %). DAT 
was significantly increased on day 0 by 34% and decreased on day 1 (by 9 %) and day 21 (by 
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13 %). In contrast to D1 receptor and DAT binding sites, D2-like receptors were not changed 
at any time point in any region (Figure 23B-D).  
 
 
Figure 23: Analyses of the 
dopaminergic system in alcohol-
dependent rats reveals a 
hyperdopaminergic state in 
protracted abstinence. (A) The 
time course of dopamine (DA) 
release in the nucleus accumbens 
(Acb) was modeled by a meta-
analysis from 16 animal studies. 
During the first 6 days of 
withdrawal, the dopamine 
concentrations decline to 30 % of the 
baseline concentrations (hypo-
dopaminergic state) but increase 
again afterwards to a 
hyperdopaminergic state. (B-D) 
Regulation of D1- (red bars), D2-
like receptors (blue) and dopamine 
transporter (DAT, green) binding 
sites during different days of 
abstinence in (B) nucleus accumbens 
shell (AcbS), (C) nucleus 
accumbens core (AcbC) and (D) 
caudate putamen (CPu) of alcohol 
dependent rats vs. control rats (set as 
0 % baseline at each time point). 
After seven weeks of CIE, rats were 
sacrificed immediately after the last 
exposure cycle (day 0) and on 1, 3, 7 
and 21 days of abstinence. D1 and 
DAT are dynamically regulated at 
different times of abstinence, while 
D2-like binding levels remain 
unaffected. Statistical analysis was 
performed by two-way ANOVA 
followed by Fisher’s post-hoc test. 
Data are expressed as percent of controls ± SEM, n=4-8/group. For expression levels in controls of each time 
point see Suppl. Table 22. Gray shaded areas in A-D indicate a hypo- or a hyperdopaminergic state during 
abstinence. (E) Representative images showing total (T) D1 ([3H]SCH23390), D2-like ([3H]raclopride) and DAT 
([3H]mazindol) binding on a coronal striatal rat brain section. Non-specific (NS) binding was determined on 
adjacent section by adding flupenthixol (D1), sulpiride (D2-like) and nomifensine (DAT) to radioligand.  
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4.4.4 ELEVATED EXTRACELLULAR DOPAMINE LEVELS AND HYPERLOCOMOTION DURING 
PROTACTED ABSTINENCE 
Extracellular levels of dopamine were measured in the AcbS region of post-dependent rats 
after 21 days of abstinence via in vivo microdialysis and basal dialysate dopamine 
concentrations were found to be significantly elevated in dependent rats ([F1,26=2.7], p<0.05; 
Figure 24A). Subsequently to baseline measurements, different doses of ethanol (0 (saline), 1, 
2 g/kg, i.p.) were injected. Application of saline did not show significant differences between 
control vs. post-dependent rats (p>0.5). However, injection of 2g/kg ethanol increased 
extracellular dopamine levels in control animals by 49 % ± 33 % as compared to baseline. 
Post-dependent rats displayed a blunted response to the same treatment with a non-significant 
increase of 9 % ± 49 % from baseline levels (Figure 24B). Repeated measurement ANOVA 
revealed a significant effect of alcohol injections ([F1,14=7.1], p<0.05), a trend for treatment 
(dependent vs. control, [F1,14=3.8], p=0.07), but  no interaction effect ([F1,14=0.8], p>0.5). A 
significant increase of TH mRNA levels in the substantia nigra pars compacta of three weeks 
abstinent post-dependent rats by 31 % that was measured by in situ hybridization gives 
support for an increase in accumbal dopamine release (Figure 24C).  
Additionally, locomotion of control and post-dependent animals was assessed in an 
OpenField experiment and in the homecage. In the OpenField (Figure 24D) during first 20 
min, under the conditions of novelty, no differences in total distance traveled were detected 
between control and post-dependent animals (post-dependent 5417.1±405.2 cm vs. control 
5234.3±419.6 cm; p>0.5). When the animals habituated to the OpenField (after the first 20 
min) basal locomotor activity was assessed. Post-dependent animals traveled significantly 
higher track lengths as compared to controls (post-dependent 753.2±72.6 cm vs. controls 
420.8±49.9 cm; mean per 5 min, Figure 24D). In the homecage, post-dependent rats displayed 
hyperlocomotion with a significantly increased total sum of body movements (post-dependent 
45928.7±1206.1 cm vs. controls 40838.4±1294.8 cm, Figure 24E). 
To consider functional consequences of the hyperdopaminergic state on the synaptic level in 
control and post-dependent rats, glutamatergic inputs to medium spiny neurons (MSNs) of the 
AcbS in brain slices were examined during alternative, electrical stimulation in the AcbS 
(Figure 24F-H). Ethanol perfusion (25 mM; for 25 min) increased excitatory post-synaptic 
currents (EPSC) in both groups of rats (n=12 MSNs from 4 control rats; n=7 MSNs from 3 
dependent rats). Subsequent perfusion of the D1 agonist SKF81297 (5 µM; for 20 min) in the 
presence of ethanol further enhanced the EPSCs in control but not post-dependent rats 
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(F[2,20]=2115, p<0.001; dependent, F[2,20]=270, p<0.001 and p>0.05 when adding 
SKF81297), also apparent from the EPSC difference between control vs. dependent rats in 
ethanol plus SKF81297 (p=0.019). 
 
 
Figure 24: Hyperdopaminergic state in three weeks alcohol abstinent rats. (A-B) A microdialysis displays 
increased dopamine levels and blunted response to ethanol treatment in alcohol-dependent rats. (A) Basal 
extracellular dopamine levels within the AcbS are markedly increased in dependent rats (n=15/group). (B) AcbS 
dopamine levels after application of consecutive doses of ethanol (1 and 2 g/kg, i.p.). Control animals show 
increase of extracellular dopamine levels after ethanol (2 g/kg, i.p.), whereas dependent rats show a blunted 
response to the treatment (n=8/group). (C) Elevated TH mRNA levels in the substantia nigar pars compacta as 
measured by in situ hybridization. (D-E) Three weeks abstinent rats display hyperlocomotion as detected by 
locomotor activity records in the homecage assessed with a homecage e-motion system for 72 hrs (D) and 
OpenField for 60 min (E). (F) Representative EPSCs recorded at -80 mV in MSNs were evoked by electrical 
stimulation in the Acb cortex before (baseline) and during perfusion of ethanol (25 mM) and ethanol (25 mM) 
plus SKF81297 (5 µM). Current traces represent the average of ten sweeps. (G) Time courses of the effects 
shown in (F) for normalized EPSCs. (H) Summary of the effects on EPSCs (control: n=12; dependent: n=7). For 
detailed statistics, see text. These data are joint work of N. Hirth, M. W. Meinhardt, H. Salgado, O. Torres-
Ramirez, S. Perreau-Lenz, G. Köhr. 
 
 
4.4.5 SUMMARY 
In summary, these data show a dynamic regulation of dopamine transporter and receptor D1 
expression during alcohol withdrawal and abstinence as measured by autoradiography 
experiments. Dopamine D2 receptors are unchanged in all regions at any time point. An 
increase in dopamine function and a hyperlocomotion in protracted abstinence is suggested 
due to increased midbrain TH mRNA and accumbal extracellular dopamine levels. Hence, a 
hyperdopaminergic state in protracted abstinence was observed.  
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5 DISCUSSION 
5.1 DISCUSSION STUDY I:  ALCOHOLISM INDUCED DOWN-REGULATION OF MU OPIOID 
RECEPTORS PREDICTS RELAPSE BEHAVIOUR: POST-MORTEM AND PET RESULTS 
Pharmacological therapies using the opioid antagonists naltrexone (NTX) or nalmefene to 
treat alcohol dependence by reducing alcohol reward, craving, and relapse, are based on the 
theory of increased MORs in the reward system. This hypothesis has been established 
according to previously published PET studies (106-108). Additionally, it has been shown 
that elevated MOR BPND correlates with alcohol carving (107). However, PET data are 
difficult to interpret. Elevated MOR BPND can either be caused by higher receptor expression 
or/and by low availability of endogenous ligands that compete with the PET tracer. This is 
particularly important as [11C]-carfentanil – the only MOR selective PET ligand established to 
date – is an agonist and thus especially sensitive to synaptic levels of endogenous ligands due 
to G-protein-mediated internalization (285, 286). 
In contrast to the above mentioned view, the here presented post-mortem study shows a clear 
reduction of OPRM1 mRNA as well as MOR binding sites in the NC and VS of alcoholic 
subjects. The finding of reduced MOR binding sites in the brain of alcoholics is consistent 
with the animal literature. Here, a meta-analysis on published rodent studies including 233 
rats found reduced mRNA levels and binding sites especially during the first 3 days of alcohol 
withdrawal. The reduction in MOR binding sites is independent of the A118G genotype 
(Suppl. Table 2). This is in line with a study in the mouse line carrying the human OPRM1 
gene with the A118G genotype (127). In contrast, other studies reported decreased MOR 
expression in G-allele carries. However, they did not analyze striatal brain tissue but the 
global brain (PET) (132), pons tissue of post-mortem specimen (125), and in vitro systems 
(131).  
As shown in Figure 25, a new model of dynamic alterations of the MOR system is proposed 
based on the combined post-mortem brain and in vivo PET data. The endogenous opioid β-
endorphin and other opioids are released upon alcohol consumption (104), thereby mediating 
positive feelings. 
 
92 
 
 
Figure 25: Initial and repeated alcohol consumption results in release of endogenous opioids by 
progressively enhancing frequency and strength of opioidergic neurotransmission. This is accompanied by 
reward and hedonia. As an adaptive mechanism MOR expression gets reduced and a new allostatic state 
develops. In alcohol withdrawal and early abstinence, which are characterized by anhedonia, alcohol-induced 
release of endogenous opioids is suddenly stopped while MOR expression is strongly diminished. During 
protracted abstinence the responsiveness of the opioidergic system is still diminished. In order to recover, the 
system has to adapt to less intense natural rewards in comparison to alcohol. [¹¹C]-carfentanil PET assesses 
MOR availability which depends on the absolute number of MOR binding sites and endogenous ß-endorphin 
levels. Therefore, PET data can only be correctly be interpreted if additional data on either of these measures is 
available. The binding potential (BPND, solid black arrows) is the specific-to non-specific equilibrium partition 
coefficient that is determined by the concentration of the endogenous ligand ß-endorphin and the absolute 
number of MOR binding sites. Saturated [3H]-Damgo autoradiography in post-mortem tissue are measures of 
number of available MOR binding sites (BS), which are reduced in alcoholics at different times of abstinence in 
relation to controls (dashed black arrows). 
 
Chronic repeated alcohol intake results in increased opioidergic neurotransmission and MOR 
expression is downregulated to compensate for this. Diminished surface density of MORs 
may contribute to tolerance to the rewarding effects of alcohol, driving further enhanced 
alcohol consumption. When alcohol use is discontinued, i.e. during acute withdrawal and 
early abstinence, the release of endogenous opioids is suddenly stopped while MOR 
expression is strongly reduced. This combination of low opioids and low MORs might 
contribute to the anhedonic state during early abstinence that is characterized by dysphoria, 
increased anxiety, and depressiveness (35). Reduced peripheral β-endorphin levels have been 
consistently observed in rats as well as alcohol dependent patients during at least the first 
month of alcohol withdrawal (147, 287, 288). Together with the here presented data, this 
suggests a diminished responsiveness of the opioidergic system during alcohol abstinence. 
The system has to recover its ability to react appropriately to less intense natural rewards than 
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alcohol, e.g. social interaction, and release endogenous opioids in response. The reduction in 
endogenous opioids during the recovery phase might constitute the neurochemical stimulus to 
increase and progressively normalize the surface density of MORs.  This is supported by the 
finding of an even stronger reduction of MOR binding sites in alcoholic subjects that were 
drinking until death.  
Previous PET studies report on increased MOR BPND in alcoholics during early abstinence 
(106, 107). Together with the knowledge of significantly reduced MOR binding sites in post-
mortem tissue and decreased plasma β-endorphin levels (147, 289), increased PET signals 
suggest reduced endogenous opioid levels (Figure 25).  
Considering the decrease in MOR binding sites, pharmacological blockade of the remaining 
receptors by antagonists such as naltrexone or nalmefene would be expected to worsen the 
condition of alcohol dependence and induce relapse. Thus, there must be other modes of 
action of this pharmacotherapy such as enhanced signaling at the MOR. However, NTX 
therapy was not effective in the here presented sample which is in line with results from the 
previously published PREDICT study (37, 184, 223). In the PREDICT study, a total of 426 
alcohol-dependent patients did not benefit from NTX when compared to placebo treatment. 
One explanation might be the degree of alcohol dependence severity as a critical factor 
influencing NTX efficiency study (37, 184, 223). In patients with high severity, as included 
into this study, the main target of NTX as well as nalmefene – the MOR – is reduced as the 
results of the post-mortem study show.  
In addition to strongly reduced MORs in the reward system, a second key finding is that low 
MOR BPND in the putamen of alcoholics may predict the risk for alcohol relapse. The here 
proposed model of regulation of the MOR system suggests low MORs to be accompanied by 
a state of anhedonia. Patients suffering from this negative mood state are more susceptible to 
relapse (35). Thus, low MOR BPND may potentially be used as a biomarker for relapse 
prediction.  
 
The investigation of post-mortem tissue can be confounded by various factors, such as 
suicide, pre-mortem medication, smoking and abuse of illicit drugs. In a sensitivity analysis, 
samples displaying such confounding factors were excluded which did not change the main 
findings. Study II gives further proof of the quality of the post-mortem tissue as analysis of 
the DOR and KOR did not show a down-regulation but rather an upregulation or unaltered 
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expression. Although a previous study showed remarkable stability of mRNA and proteins in 
post-mortem tissue – independent of duration of the post-mortem interval – this issue was 
addressed by correlating levels of OPRM1 mRNA and MOR binding sites with PMI, tissue 
pH, RIN in each group and found no significant effects. Overall, the post-mortem tissue 
samples used display a decent quality and were obtained from one of the best providers of 
post-mortem specimens of human alcoholics and healthy controls, the New South Wales 
Tissue Resource Center, University of Sidney, Australia. These samples have already been 
used successfully in numerous studies (173, 290). 
 
5.1.1 SUMMARY 
In summary, reduced MOR is suggested to be a neuroadaptation on response to alcohol-
induced released of endogenous ligands and may explain the low efficiency of naltrexone 
therapy in a subset of severely diseased alcoholic patients. Furthermore, a decreased in MOR 
is proposed to be a molecular marker for a negative disease course. The combination of post-
mortem brain and PET analysis allows the characterization of a receptor status, i.e. the 
number of cell surface receptor. Therefore, it provides more certainty in the interpretation of 
PET results that otherwise is challenging. The data show a strong decrease in MOR binding 
sites in striatal post-mortem tissue. The PET study shows low MOR availability to be 
associated with increased relapse risk. The combined approach of post-mortem and PET 
analysis has led to the development of a new model showing the dynamics of the endogenous 
MOR system during alcohol dependence.  
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5.2 DISCUSSION STUDY II : DIFFERENTIAL REGULATION OF OPIOID RECEPTORS IN 
ALCOHOL DEPENDENCE: EVIDENCE FROM THE HUMAN AND RAT BRAIN 
The results presented in Study I provide evidence for strongly reduced MOR binding sites in 
severely diseased human alcoholic subjects and proposes a new model for the dynamic 
alterations in the MOR system during alcohol dependence. Moreover, these findings suggest 
that treatment with opioid antagonists such as NTX or nalmefene would worsen the situation 
of alcoholic patients leading to relapse. Nevertheless, many patients profit from this 
pharmacological therapy and it is effective in reducing alcohol consumption in humans and 
post-dependent animals. Together, this indicates that there are additional/other mechanisms 
mediating opioid antagonist action in alcohol dependence. Research opportunities are 
undoubtedly limited in living human subjects. Thus, for this study human post-mortem tissue 
and the post-dependent animal model were used to elucidate the regulation of the opioid 
system during alcohol dependence. Dependence was induced in rats by seven weeks of CIE 
followed by three weeks of abstinence. Moreover, the DOR and KOR play a critical role in 
the development and maintenance of alcohol dependence and also NTX shows affinity for 
these receptors. Therefore, they were also included in this investigation. 
 
5.2.1 MOR 
Similar to the situation in human post-mortem tissue, MOR binding sites were significantly 
reduced in the ventral striatum (AcbS) of post-dependent rats. In the CPu, in contrast, no 
changes have been detected (Figure 12A) while in the human post-mortem tissue MOR 
binding sites were strongly reduced in the VS and NC. This most likely reflects the different 
anatomy of the human and rodent brain. In humans, the caudate and putamen are anatomically 
divided by a fiber bundle, the internal capsule, while they are one combined structure in 
rodents. Notably, effect sizes are smaller in post-dependent rats as compared to human 
alcoholics. This may be caused by the higher severity of alcohol dependence and duration of 
heavy alcohol administration in humans. Human alcoholics are likely to consume high 
amounts of alcohol over a period of months up to several years resulting in a stronger 
disruption of homeostasis of brain neurotransmitter systems and more severe 
neuroadaptations. The post-dependent rats were exposed to CIE for seven weeks, reaching 
blood alcohol levels of 150-250 mg/dl and showing withdrawal signs after alcohol 
administration was discontinued (235). Nevertheless, the post-dependent rats are a valid, well 
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established animal model to study alcohol dependence displaying good predictive, face, and 
construct validity (235). As already mentioned in the meta-analysis of MOR regulation during 
withdrawal and abstinence in Study I and in Table 4, most animal studies used a two bottle 
free choice paradigm or alcohol-containing liquid diet for chronic alcohol self-administration. 
Rat strains, duration of alcohol access and abstinence as well as method of quantitative 
analysis varies among studies. For this reason, it is not surprising that variable results on 
MOR status have been reported. Nonetheless, the meta-analysis in Study I found decreased 
MOR binding in the striatum during the first three days of abstinence (Table 9). Investigations 
during protracted abstinence in severely dependent animals were missing so far. This thesis 
aimed to fill this gap and shows a reduction of MOR binding sites in the ventral but not dorsal 
striatum of post-dependent rats and no regulation within the VTA. This decline in striatal 
binding sites appears not to be caused by transcriptional mechanisms since Oprm1 mRNA is 
unaltered in all brain regions (Figure 12C). On the other hand, accumulation of Damgo-
stimulated [35S]-GTPγS, an indicator of receptor G-protein coupling and, thus, of MOR 
signaling, is strongly elevated in the ventral striatum (Figure 12B). As reduced MOR bindings 
sites are an unlikely target of NXT therapy, blocking the alcohol-induced enhanced MOR 
signaling could be a possible target of NTX action to prevent alcohol relapse.  
Although there is no significant change in MOR binding sites within the VTA, G-protein 
coupling appears to be reduced in this region. In combination with reduced β-endorphin levels 
during abstinence as proposed by several investigators (287-289), by Study I, and indicated 
by reduced Pomc mRNA levels (Figure 12D). This may result in reduced disinhibition of 
dopaminergic activity of neurons projecting to the striatum. Consequently, firing of these 
dopaminergic neurons may be reduced resulting in a blunted dopamine response to 
alcohol/drug administration in alcohol dependent animals as shown in Study IV and human 
alcoholics (210).  
A variety of proteins, such as RanBP or RGS-proteins (291-293), can regulate MOR 
internalization and de-/sensitization processes as well as signaling. Another important adaptor 
protein is β-arrestin2 that is known to be linked to MOR signaling and alcohol reward (98, 
101). In case of MOR activation, G-protein signaling cascades are initiated, the receptor is 
phosphorylated by G-protein receptor kinases and affinity for β-arrestin2 is enhanced. In post-
dependent rats, bArr2 mRNA levels are significantly enhanced in regions with decreased 
MOR binding sites but increased Damgo-stimulated [35S]-GTPγS accumulation suggesting a 
role of β-arrestin2 in the development and maintenance of these neuroadaptations (Figure 13). 
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Importantly, Björk et al. (97) showed that elevated bArr2 transcript levels potentially translate 
into increased bArr2 mRNA. This suggests that in the post-dependent animals β-arrestin2 
proteins also are increased. Elevated β-arrestin2 availability might facilitate rapid MOR 
desensitization and internalization upon receptor activation, thereby resulting in reduced cell 
surface receptors. Indeed, overexpression of β-arrestin2 in cell culture has been shown to 
decrease cell surface localization of G-protein coupled receptors (99, 102). Increased MOR 
internalization has also been linked to elevated β-arrestin2 immunoreactivity in rats after 
natural reward (100). However, β-arrestin2 regulation of receptors belonging to several 
neurotransmitter systems including both the opioid and dopamine system is complex (294). 
 
5.2.1.1 SUMMARY: MOR IN ALCOHOL DEPENDENCE 
Taken together, the data show a potential role of β-arrestin2 in the significant reduction of 
striatal MOR binding sites. G-protein coupling of the MOR is significantly increased in the 
striatum, most likely to compensate for reduced binding sites, and this could be the target of 
NTX therapy. However, in severely diseased patients, MOR diminution appears to be more 
pronounced (Study I) and compensatory processes are unlikely to be effective. 
 
5.2.2 DOR 
In contrast to MOR, DOR binding sites were increased in the ventral striatum of human 
alcoholic subjects as measured by [3H]-DPDPE receptor autoradiography (Figure 14). In the 
NC, binding sites were numerically increased but this did not reach significance. This is 
mirrored by the results in the post-dependent animal model where elevated DOR binding sites 
have been found in the striatum and VTA (Figure 15A). In contrast, Oprd1 mRNA levels are 
decreased which may represent a compensatory mechanism to counteract the increased cell 
surface density of the receptor protein (Figure 15C). Even though transcript levels of the 
enkephalin precursor Penk are increased in the ventral striatum this does not translate into 
elevated enkephalin peptide levels as measured by RIA (Figure 15D). Levels of MEAP (Met-
enkephalin-Arg-Phe) are unchanged in all analyzed regions including the ventral striatum. 
Previous studies reported increased enkephalin levels after acute (295, 296) and chronic 
alcohol intake (297) in animals. For instance, post-dependent rats that were subjected to a 
two-bottle free choice paradigm after CIE, showed elevated Met-enkephalin levels 72 hours 
after access to alcohol (298). However, enkephalin levels tend to decline back to control 
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levels after the first week of alcohol exposure (299) and no changes have been reported during 
acute withdrawal and protracted abstinence of 21 days (158, 300). Importantly, this is in line 
with human data where plasma enkephalin levels were unchanged during acute withdrawal 
and abstinence (147). In contrast, a decline in plasma β-endorphin during withdrawal has been 
observed that normalized after five weeks of abstinence (147). The RIA for Leu-enkephalin-
Arg6 showed a small increase in the Acb of post-dependent animals. Even though this peptide 
binds to the DOR it rather is a marker for the dynorphin system as it is synthesized from the 
precursor Pdyn indicating an activation of the KOR/dynorphin system in protracted 
abstinence.  
In a previous PET study employing [11C]-carfentanil and [11C]-methylnaltrindole to assess 
MOR and DOR availability, respectively, in human alcoholics, MOR was found to be 
increased while DOR seemed only numerically but non-significantly elevated (106). On the 
first view this appears to be in contrast with the results presented in this thesis. However, the 
increase in measured [11C]-carfentanil PET signal (MOR) can be explained by a deficiency of 
β-endorphin as it is discussed in detail in Study I and, thus, actually is in line with the results 
of decreased MOR and Pomc in human alcoholics and post-dependent rats. The elevation in 
[11C]-methylnaltrindole signal, although not significant, is comparable to the here presented 
observations of increased DOR in human as well was rodent brain tissue. Even though the 
DOR possess affinity for β-endorphin, its main endogenous ligands are enkephalins. Since the 
levels of enkephalins have been shown to be unchanged or slightly increased in this thesis and 
by others (147, 158, 300), the [11C]-methylnaltrindole signal in controls and alcoholics is 
expected not to be significantly influenced by endogenous ligands. 
In the post-dependent animals, DPDPE-stimulated DOR G-protein coupling is decreased in 
the striatum of post-dependent animals by more than 50 % when compared to control animals 
indicating decreased DOR activity in this region (Figure 15 B). The decrease in DOR 
signaling might increase anxiety and thereby result in elevated alcohol-seeking. DOR 
knockout mice display high innate anxiety and alcohol consumption. Because alcohol intake 
reduced anxiety levels, this is thought to be a self-medication approach (149, 301). 
Additionally, decreased DOR G-protein coupling has been linked to anxiety during cocaine 
withdrawal (302).  
Moreover, in vitro as well as in vivo data suggest that DOR activity requires functional MOR 
expression to form MOR-DOR heteromers (148). However, the MOR and DOR are mainly 
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localized in separate neurons in the rodent forebrain (303) suggesting that the two receptors 
do not interact on the cellular level in these regions. The observations presented in this thesis 
show an opposite regulation of DOR and MOR expression and coupling in the striatum 
(compare Figure 12 and Figure 14). This opposing regulation of receptor availability and G-
protein coupling could be a compensatory mechanism. In post-dependent rats, the opioid 
system might still be flexible enough to counterbalance dependence-induced changes, at least 
in part. For instance, the increase in MOR G-protein coupling and DOR binding sites may be 
an attempt to compensate for decreased MOR binding sites and DOR G-protein coupling. In 
individuals suffering from severe alcohol dependence as most likely is the case in the human 
post-mortem tissue, neuroadaptations are much more pronounced and a compensation of, e.g. 
decreased MOR binding sites by elevated G-protein coupling, is unlikely to be sufficient. 
 
5.2.2.1 SUMMARY: DOR IN ALCOHOL DEPENDENCE 
In summary, the DOR availability is increased but its function significantly decreased in 
alcohol dependence. The increase in DOR binding sites might be a compensatory process to 
counteract strongly diminished G-protein coupling. However, this mechanisms appears no to 
be sufficient and activity of the DOR system is reduced. Functionally, this may be linked to 
increased anxiety as observed in post-dependent rats and, thus, contribute to elevated alcohol 
intake. 
  
5.2.3 KOR 
Acute alcohol releases endogenous opioids β-endorphin and enkephalin that are involved in 
mediating the positive reinforcing effects of alcohol. Furthermore, dynorphins are responsible 
for the negative reinforcing aspects via activating KORs. Higher doses of alcohol cause 
increased dynorphin release, possibly reflecting the anhedonic sensations in response to 
ingestion of large amounts of alcohol. Even though the KOR/dynorphin system is evolving as 
potential target for pharmacological interventions, a detailed description of this system during 
protracted alcohol abstinence is still lacking.  
The analysis of KOR binding sites by [3H]-U69,593 autoradiography in striatal post-mortem 
tissue of human alcoholics revealed numeric but non-significant increases within the VS when 
compared to controls. No effect was detected within the NC (Figure 17). In the post-
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dependent animals, the increases in KOR binding sites reached significance within the ventral 
and dorsal striatum (Figure 18A). Furthermore, G-protein coupling of the receptor was 
increased in the AcbS (Figure 18B). These data show enhanced activity of the KOR system in 
the striatum of post-dependent animals. Pdyn mRNA as well as dynorphin A and B peptide 
levels were unchanged in the same regions and within the VTA.  
A previous post-mortem brain tissue study demonstrated an upregulation of the 
KOR/dynorphin system in the prefrontal cortex and hippocampus of alcoholic subjects (154). 
A more recent analysis of the striatum showed unchanged dynorphin A and B in the nucleus 
caudatus and a decrease of dynorphin A in the putamen (155). The authors state that the 
striatal KOR/dynorphin system is downregulated in alcohol dependence. However, they did 
not analyze KOR mRNA or protein levels and, thus, no complete picture of the system is 
provided. In the post-dependent animals, dynorphin levels were unchanged and, thus, 
correspond well to the previously reported post-mortem data. As the receptor and its G-
protein coupling are significantly increased, the KOR/dynorphin system appears to be rather 
up- than downregulated. This assumption is supported by the fact that blockade of the KOR 
by the specific antagonist nor-BNI reduces alcohol consumption selectively in dependent 
animals (40, 41, 156, 164). 
 
5.2.3.1 SUMMARY: KOR IN ALCOHOL DEPENDENCE 
The upregulation of KOR density and signaling, suggest increased sensitivity of the 
KOR/dynorphin system in alcohol dependence that is, at least in part, responsible for alcohol 
intake behavior and the negative subjective aspects of alcohol withdrawal and abstinence. 
This makes the striatal KOR/dynorphin system a useful target for pharmacotherapies aiming 
to decrease alcohol intake in dependent individuals. 
 
5.2.4 SUMMARY OF THE COMBINED EFFECTS OF OPIOID RECEPTORS IN ALCOHOL 
ABSTINENCE 
The findings of Study II coincide with the “opponent process theory” model (304) that has 
previously been applied for the regulation of the endogenous opioid system in alcohol 
dependence (163). 
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This theory implies that a positive hedonic state as induced by alcohol intake is automatically 
opposed by a negative state (Figure 26). After chronic drug exposure the positive proportion 
would be diminished while the negative would be enhanced. When alcohol intake is ceased, 
this results in enhanced negative emotional states that force the dependent individuals to 
excessively seek and use alcohol (163). Alcohol-evoked MOR and DOR activation by β-
endorphin and enkephalins produces positive hedonic states that are followed by negative 
sensations mediated by the KOR/dynorphin system. In line with this hypothesis, several 
studies report decreased MOR- and DOR-signaling in alcohol dependence and acute 
withdrawal (112, 113, 116) but increased KOR (158-160). 
 
 
Figure 26: The opponent process theory applied for the regulation of the endogenous opioid system in 
alcohol dependence. In a non-dependent state, alcohol consumption results in a positive hedonic emotional state 
that is mediated by the MOR/DOR system. Subsequently, the stimulation of the KOR/dynorphin system 
automatically opposes this by a negative state. In an alcohol dependent individual, the positive component 
diminishes since MOR/DOR signaling is decreased and the negative state is more pronounced since the 
KOR/dynorphin system is supersensitive (adapted from (163)). 
 
The results of Study II are extending our knowledge on the endogenous opioid system in 
protracted abstinence. In post-dependent animals, MOR signaling is attenuated as reflected by 
decreased striatal MOR availability and reduced Pomc levels. DOR signaling is strongly 
diminished as reflected by significantly reduced G-protein coupling. In contrast, DOR binding 
sites are elevated. However, it is questionable if the comparably small increase in binding 
sites, as observed in post-dependent rats (Figure 15) and human brain tissue of severely 
diseased alcoholics (Figure 14), has functional impact compared to the pronounced reduction 
in G-protein coupling. 
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Thus, the positive effects of alcohol intake are diminished. The negative component mediated 
by the KOR/dynorphin system, in contrast, is augmented. This is reflected by increased 
expression and functionality of the KOR and can even be enhanced by elevated anxiety 
induced by decreased DOR G-protein coupling (302).  
 
In summary, Study II provides evidence for a severe dysregulation of the endogenous opioid 
system during alcohol dependence and abstinence. The alterations observed in the post-
dependent animals are – to a certain degree – transferrable to the human situation and, thus, 
the post-dependent animal model provides a good tool to investigate mechanisms underlying 
alcohol dependence in detail.  
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5.3 DISCUSSION STUDY III: IMPACT OF CHRONIC NALTREXONE ON THE ENDOGENOUS 
OPIOID SYSTEM IN ALCOHOL DEPENDECE 
The results of Study I, II and IV as well as the literature (for a summary see (235)) have 
proven the post-dependent animals to be a valid tool to study alcohol dependence and 
translate the results onto the human situation. Therefore, the impact of chronic NTX treatment 
on the endogenous opioid system has been investigated in this model. 
 
The unspecific opioid antagonist NTX displays the highest affinity for the MOR         
(Ki=0.37 nM), followed by KOR (Ki=4.8 nM) and DOR (Ki=9.4 nM) (305). In alcohol-
dependent patients, usually daily doses of 50 mg are recommended by the FDA. Even though 
half-life of NTX and its metabolite β6-naltrexol in humans is only four and eleven hours, 
respectively (176), a single of 50 mg NTX is sufficient to block the MOR for 48 - 72 hours 
(306). Doses that occupy about 80 – 90 % of the MOR occupy 50 - 80 % of KOR (307). DOR 
blockade is expected to be lower as NTX’s affinity is lower. In Wistar rats, NTX’s half-life is 
only about one hour and β6-naltrexol is not detectable (177). In the here presented study, a 
comparably high dose of NTX (2.5mg/kg, daily i.p. injections) was applied that was sufficient 
for blocking alcohol self-administration in rats but did not block alcohol intake the day after 
cessation of NTX treatment (personal communication Dr. Wolfgang Sommer). 
MOR expression was upregulated in the ventral striatum following chronic NTX in alcohol 
exposed (=alcohol-dependent) and not exposed (non-dependent) rats but the main effects were 
found in the VTA. Pomc mRNA levels, the precursor of β-endorphin, were strongly 
upregulated in the median eminence, the main region of Pomc synthesis. The DOR showed an 
upregulation in the dorsal striatum. Strong effects were also found in the VTA, however, only 
in non-dependent animals. KOR binding sites were increased in the dorsal and ventral 
striatum of both not exposed and exposed animals.  
To date, no studies on NTX effects on the molecular level in alcohol-dependent long-term 
abstinent rats have been published. NTX-induced alterations of opioid receptors and their 
ligands have mainly been investigated in actively drinking animals (111, 118, 268) focusing 
on the MOR. To better mimic the human situation where often detoxified alcoholics are 
treated by daily doses of NTX (see (37) and Study I), we chronically administered daily 
injections (2.5 mg/kg, i.p.) to alcohol abstinent rats. Several studies have shown that chronic 
treatment with opioid antagonists including NTX causes an increase of opioid receptors (111, 
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308-311) but no changes in affinity for the radioligand [3H]-Damgo (312). However, this 
thesis is the first study to report on the expression levels of all opioid receptors by saturated 
receptor autoradiographies in alcohol-dependent long-term abstinent rats receiving chronic 
NTX-treatment. 
Interestingly, the brain regions and opioid receptors analyzed appear to be differentially 
affected by NTX. MOR binding sites are increased in the ventral striatum but the main effects 
are observed within the VTA (Figure 20A). Investigating striatal brain regions, Oliva et al. 
(118) reported the strongest NTX effects on MOR function within the AbcS of actively 
drinking animals and suggested this might be the target region of NTX treatment. A series of 
studies proposed that the ventral striatum in alcohol dependent patients but not healthy 
controls developed increasing tolerance to the ability of alcohol to activate this region (239, 
313, 314) which may be explained by the observed dependence-induced decreases in MORs. 
NTX elevates MOR density which could be the rational for increased striatal activity after 
NTX treatment as reported by others (313). Moreover, NTX is thought to remove the 
inhibitory tone on the VS that is exerted by KORs by blocking those receptors. 
Within the VTA, MOR binding sites were increased by 61 % in not exposed and by 120 % in 
exposed rats after chronic NTX treatment. Activation of VTA MORs results in disinhibition 
of dopaminergic projection neurons and causes dopamine release in the ventral striatum (see 
feedback loop Figure 8). Blocking those receptors might be the mechanism by which NTX 
further attenuated alcohol-induced dopamine release in the striatum (174, 175).  
Since bArr2 mRNA levels are neither changed in the AcbS nor VTA of exposed and not 
exposed rats, the strong increase of receptor densities observed in those regions appears to be 
mediated by other mechanisms. For example, increases in MOR binding sites evoked by NTX 
and naloxone, a broad spectrum opioid antagonist, were accompanied by decreases in 
trafficking proteins G-protein receptor kinase 2 (GRK-2) and dynamin (DYN-2) (310, 315).  
The involvement of DOR in NTX-treatment outcome in the alcohol-dependent animals is 
debatable. Although NTX displays the lowest affinity for the DOR (as compared to MOR and 
KOR), a comparably high dose of NTX (2.5mg/kg) was applied. Thus, this dose is assumed to 
be sufficient to also affect DORs. Animal studies found heterogeneous results of DOR 
blockade on alcohol intake and reward are heterogeneous (316-321). This and the strong 
down-regulation of DOR G-protein coupling in the striatum of alcohol exposed rats (Study 
II) might indicate only a small impact of DOR in the treatment outcome of NTX therapy. 
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The KOR, on the other hand, seems to be a useful target for the treatment of alcoholism as 
antagonizing the receptor results in a reduction of alcohol self-administration specifically in 
alcohol-dependent animals (40, 41, 156). Naltrexone is effective in blocking alcohol self-
administration in alcohol-dependent rats but does so also in non-dependent animals (41). NTX 
and nalmefene show equal affinity for the MOR but nalmefene has a higher affinity to KOR. 
Equivalent low doses of both compounds reduce alcohol consumption in non-dependent 
animals, probably due to binding to MOR. However, the same dose of NTX was not sufficient 
to reduce alcohol intake in alcohol-dependent rats while nalmefene was efficient (41). This 
suggests that the compounds do not primarily exert their effects via the MOR in alcohol-
dependent animals at low doses. As the results of Study II show, MOR binding sites are 
significantly reduced in post-dependent animals and the low doses of NTX might not be 
sufficient to occupy the remaining receptors. The superiority of nalmefene in reducing alcohol 
consumption in dependent animals most likely can be assigned to its higher activity at the 
KOR/dynorphin system which is upregulated during alcohol dependence and, thus, provides a 
good target. 
 
Furthermore, NTX appears to be differently effective in increasing MOR binding sites in 
alcohol exposed than in not exposed animals which is especially marked within the VTA. 
Here, MOR binding sites were increased by 61 % in not exposed and by 120 % in exposed 
rats after chronic NTX treatment. Behaviorally, NTX dose-dependently decreased alcohol 
self-administration in alcohol exposed and control rats but might be more efficient in 
dependent animals (41). Differences in effect sizes most likely are due to differences in the 
basal state of the opioid system at which NTX therapy exert its effects. Study II revealed 
differences in opioid receptor expressions between control and post-dependent animals which 
were also observed in this study when comparing saline treated not exposed and saline treated 
exposed animals (see raw data in Suppl. Table 17, Suppl. Table 20, Suppl. Table 21). Thus, 
NTX most likely acts differentially in alcohol-dependent and non-dependent animals as 
baseline levels of opioid receptors are different. This shows the necessity to study NTX 
effects in alcohol dependent individuals and not healthy controls as outcomes can be different. 
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5.3.1 SUMMARY 
In conclusion, the MOR and KOR were the main target of NTX treatment in the here applied 
experimental setup. More precisely, the MOR within the VTA and the KOR within the 
striatum appear to play a major role in NTX pharmacology. This suggests that NTX exerts its 
effects by affecting midbrain MORs and striatal KORs to induce its anti-relapse effects. 
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5.4 DISCUSSION STUDY IV: CONVERGENT EVIDENCE FROM ALCOHOL DEPENDENT 
HUMANS AND RATS FOR A HYPERDOPAMINERGIC STATE DURING ABSTINENCE 
In this study, evidence is provided for a hyperdopaminergic state in protracted alcohol 
abstinence in humans as well as rats. Receptor autoradiographies in human post-mortem 
tissue of alcoholic subjects show significant reductions in striatal D1 receptors and DAT 
while D2 receptor levels are unchanged. In an additional analysis of D1 receptors in a larger, 
more heterogeneous sample of human alcoholics and controls, D1 downregulation is 
independent of the smoking state of the subjects or active alcohol consumption (positive 
blood alcohol levels at the time of death). These results are supported by a dynamic regulation 
of D1 and DAT in alcohol dependent animals with a pronounced reduction of both proteins 
after three weeks of alcohol abstinence. On a functional level, a lack of glutamatergic 
modulation upon stimulation of D1 was observed. Furthermore, substantia nigra pars 
compacta TH mRNA levels as well as basal extracellular dopamine in the AcbS is increased 
which is supported by a meta-analysis. Accumbal dopamine shows a blunted response to 
alcohol challenges. Behaviorally, post-dependent rats display hyperactivity. Taken together, 
all findings provide conclusive evidence for a hyperdopaminergic state during protracted 
abstinence. In accordance with the literature, the time course study suggests a dynamic 
regulation of the mesolimbic dopamine system during abstinence with a hypodopaminergic 
state during acute withdrawal (213, 322) and a hyperdopaminergic state that is characteristic 
for protracted abstinence (Figure 23 and Figure 27).  
 
A major hypothesis in the alcohol research field proposes a hypodopaminergic state as driving 
force for alcohol relapse (322, 323). This view is supported by animal experiments (213) and 
PET studies that report a reduction of striatal D2-like receptor availability in alcoholic 
patients (204-210). However, other PET studies provide incoherent results (211, 212, 324). 
Therefore, saturated receptor autoradiographies were performed in this thesis to assess the 
number of dopamine receptors and the DAT. Interestingly, D1 receptors as well as DAT are 
significantly reduced in striatal human post-mortem tissue of human alcoholics as compared 
to controls while D2 receptor levels are unaltered. The reduction of D1 receptors is 
independent of “smoking” and alcohol consumption shortly before death. This implies rather 
a hyper- than a hypodopaminergic state and shows that the interpretation of PET results is 
challenging. The commonly used low-affinity radiotracers can easily be displaced by 
competing endogenous dopamine. Hence, a decreased PET signal does not necessarily result 
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from reduced receptor levels but can be caused by increased endogenous ligands. In fact, it 
has been shown that pharmacological manipulation of dopamine levels alters striatal D2 
receptor availability as assessed by the widely used low affinity tracer [11C]-raclopride (325). 
A recent study using the PET ligand [18F]-fallypride which is less sensitive to endogenous 
dopamine levels (326) reports unaltered D2 receptor availability in abstinent alcoholics when 
compared to healthy controls (211).  
A previous post-mortem study found a similar reduction of D1 binding sites as the present 
study (327). Furthermore, they observed a reduction of D2 receptors that is in apparent 
contrast to our data. This inconsistency can be caused by various factors. Some samples in the 
study of Tupala et al. (327), display high levels of alcohol or medication at the time of death. 
Although we show with our additional analysis in an extended sample set that D1 binding 
sites are not significantly changed by active alcohol use, this is not necessarily true for D2 
binding sites. The reduction of DAT is in line with our and other observations in human in 
vivo studies and post-mortem tissue (264, 324, 328, 329). Moreover, increased dopamine 
synthesis was observed in in vivo human imaging studies by assessing the uptake of [18F]-
DOPA, an immediate precursor of dopamine synthesis (330).  
Animal studies can provide further insight into alterations of the mesolimbic dopamine 
system in alcohol dependence. The focus of preclinical studies has been set on the withdrawal 
period where reward deficits associated with suppression of accumbal dopamine release has 
been observed (12, 216, 331). Remarkably, fewer efforts have been made to elucidate 
adaptations in the dopamine system in protracted abstinence which is the most relevant 
clinical condition in alcohol and other substance use disorders (12, 35, 223). To fill this gap, a 
meta-analysis of the existing rodent literature on concentrations of dopamine and its 
metabolites in the AcbS at different time points during abstinence was performed. We found 
evidence for increased concentrations during active alcohol consumption (day 0) that was 
followed by a decline during acute withdrawal. Around the 6th day of abstinence an increase 
in dopamine and its-metabolites has been found which is augmented in protracted abstinence. 
The general pattern of dopamine and its metabolites appears to be robust and seems to be 
regulated in an oscillatory-like manner over time, even though the method of dependence 
induction in rats varies among studies.  
To confirm this pattern of regulation at the membrane level, autoradiographies were 
performed for the dopamine receptor D1 and D2 and the DAT in the AcbS, AcbC as well as 
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the CPu of alcohol dependent rats at different time points of abstinence according to previous 
studies (236, 332). A similar regulation of the dopamine receptors/DAT was found in all 
regions analyzed with no alterations of the D2 at any time point. Under conditions of alcohol 
load (day 0), D1 receptors are significantly decreased in response to increased availability of 
extracellular dopamine at this time point. This is followed by an increase of D1 until day 7 of 
abstinence which may be caused by the decrease of dopamine during acute withdrawal. At 
this time, dopamine concentrations are rising again ending the need for elevated D1 binding 
sites. When dopamine concentrations are high on day 21 of protracted abstinence, D1 binding 
sites are decreased again (Figure 27). This downregulation of D1 receptors in response to 
elevated dopamine levels is further supported on a functional level by electrophysiological 
data. Upon D1 stimulation a blunted modulation of glutamatergic transmission was observed 
in accumbal MSNs in the presence of alcohol.  
The most prominent alterations were observed for DAT. On day 0, when alcohol is still 
present and dopamine levels are high, DAT levels are increased. Most likely plasma 
membrane recruitment and transport of DAT is increased to compensate for increased 
extracellular dopamine. Dopamine concentrations decline during acute withdrawal which is 
the followed by a reduction of DAT as part of a feedback regulation (333). The mechanisms 
underlying the regulation of the DAT at the different time points of abstinence remain 
unknown. During protracted abstinence, however, dopamine concentrations increase again 
which induces a decrease in DAT (Figure 27). This downregulation of DAT may reflect an 
important vulnerability factor for a ‘relapse-prone’ state of the reward circuitry in abstinence.  
Furthermore, TH mRNA expression was increased during protracted abstinence suggesting 
increased dopamine synthesis. Indeed, an in vivo microdialysis experiment showed elevated 
extracellular dopamine levels within the AcbS. This is further supported by increased 
locomotor activity in abstinent post-dependent rats. In addition to increased dopamine levels 
in the AcbS, the microdialysis experiment showed a blunted accumbal dopamine response to 
acute alcohol injections in post-dependent rats in protracted abstinence which coincides with 
previous studies (207, 210). This is in line with reports from human PET studies after 
psychostimulant challenges in alcohol dependent patients. There are two possible 
interpretations for this lack of responsiveness: either response dynamics are state specific 
dependent on low or high extracellular dopamine levels or it reflects a relative dopamine 
deficit due to high chronic demands that have exhausted compensatory mechanisms. 
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Figure 27:  Schematic illustration of a dopaminergic synapse during the addiction cycle. Within the 
striatum of healthy individuals, D1 (red color) and D2 (blue color) receptors mainly are distributed onto different 
types of neurons to the post- and presynaptic site, respectively (192). DAT (green) is localized to the presynaptic 
site, where it is crucial for the termination of dopamine (DA, black circles) transmission and the maintenance of 
presynaptic dopamine storage (drug-naïve). Chronic alcohol exposure induces increases in extracellular 
dopamine resulting in decreased D1 and increased DAT (day 0). Cessation of alcohol exposure inhibits 
dopamine release causing a hypodopaminergic state with a compensatory increase of D1 and decrease of DAT 
during the first three days of acute withdrawal (day 1-3). After that, dopamine release is increasing, and 
subsequently D1 and DAT are increasing on the post- and presynaptic site (day 7). In protracted abstinence, 
extracellular DA concentrations are high (hyperdopaminergic state) which causes a reduction of both D1 and 
DAT (day 21). This state mirrors our post-mortem data from heavy alcoholics. D2 is not changed at any time 
point (days 0-21). 
 
On a mechanistic level, the here reported decrease in D1 and DAT binding sites in alcoholic 
subjects as well as post-dependent rats on day 21 of abstinence can be explained in several 
ways. Repeated alcohol intoxication and subsequent chronic stimulation of the D1 may result 
in internalization and degradation of the receptor. Such a mechanism has been demonstrated 
after repeated administration of dopamine agonists and produced a lack of sensitivity to 
subsequent administration of dopamine agonists on a behavioral, biochemical, and 
electrophysiological level (334, 335). Moreover, there is an intrinsic relationship between 
DAT and D1 expression as DAT knockout mice display less D1 binding sites (336). 
Alternatively, the decrease of D1 could be associated with the hyperactive corticotropin-
releasing hormone system (337). Indeed, increased activity of the extra-hypothalamic CRH 
system is well established in the post-dependent model (237).  
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During both, acute withdrawal and protracted abstinence, a high risk for alcohol relapse 
exists. According to the presented results, this increased vulnerability can be linked to either a 
hypo- or hyperdopaminergic state. In a hypodopaminergic state, relapse risk might be 
increased due to reward deficiency while in a hyperdopaminergic state hyperactivity and poor 
impulse control may cause vulnerability to relapse. Many biological functions dependent on a 
homeostatic regulation whereby too low as well as too high levels impair performance (338). 
  
5.4.1 SUMMARY 
In summary, this study shows the dynamic regulation of the mesolimbic dopamine system 
during acute alcohol exposure, withdrawal and protracted abstinence to extent our knowledge 
of the neurobiology of alcohol dependence and establishes the concept of a 
hyperdopaminergic state during alcohol abstinence. Enhanced dopaminergic activity during 
acute alcohol exposure is followed by a hypodopaminergic state that is characteristic for the 
first few days of alcohol withdrawal. Subsequently, counteradaptive changes involving D1, 
DAT and dopamine releasing properties result in a hyperdopaminergic state during protracted 
abstinence. To identify whether this hyperdopaminergic state is a vulnerability factor for 
craving and relapse in alcohol dependence clinical studies are warranted and may provide a 
window for specific interventions. 
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5.5 GENERAL DISCUSSION: THE INTERACTION OF THE ENDOGENOUS OPIOID AND 
DOPAMINE SYSTEM 
In summary, this thesis gives conclusive evidence for a dysregulation of the dopamine and 
endogenous opioid system during abstinence in alcohol dependent humans and rats. The 
dopamine system is dynamically regulated and is characterized by a hypodopaminergic phase 
during acute withdrawal but by hyperdopaminergia during protracted abstinence (Study IV). 
The endogenous opioid system is closely associated with the dopamine system and modulates 
dopamine release in the Acb. The results show a significant reduction of MOR densities in the 
striatum of human alcoholics as well as post-dependent animals (Study I and Study II). 
Within the VTA, functionality of the MOR is decreased. The reduction in MOR density is 
counteracted by chronic naltrexone treatment (Study III). DOR binding sites are increased in 
all analyzed regions while coupling of the receptor to intracellular G-proteins is strongly 
reduced (Study II). The KOR system is upregulated (Study II).  
Various studies revealed an interaction of the mesolimbic dopamine and opioid system. 
Opioid receptors are involved in the modulation of accumbal dopamine release, thereby 
contributing to the rewarding and reinforcing effects of alcohol (220, 222, 230, 339-342).  
The VTA is mainly composed of dopaminergic  (60-65 %) and GABAergic (30-35 %) 
neurons that project to various brain areas, including the striatum and amygdala (202). A 
simplified scheme of the neurocircuitry between VTA and Acb is  shown in Figure 28A. 
Accumbal GABAergic medium spiny neurons (MSNs), the major striatal cell type (90-95 %, 
(202, 343)), project back to the VTA via a direct or indirect pathway. The direct pathway is 
characterized by D1 expressing neurons that co-localize dynorphin and substance P (192, 232, 
344). MSNs of the indirect pathway are expressing D2 and enkephalin. They innervate the 
pallidum which in turn sends projections to the midbrain. Even though the distinction of D1-
rich direct and D2-rich indirect pathways is more pronounced in the dorsal striatum, it is also 
observed in the ventral striatum/Acb (202). Activation of striatal D1 receptors facilitates 
signaling via the direct pathway through induction of long-term potentiation (LTP) on 
glutamatergic synapses (345, 346). In contrast, D2 stimulation blocks signaling via the 
indirect projections by induction of long-term depression (LTD) (347). These processes are 
crucial for reward- and aversion learning, respectively (348-351). 
MSNs of the direct pathway synapse onto non-dopaminergic neurons in the VTA and their 
terminals have been proven to be sensitive to MOR agonists (352). Presynaptic activation of 
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these MORs results in hyperpolarization via G-protein dependent voltage-gated potassium 
channel pathways (353, 354). This removes GABAergic inhibition on dopaminergic neurons. 
The activity of MORs is crucial for the maintenance of baseline dopamine levels as well as 
firing in response to activating cues (220). In a non-dependent individual, alcohol intake 
results in activation of MORs by endogenous opioids and, thereby, increased striatal 
dopamine release (223). 
 
Based on the results of this thesis and the literature a new model is proposed to describe the 
link between the observed hyperdopaminergic state and the strong reduction of MOR binding 
sites in alcohol abstinence.  
In the ventral striatum of human alcoholics as well as long-term abstinent post-dependent rats, 
MOR binding sites are significantly decreased (Figure 28B). Striatal MORs have been shown 
to be involved in dopamine release in the striatum as intra-accumbens application of the MOR 
agonists fentanyl or Damgo increase accumbal dopamine (355). However, another study did 
not observe this effect (220). These differences might be due to different agonist 
concentrations used and other methodological differences (355). In the Acb, MORs are 
expressed, among others, on corticostriatal terminals, extrasynaptically on MSN dendrites 
(356, 357), and presynaptically on GABAergic afferents (357, 358). Thus, they are ideally 
located to modulate the activity of striatal neurons.  
Acute alcohol consumption releases endogenous opioids, including β-endorphin (104, 231), 
and the presynaptic activation of MOR on GABAergic afferents might result in elevated 
activity of MSNs and disinhibition of dopaminergic neurons. Consequently, extracellular 
dopamine release is transiently increased within the striatum and induces reward-learning by 
activating the direct pathway. In contrast, the indirect pathway, and thus aversion-learning, 
remains silent as elevated dopamine concentrations act on the D2 receptor (Figure 28B).  
The proposed model (Figure 28C) suggests that a decrease in MORs in the striatum during 
abstinence results in reduced inhibition of GABAergic MSNs. This might be due to 
diminished MOR-mediated inhibition of cortical glutamatergic inputs to the striatum (359-
361). Consequently, MSN efferents to the VTA are increasingly active and exert inhibition on 
GABAergic VTA neurons. Since these VTA neurons regulate the activity of dopaminergic 
afferents to the striatum, this causes elevated striatal dopamine release as measured as a 
hyperdopaminergic state by in vivo microdialysis (Study IV).  
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Figure 28: Feedback loop between the ventral striatum and the VTA. D1 expressing striatal GABAergic 
medium spiny neurons (MSNs) innervate GABAergic VTA neurons via the direct pathway. D2 expressing 
MSNs project via an indirect pathway to the VTA. (A) Dopaminergic VTA neurons are under inhibitory control 
by GABAergic inputs. Disinhibition of the dopamine neurons, i.e. by activation of MOR, results in striatal 
dopamine release. Activation of striatal D1 receptors facilitates signaling through the direct pathway which is 
associated with reward learning. D2 stimulation blocks the indirect pathway and, thereby, aversion-learning. (B) 
Acute alcohol intake activates the MOR in the striatum and VTA resulting in disinhibition of dopamingeric VTA 
neurons and dopamine release in the striatum is transiently increased. By stimulating D1 receptors the direct 
pathway is activated causing reward learning. (C) In alcohol dependence, MORs are strongly decreased in the 
striatum resulting in elevated GABAergic input on VTA GABA neurons. Thus, dopaminergic neurons are 
disinhibited and a hyperdopaminergic state can be observed within the striatum. Due to elevated basal dopamine 
levels, the direct pathway might be continuously activated and the system decreases D1 receptors to counteract. 
The indirect pathway may be activated as well since D2 receptors might be desensitized by long-term elevated 
dopamine levels (362). DA – dopamine, bEND – β-endorphin, inhibitory projections (GABAergic) – red, 
modulatory (dopaminergic) – yellow 
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The hyperdopaminergic state in post-dependent animals is accompanied by decreased striatal 
D1 and unchanged D2 binding. Densities of the D1 receptor most likely are decreased to 
counteract the elevated dopamine concentrations (334, 335). As compared to the situation of 
acute alcohol administration, the direct pathway might still be activated but to a lesser degree. 
Consequently, the rewarding effects of alcohol would be diminished. Although D2 receptor 
densities are unaltered in post-dependent animals, the proposed model suggests increased 
activation of the indirect pathway during alcohol abstinence (Figure 28C). Most likely, a new 
allostatic state developed in the dopamine and opioid system in alcohol dependence and the 
system adapts to these new conditions. The elevated dopamine concentrations in the striatum 
can lead to desensitization of the D2 receptor, e.g. by functional uncoupling of the receptor 
(362), which might be linked to elevated β-arrestin2 levels as found in Study II (363). The 
D2 would now need even higher dopamine levels to effectively block the “aversion”-pathway. 
Alcohol challenges, however, showed only blunted dopamine responses. Thus, the 
hypothetical combination of a decrease in activity of the direct (“reward”) and increase in the 
indirect (“aversion”) pathway may contribute to the elevated negative emotional states and 
vulnerability to relapse in alcohol abstinence. 
In the post-dependent animals, an increase in striatal MOR G-protein coupling has been found 
and is interpreted as a compensatory mechanism. However, this is unlikely to be sufficient to 
counteract the significant reduction in MOR density levels as the endogenous ligand, β-
endorphin, is reduced during abstinence as well (Study I, II, and (147, 287, 288)). 
Furthermore, in heavy human alcoholics the reduction in striatal MOR binding sites is even 
more pronounced suggesting that an increase in G-protein coupling of the remaining receptors 
would not be sufficient to restore MOR function.  
Within the VTA, MOR binding sites are unchanged and the proposed model (Figure 28C) 
assumes that VTA MORs do not considerably contribute to the hyperdopaminergic state in 
alcohol abstinence. However, G-protein coupling is slightly decreased in this area indicating 
disruptions in MOR signaling. In combination with diminished alcohol-induced β-endorphin 
release this might lead to a dysfunctional disinhibition of dopaminergic neurons upon alcohol 
intake. This may be reflected by the blunted dopamine release in response to an alcohol 
challenge (Study IV) and might contribute to a reward deficit. 
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The anti-relapse pharmacotherapy NTX has been proven to be efficient in post-dependent 
animals (235). In abstinent rats subjected to seven weeks of CIE, 14 days of daily NTX 
injections resulted in strongly increased MOR binding sites in the AcbS and VTA. Thus, the 
NTX-induced increase in MOR density and Pomc is suggested to counteract the alcohol 
induced receptor/ligand losses and restore normal receptor function. However, based on the 
here presented data it cannot be explained how NTX counteracts alcohol-induced dopamine 
release (174, 175). To answer this question, more studies have to be conducted resolving the 
precise localization of elevated MOR in the involved brain regions. Moreover, analyzing the 
effect of NTX on the dopamine receptors and dopamine release in the post-dependent animals 
would be helpful. 
 
Certainly, the proposed model has limitations. First, the analysis of binding sites by 
autoradiography methods is not suitable to distinguish cell types expressing the MOR. For 
this reason, it is unclear if the reduction of striatal MOR is found mainly on dendrites or 
terminals. Depending on cell type and cellular localization activation of MOR can have 
inhibitory or excitatory effects. Second, the model only considers the ventral striatum and 
VTA. The feedback loop including the dorsal striatum and substantia nigra is excluded. 
However, it might be assumed that similar processes are involved in the opioid and dopamine 
systems in those regions. Study IV reveals a comparable regulation of the dopamine receptors 
in the dorsal striatum suggesting that a hyperdopaminergic state is also present there. 
Moreover, no data are available on the ventral pallidum and should be collected to strengthen 
the model. Third, additional MOR-sensitive GABAergic terminals arising from cell 
populations outside the VTA to modulate dopamine output that have not been studied in this 
thesis. This, for example, includes GABAergic neurons directly projecting from the rostral 
medial tegmental nucleus onto dopaminergic neurons within the VTA (364, 365). It has also 
been proposed that projections from the CeA modulate the activity of GABAergic neurons 
within the VTA and this can result in disinhibition of dopaminergic projection neurons to the 
striatum (366). Moreover, agonist-stimulation (Damgo) of MORs can directly excite VTA 
neurons, including dopaminergic neurons via opening of Cav2.1 channels. This effect is 
independent of GABA or glutamate signaling (367). Fourth, the opioid receptors DOR and 
KOR also modulate striatal dopamine release but have not been included in the model.  
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Agonist stimulation of DORs but not KORs results in elevation of dopamine in the striatum 
(220, 222, 368). DORs are predominantly expressed presynaptically and localized on axons 
and axon terminals to regulate dopaminergic and glutamatergic activity (369-371). Although 
to a lower extent, DORs are also expressed postsynaptically to regulate the responses of 
MSNs (370). In the VTA, the DOR is expressed at significantly lower levels than MOR. 
However, receptor density as well as signaling is increased in post-dependent abstinent rats. 
This upregulation might be a compensatory mechanism to counteract diminished MOR 
functionality and maintain dopaminergic signaling at least at lower levels.  
KORs within the striatum are expressed on dopamine terminals, on GABAergic inputs to the 
AcbS, and, to a lesser extent, on presumably excitatory synapses (163, 372, 373). Importantly, 
agonist-activation of KORs in the striatum reduces basal dopamine release while antagonists, 
such as nor-BNI, enhance dopamine (220, 230). In this thesis, it was methodologically not 
possible to detect KOR within the VTA. Nevertheless, KORs are expressed in this brain 
region, e.g. presynaptically on glutamatergic inputs to the VTA and directly on VTA 
dopamine neurons (163, 374, 375). However, stimulation of KORs within this brain region 
does not modulate striatal dopamine responses but rather decreases prefrontal dopamine 
release (220, 222, 375).  
 
5.5.1 SUMMARY 
Together, this provides evidence for an opposing regulation of dopamine by the opioid 
receptors MOR/DOR and KOR. Furthermore, the observations that KOR agonists produce 
aversive and dysphoric effects implies that a blunted dopamine release is responsible for the 
behavioral and emotional changes (340). The increase in KOR signaling within the striatum 
of post-dependent rats (Study II) may contribute to the blunted dopamine response to an 
alcohol challenge (Study IV) and contribute to anhedonic emotional states that further 
enhance drug-seeking.  
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6 SUMMARY AND OUTLOOK 
By combining the analysis of human post-mortem tissue of alcoholics and an animal model of 
alcohol dependence this thesis gives important insight into the regulation of the endogenous 
opioid and dopamine system. Dependence-induced neuroadaptations in these neurotransmitter 
systems are characterized in detail and new models of the time course and consequences of 
these neuronal changes are proposed. 
The analysis of the endogenous opioid system revealed reduced functionality of the 
MOR/DOR but an increase in the KOR system. It is suggested that these alterations are, at 
least in part, responsible for the elevated anhedonic states during alcohol abstinence and are a 
vulnerability factor for alcohol relapse. Furthermore, the data indicate a disruption of 
opioidergic modulation of dopamine transmission during alcohol abstinence. This might result 
in increased basal dopamine levels, blunted dopamine release in response to alcohol cues and 
anhedonic states. NTX may counteract these neuroadaptations.  
Based on the time-dependent regulation of the dopamine system during alcohol withdrawal 
and abstinence, it can be hypothesized that neurotransmitter systems do not assume a static 
new state but rather show an oscillatory-like behavior. The deviations from the state in 
healthy subjects, either increased or decreased activity of the system, lead to phases of 
vulnerability which are interspersed with phases of higher stability when the state of the 
system resembles more the state of a healthy subject.  
However, further studies are needed to investigate these hypotheses in detail. 
The findings of the applied translational approach provide a solid basis for the design of 
future investigations and suggest a reinterpretation of previous PET results. It is proposed that 
PET studies ideally should be combined with the analysis of human post-mortem tissue to 
optimize the gain of knowledge and achieve more precise pictures of neuronal changes 
underlying diseases.  
Taken together, this thesis is an important step towards the development and/or improvement 
of pharmacological therapies for alcoholism by providing a detailed picture of dependence-
induced neuroadaptations in protracted abstinence that are relapse-preventing targets. 
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9 APPENDIX 
Suppl. Table 1: Demographic data and tissue characteristics of human post-mortem subjects. 
Age PMI Brai
n 
pH 
Clinical cause of death Toxicology DSM IV 
Alcohol class 
Smo
k-
ing 
A11
8G 
34 8.5 6.61 Hanging Blood alcohol 0.341g/100ml Alcohol abuse 
Chronic > 80g 
Yes AG 
54 17 6.41 Chest and abdominal injury Blood alcohol 0.016g/100ml Alcohol abuse 
Chronic > 80g 
Yes AA 
46 24 6.51 Alcohol toxicity Blood alcohol 0.315g/100ml, 
Nordiazepam 0.2mg/l 
Alcohol abuse 
Chronic > 80g 
? AA 
51 27 5.58 Gastrointestinal 
haemorrhage 
Blood alcohol 0.119/100ml Alcohol abuse 
Chronic > 80g 
Yes AG 
50 24 6.59 Gastrointestinal 
haemorrhage, cirrhosis 
Blood alcohol 0.241g/100ml Alcohol abuse 
Chronic > 80g 
Yes AG 
73 24 6.3 Cirrhosis Blood alcohol 0.118g/100ml  Alcohol abuse 
Chronic > 80g 
No AA 
56 45 6.51 Bleeding oesophageal 
varices 
Blood alcohol 0.283g/100ml Alcohol abuse 
Chronic > 80g 
? AA 
37 17 6.33 Acute alcohol poisoning Blood alcohol 0.479g/100ml 
Carbamazepine 1mg/l 
Alcohol abuse 
Chronic > 80g 
No AA 
25 44 6.7 Carbon monoxide and 
alcohol intoxication 
Blood alcohol 0.193g/100ml 
CO saturation >80 % 
Alcohol abuse 
Chronic > 80g 
? AA 
61 21 6.93 Hypertensive heart disease 
and chronic alcoholism 
Blood alcohol 0.020g/100ml 
Metoprolol 0.5mg/l 
Alcohol abuse 
Chronic > 80g 
Yes AA 
42 41 6.5 Combined bromoxynil and 
alcohol toxicity 
Blood alcohol 0.174g/100ml 
CNS Drugs (DL:01mg/l), 
Bromoxynil 1.5mg/l 
Alcohol abuse 
Chronic > 80g 
No AG 
60 17 6.48 Alcoholism liver cirrhosis 
and drug toxicity 
Blood alcohol: 0,017g/100ml, 
Codeine  
Alcohol abuse 
Chronic > 80g 
Yes AA 
55 48 7.02 Ischaemic heart disease Blood alcohol 0.246g/100ml, 
Diazepam 0.8mg/l, 
Nordiazepam 0.5mg/l 
Alcohol-
dependent 
Chronic > 80g 
Yes AA 
64 39 6.76 Acute alcohol toxicity Alcohol 0.293g/100ml Alcohol-
dependent  
Chronic >80g 
Yes  AA 
55 17 6.85 Asphyxia due to choking 
with food 
Alcohol 0.206g/100ml, 
Amiodarone 1.2mg/l, 
Nordiazepam 0.1mg/l, 
Paracetamol 4mg/l, valporic 
acid <10mg/l 
Alcohol abuse 
Chronic > 80g 
No AG 
59 35 6.57 Coronary artery thrombosis Alcohol 0.063g/100ml Harmful 
Heavy 50-80g 
Yes AA 
61 28 5.29 Multiple organ failure - Alcohol abuse 
Chronic > 80g 
? AA 
67 48 6.4 Acute bronchopneumonia, 
morphine toxicity 
Morphine 3mg/l, Nordiazepam 
0.2mg/l, paracetamol 5mg/l 
Alcohol abuse 
Chronic > 80g 
Yes AA 
53 57 6.75 Chronic airflow limitation  Alcohol abuse 
Chronic > 80g 
Yes AA 
41 54 6.7 Epilepsy, chronic 
alcoholism 
Δ-9-THC acid 0.01mg/l, Δ-9-
THC 0.005mg/l, Phenytoin 
0.1mg/l 
Alcohol abuse 
Chronic > 80g 
Yes AA 
60 51 6.7 Hepatic cirrhosis Paracetamol 22mg/l Alcohol abuse 
Moderate 20-50g 
No AG 
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Suppl. Table 1 (continued) 
73 44 6.59 Coronary artery atheroma  Alcohol abuse 
Chronic > 80g 
No AA 
54 27 6.16 Ischaemic heart disease  Δ-9-THC acid 0.01mg/l, 
Amiodarone 5.0umol/l, 
marijuana breakdown product 
Alcohol abuse 
Chronic >80g 
Yes AG 
56 67 6.47 - - Alcohol abuse 
Chronic >80g 
Yes AG 
58 45 6.47 - - Alcohol abuse 
Heavy 50-80g 
Yes AA 
65 72 6.88 Acute intracerebral 
haemorrhage (right 
caudate), cerebral vascular 
malformation 
- Alcohol-
dependent 
Heavy 50-80g 
Yes AA 
41 39 6.55 Alcohol related - Alcohol abuse 
Heavy 50-80g 
Yes AG 
69 22  Prescription drug overdose - Alcohol-
dependent 
Chronic > 80g 
Yes AA 
63 26 6.21 Combined effects of 
ischemic heart disease and 
chronic lung disease 
Paracetamol < 3mg/l Alcohol abuse 
Chronic >80g 
Yes AA 
70 32 6.05 Sepsis, alcohol liver disease - Alcohol abuse 
Chronic > 80g 
? AA 
65 32 5.66 Complication of chronic 
alcoholism 
Moclobemide: 17mg/l, , 
Phenytoin 6mg/l, 
Paracetamol7mg/l, Quinine 
0.4mg/l 
Alcohol abuse 
Chronic > 80g 
? AA 
52 46 6.78 Lobar pneumonia and 
chronic alcoholism 
- Alcohol abuse 
Chronic > 80g 
Yes AG 
61 28 5.87 Liver failure Metoclopramide <0.1mg/l,  Alcohol-
dependent 
Chronic >80g 
Yes AG 
66 12 6.14 Pneumonia - Alcohol abuse 
Chronic >80g 
Yes AA 
39 24 6.56 Aortic stenosis - 
 
Chronic >80g Yes AG 
70 34 6.24 Respiratory failure - 
 
Alcohol abuse 
Heavy 50-80g 
Yes AG 
56 15 6.66 Ischaemic heart disease and 
emphysema 
 Alcohol abuse 
Chronic >80g 
? AG 
50 17 6.3 Ischaemic heart disease - Alcohol abuse 
Chronic >80g 
? AA 
58 20 6.64 Ischaemic heart disease, 
cirrhosis 
Guaiphenesis 8.5mg/l, 
ibuprofen 3.5 mg/l, paracetamol 
16 mg/l 
Alcohol abuse 
Chronic >80g 
Yes 
 
AG 
43 29 6.29 Intra-abdominal 
haemorrhage, complications 
of sepsis, multiple 
abdominal surgeries, 
massive hepatic necrosis, 
chronic hepatitis, chronic 
cholecystitis 
- Alcohol abuse 
Chronic >80g 
Yes 
 
AG 
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Suppl. Table 1 (continued) 
58 22 6.65 Focal acute and chronic 
pancreatitis 
- Alcohol abuse 
Chronic >80g 
Yes 
 
AA 
73 19 6.84 Ischeamic bowl, atherro-
sclerotic cardio-vascular 
disease 
- Alcohol abuse 
Heavy 50-80g 
Yes 
 
AG 
45 19 6.57 - - Alcohol 
dependence 
Chronic >80g 
Yes 
 
AG 
43 13 6.43 Thrombotic coronary artery 
occlusion 
- Control  
<20g 
Ex-  AA 
51 20 5.88 Cardiac tamponade - Control  
<20g 
? AA 
46 25 6.65 Mitral valve prolapse - Control  
<20g 
? AA 
44 50 6.6 Ischaemic heart disease - Control  
<20g 
Ex-  AA 
63 72 6.9 Severe coronary artery 
atherosclerosis 
- Control  
< 20g 
Ex-  AA 
69 16 6.6 Atherosclerotic 
cardiovascular disease 
Paracetamol 23mg/l, 1% blood 
saturation of CO (low) 
Control 
20-50g 
Yes AA 
63 24 6.94 Atherosclerotic 
cardiovascular disease 
Atenolol <1mg/l Control 
20-50g 
Yes AA 
73 48 6.8 Dilated cardiomyopathy, 
ischaemic heart disease 
- Control  
<20g 
Yes AG 
64 9.5 6.94 Ischaemic heart disease - Control  
20-50g 
Yes AA 
73 51 6.82 Congestive cardiac failure, 
atrial fibrillation, ischemic 
heart disease 
- Control 
20-50g 
Yes AA 
53 27 6.64 Acute myocardial infarct of 
the anterolateral wall of the 
left ventricle, 
atherosclerotic coronary 
artery disease with 90% 
stenosis of the left marginal 
artery 
- Control <20g ? AA 
24 43 6.27 Idiopathic cardiac 
arrhythmia 
- Control < 20g Yes AG 
55 39 6.89 Coronary artery 
atherosclerosis 
Irbesartan 0.4mg/l Control <20g No AG 
64 40 6.68 Coronary artery thrombosis - Control  
20-50g 
No AA 
59 43 6.69 Atherosclerotic 
cardiovascular disease 
 Control 
20-50g 
Yes AA 
68 46 6.12 Ischaemic heart disease Amiodarone 0.7mg/l, 
Paracetamol 3mg/l 
Control <20g No AG 
59 40 6.53 Ischaemic heart disease, 
coronary atherosclerosis 
Amiodarone 1.9mg/l Control <20g Ex AA 
55 12 6.39 Hypertensive heart disease - Control 
20-50g 
No AA 
73 39 6.28 - - Control <20g Ex AA 
66 63 6.91 - - Control <20g No AA 
62 46 6.95 - - Control <20g Ex AA 
36 34 6.67 - - Control <20g Ex AA 
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Suppl. Table 1 (continued) 
60 25 6.7 Bacterial peritonitis, ascites, 
carcinomatosis, 
gastrointestinal stomach 
tumor 
- Control 
20-50g 
No AA 
37 21 6.64 Ischaemic heart disease - Control <20g ? AA 
47 38 6.74 Dilated Cardiomyopathy, 
morbid obesity 
Blood alcohol 0.029g/100ml Control <20g Yes AA 
50 29 6.68 Ischeamic heart disease - Control <20g No AA 
55 8 6.9 Atherosclerotic 
cardiovascular disease 
Amphetamines positive, THC 
positive 
Control <20g ? AA 
68 22 6.59 Suicide by hanging. 
Asphyxia 
Citalopram 0.4mg/l, 
Thioridazine 0.6mg/l, 
Mianserin <0.1mg/l 
Control <20g Yes AA 
59 
 
20 6.56 Coronary thrombosis - Control <20g Yes AA 
56 37 6.76 Ventricular scarring, 
hypertension and 
cardiomegaly 
- Control <20g Yes AA 
60 28 6.8 Ischaemic heart disease 
 
- Control 
20-50g 
No AA 
69 19 6.34 Cardiac tamponade, acute 
myocardial infarction 
- Control <20g No AA 
54 28 - Cardiac arrest  - Control <20g Ex AA 
38 14 6.26 Atherosclerotic 
cardiovascular disease 
- Control <20g Yes AA 
53 16 6.84 Dilated cardiomyopathy Lignocaine 0.9mg/l, Sotalol 
3.8µmol/l 
Control< 20 No AA 
48 24 6.73 Ischaemic heart disease - Control <20g Yes AG 
57 18 6.6 Ischaemic heart disease - Control <20g Ex AA 
66 23 6.74 Ischaemic and 
hypersensitive heart disease 
Irbesartan 0.6mg/l, 
Sulphapyridine detected 
Control <20g Ex AA 
56 19 6.9 Atherosclerotic coronary 
artery disease 
- Control <20g No AA 
60 22 6.66 Ischaemic heart disease - Control <20g No AA 
50  19 6.26 Ischaemic heart disease - Control <20g Ex AA 
34 21 6.73 Acute exacerbation of 
asthma 
- Control <20 Yes AA 
58 12 6.46 Ischeamic heart disease - - Yes AA 
 ‘Core samples’ of alcoholics and controls are highlighted in grey. 
 
  
 151 
 
Study I 
Suppl. Table 2: Post-mortem study - Results genotype x condition interaction analysis in 
striatal post-mortem brain tissue. No significant influence of the A118G genotype 
(rs1799971) on OPRM1 transcript (qRT-PCR) or MOR binding sites expression 
(autoradiography) was detected. 
Nucleus caudatus qRT-PCR 
F[2,55]=1.08, p=ns 
Receptor autoradiography 
F[2,74]=1.11, p=ns 
Group Genotype Mean  
(ddCt) 
SEM N Mean 
(fmol/mg) 
SEM N 
Control AA 0.00 0.14 27 168.75 7.39 34 
 AG 0.00 0.36 4 145.71 17.58 6 
Non-intoxicated AA -0.59 0.25 8 109.15 12.63 12 
 AG -0.91 0.24 9 119.02 11.94 13 
Intoxicated AA -0.63 0.24 9 123.94 13.00 11 
 AG -0.15 0.36 4 98.65 19.66 5 
 
Ventral striatum qRT-PCR 
F[2,56]=2.24, p=ns 
Receptor autoradiography 
F[2,72]=0.28, p=ns 
Group Genotype Mean  
(ddCt) 
SEM N Mean 
(fmol/mg) 
SEM N 
Control AA 0.00 0.13 31 122.14 6.83 34 
AG 0.00 0.35 4 115.70 16.25 6 
Non-intoxicated AA -0.32 0.27 8 101.75 11.04 13 
AG -1.15 0.25 7 82.17 12.00 11 
Intoxicated AA -0.41 0.24 9 69.06 12.59 10 
AG -1.58 0.41 3 42.13 19.90  4 
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Suppl. Table 3: PET study - Cox regression of the association of μ-opioid receptor (MOR) 
availability and relapse risk controlling for OPRM1 genotype, sex, age, smoking and 
medication (naltrexone /placebo). NC – nucleus caudatus, Put – putamen, VS – ventral 
striatum, ST – total striatum, Cov – covariate, FTND – Fagerström Test for Nicotine 
Dependence 
MOR
-BPND 
and 
relaps
e risk 
 controlling 
for OPRM1 
genotype 
 
B              P 
 controlling 
for sex 
 
   
 B           P 
 controlling 
for age  
 
 
B               P 
 controlling 
for smoking 
(FTND)  
 
B               P 
 controlling 
for 
medication 
(nal/pla) 
  B            P 
NC NC -1.4 0.09 NC -1.6 0.07 NC -1.7 0.07 NC -1.4 0.12 NC -1.3 0.11 
Cov gene -0.5 0.34 Sex 0.4 0.37 Age -0.0 0.18 FTND 0.5 0.44 Med -0.0 0.97 
Put Put -2.1 0.03 Put -2.1 0.04 Put -2.2 
 
0.04 Put -2.0 0.06 Put -2.1 0.04 
Cov gene -0.6 0.26 Sex 0.2 0.62 Age -0.0 0.26 FTND 0.01 0.86 Med 0.2 0.96 
VS VS -1.2 0.07 VS -1.2 0.08 VS -1.4 0.04 VS -1.1 0.12 VS -1.2 0.10 
Cov gene -0.6 0.29 Sex 0.3 0.49 Age -0.0 0.14 FTND 0.03 0.63 Med -0.0 0.93 
ST ST -1.8 0.04 ST -1.8 0.04 ST -1.9 0.04 ST -1.6 0.08 ST -1.7 0.06 
Cov gene -0.6 0.29 Sex 0.3 0.49 Age -0.4 0.18 FTND 0.03 0.67 Med 0.0 1.0 
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Study II 
µ-opioid receptor 
Suppl. Table 4: [3H]-Damgo receptor autoradiography in alcohol-dependent rats 
 Not exposed Exposed  
Region Mean  ± SEM 
[fmol/mg] 
n Mean  ± SEM 
[fmol/mg] 
n F-value p-value 
AcbS 378.96 ± 13.83 6 342.06 ± 5.19 6 [1,10]=6.24 0.032* 
AcbC 165.20 ± 2.90 6 149.36 ± 5.16 6 [1,10]=7.15 0.023* 
CPu 279.52 ± 30.46 6 249.47 ± 24.94 6 [1,10]=0.58 0.462 
VTA 135.58 ± 10.63 5 123.47 ± 7.01 6 [1,9]=0.96 0.352 
CeA 54.36 ± 5.68 6 92.79 ± 9.74 6 [1,10,]=11.61 0.007** 
BLA 922.76 ± 52.62 6 668.05 ± 53.17 5 [1,9]=11.41 0.008** 
 
 
Suppl. Table 5: Damgo-stimulated [35S]GTPgS autoradiography 
Region [35S]GTPgS 
baseline 
not exposed 
[35S]GTPgS 
% 
stimulated  
not exposed 
n [35S]GTPgS 
baseline 
exposed 
[35S]GTPgS 
% 
stimulated  
exposed 
n F-value p-value 
AcbS 584.14 ± 
17.99 
50.31 ± 
1.54 
6 656.09 ± 
21.73 
84.12 ± 
11.87 
8 [1,12]=5.90 0.032* 
AcbC 517.03 ± 
27.94 
14.05 ± 
1.11 
7 649.03 ± 
28.90 
49.04 ± 
6.82 
5 [1,10]=36.35 0.000*** 
CPu 534.53 ± 
34.01 
48.95 ± 
2.32 
5 657.32 ± 
20.74 
61.43 ± 
6.57 
7 [1,10]=2.36 0.155 
 
VTA 376.33 ± 
16.21 
113.43 ± 
4.13 
8 387.68 ± 
23.04 
98.53 ± 
5.42 
7 [1,12]=4.79 0.049* 
 
 
Suppl. Table 6: Oprm1 in situ hybridization in alcohol-dependent rats 
 Not exposed Exposed  
Region Mean  ± SEM 
[nCi/g] 
n Mean  ± SEM 
[nCi/g] 
n F-value p-value 
AcbS 13.63 ± 0.32 6 14.61 ± 0.68 6 [1,10]=1.69 0.22 
AcbC 7.20 ± 0.78 6 6.03 ± 0.89 6 [1,10]=0.98 0.35 
CPu 5.37 ± 0.46 6 5.83 ± 0.65 6 [1,10]=0.46 0.51 
VTA 3.87 ± 0.73 5 2.58 ± 0.24 5 [1,8]=2.81 0.13 
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Suppl. Table 7: Pomc in situ hybridization in alcohol-dependent rats 
 Not exposed Exposed  
ME Mean  ± SEM 
[nCi/g] 
n Mean  ± SEM 
[nCi/g] 
n F-value p-value 
active 
cycle 
369.97 ± 18.80 8 307.67 ± 12.42 7 [1,13]=7.17 0.019* 
 
 
Suppl. Table 8: bArr2 in situ hybridization in alcohol-dependent rats 
 Not exposed Exposed  
Region Mean  ± SEM 
[nCi/g] 
n Mean  ± SEM 
[nCi/g] 
n F-value p-value 
AcbS 7.27 ± 0.46 8 11.02 ± 0.45 7 [1,13]=33.41 0.00006*** 
AcbC 6.07 ± 0.53 8 9.32 ± 0.75 7 [1,13]=12.97 0.003** 
CPu 4.30 ± 0.22 7 4.74 ± 0.29 8 [1,13]=1.39 0.26 
VTA 8.72 ± 0.53 7 8.96 ± 0.31 7 [1,12]=0.16 0.70 
 
 
δ-opioid receptor 
Suppl. Table 9: [3H]-DPDPE receptor autoradiography in alcohol-dependent rats 
 Not exposed Exposed  
Region Mean  ± SEM 
[fmol/mg] 
n Mean  ± SEM 
[fmol/mg] 
n F-value p-value 
AcbS 105.62 ± 4.17 8 116.91 ± 3.73 8 [1,14]=4.07 0.06 
AcbC 59.21 ± 1.28 6 80.33 ± 4.66 8 [1,12]=14.51 0.002** 
CPu 115.18 ± 4.05 8 131.82 ± 3.28 8 [1,14]=10.19 0.007** 
VTA 10.61 ± 0.46 8 14.27 ± 1.26 8 [1,14]=7.45 0.02* 
 
 
Suppl. Table 10: DPDPE-stimulated [35S]GTPgS autoradiography 
Region [35S]GTPgS 
baseline 
not exposed 
[35S]GTPgS 
% 
stimulated  
not exposed 
n [35S]GTPgS 
baseline 
exposed 
[35S]GTPgS 
% 
stimulated  
exposed 
n F-value p-value 
AcbS 313.47 ± 
19.95 
51.16 ± 
6.93 
6 416.61 ± 
18.03 
20.58 ± 
2.04 
7 [1,11]=20.58 0.0009*** 
AcbC 312.83 ± 
20.59 
 43.88 
± 5.54 
8 392.75 ± 
16.11 
15.88 ± 
2.05 
7 [1,13]=20.10 0.0006*** 
CPu 294.01 ± 12 
01 
62.48 ± 
5.97 
8 377.90 ± 
17.25 
25.05 ± 
3.76 
8 [1,14]=28.16 0.0001*** 
VTA 240.01 ± 
6.46 
16.64 ± 
3.33 
4 279.15 ± 
21.94 
31.50 ± 
2.81 
5 [1,7]=11.78 0.01* 
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Suppl. Table 11: Oprd1 in situ hybridization in alcohol-dependent rats 
 Not exposed Exposed  
Region Mean  ± SEM 
[nCi/g] 
n Mean  ± SEM 
[nCi/g] 
n F-value p-value 
AcbS 9.69 ± 0.43 6 8.49 ± 0.56 6 [1,10]=2.95 0.12 
AcbC 3.85 ± 0.41 6 2.89 ± 0.11 6 [1,10]=4.93 0.05 
CPu 6.63 ± 0.41 6 4.73 ± 0.28 6 [1,10]=14.79 0.003** 
VTA 1.68 ± 0.08 6 2.11 ± 0.10 4 [1,8]=10.71 0.01 
 
 
Suppl. Table 12: Penk in situ hybridization in alcohol-dependent rats 
 Not exposed Exposed  
Region Mean  ± SEM 
[nCi/g] 
n Mean  ± SEM 
[nCi/g] 
n F-value p-value 
AcbS 467.27 ± 589.26 6 589.26 ± 32.06 6 [1,10]=13.11 0.005** 
AcbC 216.62 ± 3.68 6 269.31 ± 6.76 6 [1,10]=46.85 0.00004*** 
CPu 420.37 ± 31.45 6 444.17 ± 16.96 16.96 [1,10]=0.44 0.52 
VTA 6.40 ± 0.44 6 5.03 ± 0.37 5 [1,9]=5.35 0.046* 
 
 
κ-opioid receptor 
Suppl. Table 13: [3H]-U69,593 receptor autoradiography in alcohol-dependent rats 
 Not exposed Exposed  
Region Mean  ± SEM 
[fmol/mg] 
n Mean  ± SEM 
[fmol/mg] 
n F-value p-value 
AcbS 50.20 ± 2.02 7 68.56 ± 3.47 8 [1,13]=19.34 0.0007*** 
AcbC 41.42 ± 1.61 8 50.57 ± 3.14 8 [1,14]=6.75 0.02* 
CPu 13.12 ± 0.74 7 16.93 ± 1.04 8 [1,13]=8.48 0.01* 
VTA n.d. - n.d. - - - 
 
Suppl. Table 14: U50,488H-stimulated [35S]GTPgS autoradiography 
Region [35S]GTPgS 
baseline 
not exposed 
[35S]GTPgS 
% 
stimulated  
not exposed 
n [35S]GTPgS 
baseline 
exposed 
[35S]GTPgS 
% 
stimulated  
exposed 
n F-value p-value 
AcbS 287.49 ± 
10.86 
8.40 ± 2.88 7 288.73 ± 
8.16 
21.24 ± 
2.08 
7 [1,12]=13.03 0.004** 
AcbC 284.57 ± 
15.02 
12.90 ± 
1.02 
6 279.17 ± 
10.13 
10.33 ± 
0.85 
7 [1,11]=3.80 0.08 
CPu 259.70 ± 
11.06 
60.70 ± 
0.58 
5 264.75 ± 
7.80 
4.41 ± 2.81 8 [1,11]=1.03 0.33 
VTA n.d. n.d. - n.d. n.d. - - - 
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Suppl. Table 15: Oprk1 in situ hybridization in alcohol-dependent rats 
 Not exposed Exposed  
Region Mean  ± SEM 
[nCi/g] 
n Mean  ± SEM 
[nCi/g] 
n F-value p-value 
AcbS 64.44 ±.1.45 7 59.42 ± 2.70 6 [1,11]=2.91 0.12 
AcbC 56.64 ± 2.60 7 54.96 ± 2.97 5 [1,10]=0.18 0.68 
CPu 29.78 ± 0.67 5 35.48 ± 1.36 7 [1,10]=10.94 0.008** 
VTA n.d. - n.d. - - - 
 
 
Suppl. Table 16: Pdyn in situ hybridization in alcohol-dependent rats 
 Not exposed Exposed  
Region Mean  ± SEM 
[nCi/g] 
n Mean  ± SEM 
[nCi/g] 
n F-value p-value 
AcbS 161.93 ± 4.63 6 159.67 ± 1.96 6 [1,10]=0.20 0.66 
AcbC 66.47 ± 4.99 6 72.34 ± 2.25 5 [1,9]=1.00 0.34 
CPu 42.60 ± 1.96 6 45.26 ± 0.85 5 [1,9]=1.35 0.27 
VTA 6.29 ± 0.72 6 4.93 ± 0.44 5 [1,9]=2.29 0.16 
 
 
Study III 
µ-opioid receptor 
Suppl. Table 17: [3H]-Damgo binding in saline/NTX treated animals 
Region Saline  
not 
exposed 
[fmol/mg] 
NTX  
not 
exposed 
[fmol/mg] 
F-value p-value Saline 
exposed 
[fmol/mg] 
NTX 
exposed 
[fmol/mg] 
F-value p-value 
AcbS 601.64 ± 
15.47 
n=7 
694.62 ± 
18.28 
n=8 
[1,13]= 
14.580 
0.002*
* 
590.65 ± 
13.41 
n=6 
721.88 ± 
22.11 
n=8 
[1,12]= 
21.62 
0.001** 
AcbC 312.58 ± 
10.79 
n=7 
284.23 ± 
11.13 
n=6 
[1,11]= 
3.32 
0.096 264.22 ± 
17.05 
n=6 
315.17 ± 
16.82 
n=8 
[1,12]= 
4.35 
0.059 
CPu 499.96 ± 
32.88 
n=8 
484.66 ± 
37.71 
n=8 
[1,14]= 
0.09 
0.764 500.27 ± 
11.21 
n=7 
462.84 ± 
32.72 
n=8 
[1,13]= 
1.04 
0.326 
VTA 191.18 ± 
8.22 
n=6 
307.05 ± 
3.60 
n=6 
[1,10]= 
166.70 
0.000*
** 
175.57 ± 
7.17 
n=7 
386.73 ± 
12.00 
n=5 
[1,10]= 
184.07 
0.000*** 
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Suppl. Table 18: bArr2 in situ hybridization in saline/NTX treated animals 
Region Saline  
not 
exposed 
[fmol/mg] 
NTX  
not 
exposed 
[fmol/mg] 
F-value p-value Saline 
exposed 
[fmol/mg
] 
NTX 
exposed 
[fmol/mg
] 
F-value p-value 
AcbS 8.31 ± 
0.46 
n=7 
8.73 ± 
0.46 
n=8 
[1,13]=0.4
0 
0.54 9.90 ± 
0.81 
n=7 
9.74 ± 
0.63 
n=7 
[1,12]=0.
02 
0.88 
AcbC 8.19 ± 
0.40 
n=8 
7.80 ± 
0.61 
n=8 
[1,14]=0.2
9 
0.60 9.00 ± 
0.27 
n=7 
9.08 ± 
0.87 
n=6 
[1,11]=0.
01 
0.92 
CPu 6.22 ± 
0.23 
n=8 
6.30 ± 
0.21 
n=7 
[1,13]=8.8
0 
0.01* 5.72 ± 
0.40 
n=8 
5.34 ± 
0.24 
n=7 
[1,13]=0.
58 
0.46 
VTA 9.26 ± 
0.20 
n=6 
8.54 ± 
0.50 
n=8 
[1,12]=1.4
1 
0.26 9.07 ± 
1.01 
n=7 
8.69 ± 
0.35 
n=7 
[1,12]=0.
12 
0.73 
 
 
Suppl. Table 19: POMC in situ hybridization in saline/NTX treated animals 
Region Saline  
not 
exposed 
[fmol/mg] 
NTX  
not 
exposed 
[fmol/mg] 
F-value p-value Saline 
exposed 
[fmol/mg] 
NTX 
exposed 
[fmol/mg] 
F-value p-value 
POM
C 
372.40 ± 
14.61 
n=7 
540.69 ± 
14.23 
n=7 
[1,12]=68.
09 
0.000*** 482.48 ± 
10.29 
n=7 
545.31 ± 
11.52 
n=7 
[1,12]=16.
56 
0.002** 
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δ-opioid receptor 
Suppl. Table 20: [3H]-DPDPE binding in saline/NTX treated animals 
Region Saline  
not 
exposed 
[fmol/mg
] 
NTX  
not 
exposed 
[fmol/mg
] 
F-value p-value Saline 
exposed 
[fmol/mg
] 
NTX 
exposed 
[fmol/mg
] 
F-value p-value 
AcbS 23.64 ± 
1.03 
n=8 
24.17 ± 
0.86 
n=8 
[1,14]=0.
16 
0.70 25.59 ± 
1.84 
n=7 
24.63 ± 
0.96 
n=7 
[1,12]=0.
21 
0.65 
AcbC 19.49  ± 
1.56 
n=8 
17.85 ± 
1.75 
n=8 
[1,14]=0.
49 
0.50 20.73 ± 
1.57 
n=7 
20.65 ± 
0.78 
n=7 
[1,12]=0.
002 
0.96 
CPu 27.56 ± 
0.69 
n=8 
31.71 ± 
0.72 
n=8 
[1,14]=17
.48 
0.0009**
* 
27.90 ± 
1.37 
n=8 
32.08 ± 
1.46 
n=8 
[1,14]=4.
36 
0.06 
VTA 13.63 ± 
1.08 
n=8 
22.22 ± 
1.34 
n=8 
[1,14]=24
.85 
0.0002**
* 
17.39 ± 
2.22 
n=8 
18.83 ± 
1.48 
n=8 
[1,14]=0.
29 
0.60 
 
 
 
κ-opioid receptor 
Suppl. Table 21: [3H]-U69,593 binding in saline/NTX treated animals 
Region Saline  
not 
exposed 
[fmol/mg] 
NTX  
not 
exposed 
[fmol/mg] 
F-value p-value Saline 
exposed 
[fmol/m
g] 
NTX 
exposed 
[fmol/m
g] 
F-value p-value 
AcbC 50.21 ± 
2.19 
n=7 
61.49 ± 
3.29 
n=8 
[1,13]=7.6
6 
0.02* 50.15 ± 
2.13 
n=7 
71.99 ± 
4.01 
n=8 
[1,13]=21.23 0.0005**
* 
AcbS 56.62 ± 
2.98 
n=8 
84.93 ± 
3.46 
n=8 
[1,14]=38.
39 
0.00002*
** 
61.88 ± 
2.07 
n=8 
101.31 
± 5.91 
n=8 
[1,14]=39.59 0.00002*
** 
CPu 22.72 ± 
1.09 
n=8 
30.07 ± 
1.46 
n=8 
[1,14]=16.
24 
0.001** 19.99 ± 
0.71 
n=6 
25.81 ± 
2.50 
n=8 
[1,12]=3.83 0.07 
VTA n.d. n.d. - - n.d. n.d. - - 
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Study IV 
Suppl. Table 22: Dopamine transporter (DAT), D1 and D2-like binding levels at different 
time points after air exposure of rats (controls) in the striatum. Data are expressed as fmol/mg 
(mean values ± SEM); n=number of animals/group. AcbC – nucleus accumbens core, AcbS – 
nucleus accumbens shell, CPu – caudate putamen. 
 
D1 (fmol/mg) n D2  (fmol/mg) n DAT  (fmol/mg) n 
AcbS 
0d 
1d 
3d 
7d 
21d 
 
4086,96 ± 78,69 
3593,05 ± 159,31 
3533,65 ± 118,09 
3211,08 ± 129,53 
3341,14 ± 122,21 
 
7 
6 
6 
4 
6 
 
328,19 ± 11,30 
281,85 ± 24,06 
292,87 ± 26,32 
267,00 ± 25,44 
271,99 ± 10,36 
 
7 
6 
4 
5 
6 
 
837,00  ±  58,73 
755,06 ± 50,06 
717,58 ± 59,57 
706,73 ± 56,56 
786,96 ± 61,20 
 
5 
5 
6 
7 
6 
AcbC 
0d 
1d 
3d 
7d 
21d 
 
 
3375,96 ± 63,32 
2880,18 ± 250,63 
3252,50 ± 79,18 
2319,81 ± 101,37 
2650,33 ± 117,17 
 
6 
7 
6 
8 
7 
 
342,66 ± 9,57 
301,64 ± 6,05 
318,10 ± 10,26 
280,41 ± 21,73 
277,88 ± 14,93 
 
6 
6 
5 
7 
6 
 
990,85 ± 51,22 
1151,70 ± 31,08 
1074,52 ± 58,41 
1026,81 ± 25,07 
1208,06 ± 28,80 
 
6 
7 
6 
7 
7 
CPu 
0d 
1d 
3d 
7d 
21d 
 
3709,91 ± 58,07 
3297,98 ± 45,14 
3313,21 ± 69,84 
3154,57 ± 69,10 
3013,47 ± 74,09 
 
8 
6 
6 
8 
7 
 
627,32 ± 7,98 
610,63 ± 11,03 
614,41 ± 13,30 
627,85 ± 9,01 
573,43 ± 10,56 
 
7 
8 
4 
7 
7 
 
1432,58 ± 53,24 
1928,93 ± 73,43 
2005,07 ± 34,54 
1918,01 ± 32,15 
2045,78 ± 32,36 
 
4 
7 
6 
7 
7 
 
 
